Conditions: Mantle Cell Lymphoma Lymphoma, Mantle Cell
Keywords: Lymphoma Vaccines Immune Response Against Lymphoma Molecular Complete Remissions Novel Treatment Approach Mantle Cell Lymphoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 26
Healthy volunteers: no

Brief summary:
This study will evaluate the safety and effectiveness of an experimental cancer vaccine for mantle cell lymphoma a form of cancer of the white blood cells called lymphocytes. Although standard treatments for lymphoma may achieve disease remission, none provides a cure.

Patients with mantle cell lymphoma 18 years and older who have not been treated previously with chemotherapy may participate in this study. Candidates will be screened for eligibility with a medical history and physical examination. Other tests that may be required include blood and urine tests; lung function studies; imaging tests such as magnetic resonance imaging, computed tomography and X-rays; and biopsy (surgical removal of a small tissue sample) of tumor, bone marrow, or other tissue.

Patients enrolled in the study will begin treatment with chemotherapy designed to reduce disease to a minimum that is, to achieve remission or shrink the tumor as much as possible. Chemotherapy will be administered on an outpatient basis over a period of around 12 to 18 weeks in 3-week cycles as follows: prednisone by mouth on days 1 through 5; etoposide, doxorubicin and vincristine intravenously through (a vein) on days 1 through 5; and cyclophosphamide intravenously on day 5. Starting day 6, patients receive no chemotherapy for 16 days. In addition, an antibody called rituximab, which attaches to lymphoma cells and may increase the effectiveness of the chemotherapy, will be given on day 1 of the cycle. Patients will also receive a protein called granulocyte colony-stimulating factor (G-CSF) starting day 6 of the cycle and continuing until the white blood cell count recovers or until day 19. G-CSF is naturally produced by bone marrow and may boost the immune system. The chemotherapy drugs and rituximab are infused through a vein by means of a lightweight portable pump, which patients are taught how to use. Patients are also how taught how to give themselves G-CSF injections under the skin, similar to insulin injections.

The first vaccination will be given at least 3 months after chemotherapy ends and will be repeated every 4 weeks for a maximum of 5 vaccinations. The vaccinations will be given in the clinic. Patients will also receive daily injections of granulocyte-macrophage colony-stimulating factor (GM-CSF), a growth factor naturally produced by bone marrow that can boost the immune system. These injections will be given the day of the vaccination and for the next 3 days.

When vaccine therapy is completed, patients who were treated successfully will be followed with periodic clinic visits for follow-up examinations and tests. Patients in whom the lymphoma did not disappear entirely or who have a recurrence of disease will be advised of further treatment possibilities....

Detailed description:
Background:

* Mantle cell lymphoma presents a particular clinical challenge because it is aggressive and incurable with chemotherapy. Thus, novel treatment approaches are needed.
* In follicular center cell lymphomas, another incurable disease, recent evidence suggests that molecular complete remissions may be achieved following idiotype vaccination in patients who have achieved minimal residual disease with combination chemotherapy.
* These results suggest that idiotype vaccines may be able to induce a clinically significant immune response against lymphoma.

Objectives:

* To assess if etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R)/idiotype vaccination is associated with a median progression-free survival consistent with 36 months;
* To assess if rituximab affects generation of T-cell immunity against the idiotype.
* To compare T-cell immunity using two different methods of isolating the idiotype protein.

Eligibility:

* Tissue diagnosis of mantle cell lymphoma.
* Age greater than or equal to 18 years.
* Previously untreated with cytotoxic chemotherapy. All stages of disease.
* Lymph node of greater than or equal to 2 cm accessible for biopsy/harvest or greater than 1000/microl of circulating tumor cells in the blood.
* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 3.

Design:

* In the present study, we propose to investigate the efficacy of idiotype vaccine treatment in previously untreated patients with mantle cell lymphomas. In order to achieve minimal residual disease, patients will receive 6 cycles EPOCH chemotherapy and rituximab (EPOCH-R) followed by 5 idiotype vaccine injections.
* This study has completed accrual of 26 patients and study is closed as of 4/18/2022.

Arms:
arm 1: Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) followed by idiotype vaccine and granulocyte-macrophage colony-stimulating factor (GM-CSF).

Interventions: intervention 1: EPOCH-R intervention 2: GM-CSF intervention 3: Idiotype vaccine
Intervention descriptions: intervention 1: EPOCH-R for 6 cycles intervention 2: Granulocyte-macrophage colony-stimulating factor (GM-CSF) monthly with the vaccine for 5 doses intervention 3: 1 injection of vaccine monthly for 5 doses

Protocol document:
Prot_SAP_000.pdf: 








 

!"#$
%

&'()*(+&)*
,
.//01234516
83591:
;<=>?@A
B
CDEEFGH
IJK
L>M
NN
O0P5PQP9
R:

SS@>@S,TT
U
VNWN8XO
O0P5PQP9
R:

,STT
YU=Z;[

<KJ\JEJ]
^D_
EJ`a]H\Hb
^F\c
>Z;<
JG
SdeSfegSShi
j10k3Pl
m451:
She,negS,n

VN8
Vop/10:

U>ZSSSSdqrS


OWst8
u8vmw
tx
WmWt8wOX
j.NNWVX
.Vm
XOtNyz{W8v|W}.~
NyX}t8yX{.Ow
WV
vV8{X.8Xm
}.V8sX
NXss
sw}Oyt}.


U>
<KFGEFaD]
GCH_\FD\JK[
>cKF_\JacHK
LH]DGF
L


M`acJFb
LD]FGDGEFH_
KDGEc
YMLi
>HG\HK
IJK
>DGEHK
AH_HDKEc
Y>>Ai
UD\FJGD]
>DGEHK
G_\F\\H
YU>i
UD\FJGD]
G_\F\\H_
JI
?HD]\c
YU?i
F]bFG
,S
AJJ`
fU,,d
,S
>HG\HK
KFCH
H\cH_bD
L

gSrng
<cJGH[

gfS@qhS@hSdq

;`DF][

EcKF_\JacHK`H]DGFGFcJC

Wl21k53453Pl49
.1l5k:
KUD`H[
b@M?
DEEFGH
e
L@>
YDKKD`J_\F`i
UU`HK_[
U[
dfgq
e

U[
ghTg
aJG_JK[
>Z;<
LDGIDE\KHK[
Z
D_cFG\JG
e
``GH
NPpp10Q349
.1l5k[

;<=>?@A

H\JaJ_FbH
aKHbGF_JGH
CFGEKF_\FGH
EE]JacJ_acD`FbH
bJJKFEFG
KF\F`D










 

!"#$
%

&'()*(+&)*
,
./0123
56789:;<=>?
@ BCDEFG
HGFF
FIJKLMJC
KNGOGDEO
C
KCNEPHQFCN
HFPDPHCF
HLCFFGDRG
SGHCQOG
PE
PO
CRRNGOOPTG
CDU
PDHQNCSFG
VPEL
HLGJMELGNCKIW

XLQOY
DMTGF
ENGCEJGDE
CKKNMCHLGO
CNG
DGGUGUW

@ ZD
[MFFPHQFCN
HGDEGN
HGFF
FIJKLMJCOY
CDMELGN
PDHQNCSFG
UPOGCOGY
NGHGDE
GTPUGDHG
OQRRGOEO
ELCE
JMFGHQFCN
HMJKFGEG
NGJPOOPMDO
JCI
SG
CHLPGTGU
[MFFMVPDR
PUPMEIKG
TCHHPDCEPMD
PD
KCEPGDEO
VLM
LCTG
CHLPGTGU
JPDPJCF
NGOPUQCF
UPOGCOG
VPEL
HMJSPDCEPMD
HLGJMELGNCKIW


@ XLGOG
NGOQFEO
OQRRGOE
ELCE
PUPMEIKG
TCHHPDGO
JCI
SG
CSFG
EM
PDUQHG
C
HFPDPHCFFI
OPRDP[PHCDE
PJJQDG
NGOKMDOG
CRCPDOE
FIJKLMJCW

\]^_7`ab_c?
@ XM
COOGOO
P[
defghijkPUPMEIKG
TCHHPDCEPMD
PO
COOMHPCEGU
VPEL
C
JGUPCD
KNMRNGOOPMDi[NGG
OQNTPTCF
HMDOPOEGDE
VPEL
lm
JMDELOn

@ XM
COOGOO
P[
NPEQoPJCS
C[[GHEO
RGDGNCEPMD
M[
XiHGFF
PJJQDPEI
CRCPDOE
ELG
PUPMEIKGW


@ XM
HMJKCNG
XiHGFF
PJJQDPEI
QOPDR
EVM
UP[[GNGDE
JGELMUO
M[
POMFCEPDR
ELG
PUPMEIKG
KNMEGPDW









pqa9a]aqa`r?
@ XPOOQG
UPCRDMOPO
M[
JCDEFG
HGFF
FIJKLMJC

@ sRG
t
uv
IGCNOW
@ eNGTPMQOFI
QDENGCEGU
VPEL
HIEMEMoPH
HLGJMELGNCKIW
sFF
OECRGO
M[
UPOGCOGW

@ wIJKL
DMUG
M[
t
,
HJ
CHHGOOPSFG
[MN
SPMKOIkLCNTGOE
MN
x
uyyykzF
M[
HPNHQFCEPDR
EQJMN
HGFFO
PD
ELG
SFMMUW


@ dgf{
KGN[MNJCDHG
OECEQO
|l
}_ca9=?
@ ZDELG
KNGOGDE
OEQUIY
VG
KNMKMOG
EM
PDTGOEPRCEG
ELG
G[[PHCHI
M[
PUPMEIKG
TCHHPDG
ENGCEJGDE
PDKNGTPMQOFI
QDENGCEGU
KCEPGDEO
VPEL
JCDEFG
HGFF
FIJKLMJCOW

ZD
MNUGN
EM
CHLPGTG
JPDPJCF
NGOPUQCF
UPOGCOGY
KCEPGDEO
VPFF
NGHGPTG
m
HIHFGO
defgh
HLGJMELGNCKI
CDU
NPEQoPJCS
~defghij
[MFFMVGU
SI

PUPMEIKG
TCHHPDG
PDGHEPMDOW
@ XLPO
OEQUI
LCO
HMJKFGEGU
CHHNQCF
M[
,m
KCEPGDEO
CDU
PO
MDFI
MKGD
[MN
[MFFMViQKW










 

!"#$
%

&'()*(+&)*
,
./01245
647.27.8


9:;<=>???????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
@
BCDEFGH
<GIBFIB>
????????????????????????????????????????????????????????????????????????????????????????????????????????????????
,
J? =IB:GKL<B=GI
???????????????????????????????????????????????????????????????????????????????????????????????????????????????????
M
J?J
>NOPQ
GRSTUNVWTX
??????????????????????????????????????????????????????????????????????????????????????????????????????????????
M
J?@
DYUZ[\]O^P
Y^P
:YNV]^Y_T
???????????????????????????????????????????????????????????????????????????????????????????????
M
@? FE=`=D=E=Ba
C>>F>>bFIB
CIK
FI:GEEbFIB
FE=`=D=E=Ba
<:=BF:=C
?????????????
c
@?J
F_V[VRV_VNQ
<\VNT\VY
????????????????????????????????????????????????????????????????????????????????????????????????????????????
c
@?@
>U\TT^V^[
FWY_OYNV]^????????????????????????????????????????????????????????????????????????????????????????????????????????
c
@?,
:T[VXN\YNV]^
9\]UTPO\TX??????????????????????????????????????????????????????????????????????????????????????????????????
Jd
,? >BLKa
=b9EFbFIBCB=GI
?????????????????????????????????????????????????????????????????????????????????????????????
Jd
,?J
>NOPQ
KTXV[^
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????
Jd
,?@
eYUUV^T
CPfV^VXN\YNV]^??????????????????????????????????????????????????????????????????????????????????????????????????
J@
,?,
B\TYNfT^N
b]PVgVUYNV]^X
????????????????????????????????????????????????????????????????????????????????????????????????
J@
,?h
G^
>NOPQ
FWY_OYNV]^X
?????????????????????????????????????????????????????????????????????????????????????????????????????
J,
,?M
<\VNT\VY
g]\
:Tf]WY_
g\]f
9\]N]U]_
BiT\YjQ
Y^P
Gggk>NOPQ
<\VNT\VY
????????????????????????????
JM
h? >L99G:B=eF
<C:F
???????????????????????????????????????????????????????????????????????????????????????????????????????????
JM
h?J
9^TOf]UQXNVX
lV\]WTUV
????????????????????????????????????????????????????????????????????????????????????????????????????
JM
h?@
BOf]\
EQXVX
>Q^P\]fT
m<QU_T
J
]^_Qn
??????????????????????????????????????????????????????????????????????????
Jo
M? D=G>9F<=bFI
<GEEF<B=GI
??????????????????????????????????????????????????????????????????????????????????????????
Jo
M?J
<]\\T_YNVWT
>NOPVTX
?????????????????????????????????????????????????????????????????????????????????????????????????????????
Jo
M?@
>Yfj_T
>N]\Y[Tp
B\YUZV^[
Y^P
KVXj]XVNV]^
????????????????????????????????????????????????????????????????????
Jq
M?,
`T^TNVUr`T^]fVU
C^Y_QXVX
?????????????????????????????????????????????????????????????????????????????????????????????
Jq
o? KCBC
<GEEF<B=GI
CIK
FeCELCB=GI
?????????????????????????????????????????????????????????????????????
Jc
o?J
KYNY
<]__TUNV]^
???????????????????????????????????????????????????????????????????????????????????????????????????????????????
Jc
o?@
KYNY
>iY\V^[
9_Y^
???????????????????????????????????????????????????????????????????????????????????????????????????????????
@d
o?,
:TXj]^XT
U\VNT\VY
????????????????????????????????????????????????????????????????????????????????????????????????????????????
@d
o?h
B]sVUVNQ
<\VNT\VY
?????????????????????????????????????????????????????????????????????????????????????????????????????????????
@J
t? I=u:F9G:B=I`
:FvL=:FbFIB>rKCBC
CIK
>CHFBa
bGI=BG:=I`
9ECI?????
@J
t?J
KTgV^VNV]^X
??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
@J
t?@
Gu>:9GggVUT]g<]fj_VY^UTY^PB\YV^V^[r=:D:Tj]\NV^[???????????????????????????????????????@J
t?,
I<=<_V^VUY_KV\TUN]\:Tj]\NV^[????????????????????????????????????????????????????????????????????????????????????@J










 

!"#$
%

&'()*(+&)*
,
./,
123
4567869
:;569<=7>
?9=<;9=@
////////////////////////////////////////////////////////////////////////////////////
AB
./C
3@<@
@7D
4@E;<F
G67=<69=7>
HI@7
///////////////////////////////////////////////////////////////////////////////////
AB
J/ 4KLK14K1?LM
?N2413O:LK1N24
//////////////////////////////////////////////////////////////////////////////////
AA
P/ ?NMMLQN:LK1RO
LS:OOGO2K4
//////////////////////////////////////////////////////////////////////////////////
AT
P/B
G@<;9=@I8
K9@78E;9
L>9;;U;7<V

Q=6W;8<
17<;97@<=67@I
///////////////////////////////////////////////////
AT
P/A
G@<;9=@I
K9@78E;9
L>9;;U;7<V

LD@5<=W;
Q=6<;XY
//////////////////////////////////////////////////////////
A,
BZ/ [\GL2
4\Q]O?K4
H:NKO?K1N24
////////////////////////////////////////////////////////////////////////////
A,
BZ/B :@<=67@I;
E69
4^_`;X<
4;I;X<=67
//////////////////////////////////////////////////////////////////////////////////////
A,
BZ/A H@9<=X=5@<=67
6E
4^_`;X<8
\7@_I;
<6
S=W;
?678;7<
/////////////////////////////////////////////////////////
A,
BZ/T OW@I^@<=67
6E
Q;7;E=<8
@7D
:=8a8b3=8X6UE69<8
//////////////////////////////////////////////////////////////
AC
BZ/, :=8abQ;7;E=<
L7@IF8=8
/////////////////////////////////////////////////////////////////////////////////////////////////////
AC
BZ/C ?678;7<
H96X;88
@7D
36X^U;7<@<=67
/////////////////////////////////////////////////////////////////////////////
Ac
BB/ H[L:GL?O\K1?LM
12dN:GLK1N2
//////////////////////////////////////////////////////////////////////////
Ac
BB/B OHN?[e:=<^f=U@_/////////////////////////////////////////////////////////////////////////////////////////////////////////
Ac
BA/ :OdO:O2?O4
//////////////////////////////////////////////////////////////////////////////////////////////////////////////////
TZ
BT/ LHHO231?O4
///////////////////////////////////////////////////////////////////////////////////////////////////////////////////
TA
BT/B LHHO231g
BV
H:N?O3\:O4
dN:
4KN:O3
4HO?1GO24
/////////////////////////////////////
TA










 

!"#$
%

&'()*(+&)*
,
./123456783152
./. :376;
5<=>831?>:
@A@A@ CDEFGDH
I JK
GLLMLL
EN
OCPQRST
NKUUKVMW
XH
EWEKYHZM
[G\\E]GYEK]
EL
GLLK\EGYMW
VEY^
G
FMWEG]
ZDK_DMLLEK]SNDMM
L`D[E[GU
aCbcd
\K]LELYM]Y
VEY^
ef
FK]Y^L



I JK
GLLMLL
EN
EWEKYHZM
[G\\E]M
VEUU
_M]MDGYM
G
Y`FKD
LZM\ENE\
J
\MUU
DMLZK]LM
@A@Ag cM\K]WGDH
I JK
GLLMLL
Y^M
DMLZK]LM
DGYM
G]W
YKhE\EYH
KN
OCPQRST
E]
ZDM[EK`LUH
`]YDMGYMW
FG]YUM
\MUU
UHFZ^KFG
I JK
GLLMLL
Y^M
`LM
KN
FKUM\`UGD
FGDiMDL
KN
FG]YUM
\MUU
UHFZ^KFGj
E]\U`WE]_
CQTSXGLMW
FMY^KWKUK_EML
NKD
WMYM\YEK]
KN
X\US@
G]W
k_R
DMGDDG]_MFM]YL
I JK
KXYGE]
\lmn
FE\DKGDDGH
ZDKNEUE]_
KN
`]YDMGYMW
FG]YUM
\MUU
UHFZ^KFGL
I JK
WMYMDFE]M
K[MDGUU
G]W
ZDK_DMLLEK]SNDMM
L`D[E[GU

@A@Ae OhZUKDGYKDH
I JK
MhZUKDM
FKUM\`UGD
G]W
_M]KFE\
LY`WEML
Y^GY
FGH
ZDMWE\Y
DMLZK]LM
G]W
K`Y\KFML
./o <p8qr45726
p26
4p3152ps>

@AgA@ tG]YUM
\MUU
UHFZ^KFG
uvxyz{|}~
zM]X`D_MD
G]W
CGU`YiM
WML\DEXMW
GYHZE\GU
LFGUU
UHFZ^KEW
\MUUL
E]
Y^M
FG]YUM
L`DDK`]WE]_
Y^M
XM]E_]
_MDFE]GU
\M]YMD
Y^GY
Y^MH
]GFMW
FG]YUM
K]M
UHFZ^KFG
atQda@dA
J^M
\HYKUK_HKN
tQ
\K]LELYL
KN
FK]KYK]K`L
ZKZ`UGYEK]
KN
GYHZE\GU
LFGUU
YK
FMWE`FSLEM
UHFZ^KEW
\MUULVEY^E]WM]YMW
]`\UMEj
G]W
L\G]Y
\HYKZUGLFA
RELYKUK_E\GUUHj
Y^M
\MUUL
FGH
DG]_M
NDKF
Y^KLM
VEY^ZDMWKFE]G]YUH
DK`]W
]`\UME
KD
LUE_^Y
]`\UMGD
EDDM_`UGDEYH
YK
Y^KLM
VEY^
FGDiMWUH
G]_`UGYMW
vzz
vz
uv
~


z

v
zzvx

vx
zvxxz

x
[GDEG]YagdA
J^M
tQ
Z^M]KYHZM
\KDDMLZK]WL
YK
Y^GY
KN
G
FK]K\UK]GU

\MUUj
Ql@j
Qlgj
QlggjQl
gj
k_tj
k_l
ZKLEYE[Mj
VEY^
\KSMhZDMLLEK]
KN
k_
E]
g
G]W
FK]K\UK]GU
UGFXWG
UE_^Y\^GE]
E]
f
KN
\GLMLA
QUGLLE\GUUHj
Y^M
\MUUL
GDM
Ql,
ZKLEYE[M
G]W
Ql@
]M_GYE[MA
J^M
XUGLYE\[GDEG]Y
EL
UMLL
UEiMUH
YK
MhZDMLL
Ql,j
k_l
G]W
Qle
G]W
FGH
MhZDMLL
Ql@A
a@SgdA
tQ
^GLG\^GDG\YMDELYE\
\HYK_M]MYE\
GX]KDFGUEYH
Ya@@ @da¡@e 
¡egdA
J^M
FKUM\`UGD
\K`]YMDZGDY
E][KU[MLG
YDG]LUK\GYEK]
KN
Y^M
K]\K_M]M
X\US@
XDMGiZKE]Y
E]YK
Y^M
ZDKhEFEYH
KN
Y^M
M]^G]\MD
DM_EK]KNY^M
^MG[H
\^GE]
_M]MA

J^M
Z`YGYE[M
_M]M
^GL
XMM]
]GFMW
QQml@
G]W
M]\KWML
NKD
\H\UE]l@Y^GY
EL
K[MDMhZDMLLMW
E]
FKLY
KN
\GLML
KN
tQ
aedA
J^M
Ya@@ 
@d
\G]
XM
`LMW
YK
M[GU`GYMFE]EFGU
DMLEW`GU
WELMGLM
XH
MEY^MD
CQT
KD
bkcRA
J^M
ZDMLM]\M
KN
G
\KFZUMh
iGDHKYHZMj
G]W^HZMDWHZUKEWH
^GL
XMM]
GLLK\EGYMW
VEY^
G]
G__DMLLE[M
\UE]E\GU
XM^G[EKDA

tQ\KFZDELML
gA,
YK

KN
GUU
mR
E]
¢cn
a@Sgj
dA
J^M
\UE]E\GU
ZDMLM]YGYEK]
KN
tQ
NDM¡`M]YUH
E]\U`WML
G]
MUM[GYMW
lRj
UHFZ^GWM]KZGY^Hj
SLHFZYKFL
adj
GW[G]\M
LYG_M
kkk
KDk£adjLZUM]KFM_GUHjZKLEYE[MtE][KU[MFM]YG]WY^MkYDG\YELE][KU[MWE]gKN
\GLMLAJ^M\UE]E\GUXM^G[EKDKNtQYM]WLYKXMG__DMLLE[MX`YFGH[GDHNDKFDMUGYE[MUHE]WKUM]Y
YK[MDHG__DMLLE[MAtMWEG]L`D[E[GUELeYKHMGDLG]WZGYEM]YLGDMDGDMUHENM[MD\`DMWAJ^M










 

!"#$
%

&'()*(+&)*
,
./01230/.45/
64.7/0
89
0/.7/0:
.43;73;
<.2=
>?@
52
,A
@
BC
43D
EA@
52
FE@
GC
HI48J/
>KL
M5ND7/0O46/
0O2P3
/6/35Q<.//
0N.6764J0
.43;73;
<.2=
A
52
>R
=235O0:
43D
D70/40/
<.//
0N.6764J
.43;73;<.2=
>R
52
EF
=235O0:
D/1/3D73;
23
5O/
0/.7/0
HI48J/
>KL

M1/S7<7S4JJ9:
I/2D2.267S
/5
4J
5./45/DER1457/350
P75O
=435J/
S/JJ
J9=1O2=4
N073;
43
4;;./0076/
D2T2.N87S73QS23547373;
./;7=/3HFKL

U6/.4JJ
FE@
4SO7/6/D
4
S2=1J/5/
./=700723
43D
5O/
=/D743
D70/40/
<.//
0N.6764J
P40EV=235O0L

IO70
P40
325
07;37<7S435J9
D7<</./35
<.2=
5O/7.
GWM
2<
>R
=235O0L


M/.7/0

3
GC
H@K
BC
H@K
X/D743
YWM
H=235O0K
X/D743

GWM


H=235O0K
X/D743
MN.6764J
H=235O0K
ZL[L
\/JD/.0
,
]>
QQQ
^E
EF
QQQ
E]
_L`7DD/3=433?
 ]F
FE
>?
QQQ
A
EA
`L
M2=4O4
A
>E>
EA
,A
QQQ
QQQ
^A
aL
I/2D2.267S
F
,F
QQQ

FE
EV
>R
]F
bL
cNSS4
R
E,
QQQ
FV
>R
QQQ
^^
dL
[.=754;/
>V
A^
QQQ
QQQ
QQQ
QQQ
^E

eO2N.7/54J
5/05/D
43
4;;./0076/
./;7=/3
2<
O91/.QB\[Y
43D
O7;OQD20/
=/5O25./T45/fS954.4873/
<2JJ2P/D
89
05/=
S/JJ
5.4301J43545723
73
1457/350
P75O
./J410/D
2.
1./672N0J9
N35./45/D
=435J/
S/JJ
J9=1O2=4
H>>KL

[=23;
5O/
EF
1./672N0J9
N35./45/D
1457/350:
5O/26/.4JJ
0N.6764J
HUMK
43D
/6/35Q<.//
0N.6764J
HbWMK
45
^
9/4.0
P/./
RE@
43D
?E@
./01/S576/J9L

a3
S235.405:
5O/
bWM
45
^
9/4.0
P40
>?@
73
5O/
1./672N0J9
5./45/D
1457/350L

[J5O2N;O5O/
./0NJ50
4./
7=1./0076/
73
5O/
N35./45/D
;.2N1:
5O/
./0NJ50
<.2=
5O/
1./672N0J9
5./45/D
;.2N10N;;/05
5O45
5O70
S2=87345723
411.24SO
S43
04J64;/
</P
7<
439
1457/350
43D
70
5O/./<2./
N3J7g/J952
8/
SN.4576/
73
5O/
N35./45/D
;.2N1L

WN.5O/.=2./:
25O/.
05ND7/0
O46/
0O2P3
J755J/
/67D/3S/5O45
O7;OQD20/
5./45=/35
P75O
5.4301J435
70
125/3574JJ9
SN.4576/L
W.//D=43
/5
4J
5./45/D
EAXBh1457/350
P75O
O7;OQD20/
SO/=2Q.4D725O/.419
43D
4357QiQS/JJ
=232SJ234J
435782D9
1N.;/D4N52J2;2N0
823/
=4..2P
5.4301J43545723
H>EKL

IP/359
1457/350
O4D
./S/76/D
1.72.
./;7=/308/<2./
5.4301J435:
43D
A
P/./
73
<7.05
BCfGC
<2JJ2P73;
B`UGL

j73/5//3
H,A@K
1457/350./J410/D
45
4
=/D743
2<
E>
=235O0:
43D
2<
A
1457/350
73
<7.05
BCfGC:
F
O4D
./J410/DL

_75O4=/D743
<2JJ2PQN1
2<
E]
=235O0:
YWM
43D
UM
P/./
/057=45/D
52
8/
^>@
43D
,E@:
./01/S576/J9:
45
]
9/4.0:
73D7S4573;
5O45
5.4301J435
SN./0
</P
7<
439
1457/350L



G./J7=734.9
./0NJ50
P75O
.75NT7=48
43D
B`UG
SO/=25O/.419
0N;;/05
5O45:
4J5O2N;O
.75NT7=48
=4973S./40/
5O/
./01230/
.45/:
5O/./
70
9/5
32
/67D/3S/
<2.
1.2J23;/D
./01230/L

`2P4.D
/5
4J
./12.5/D5O/7.
./0NJ50
2<
B`UG
43D
.75NT7=48
73
]V
3/PJ9
D74;320/D
1457/350
P75O
=435J/
S/JJ
J9=1O2=4
H>^KL

U6/.4JJ:
RF@
2<
1457/350
./0123D/D:
P75O
>R
H]A@K
BCfBCN:
8N5
5O/
=/D743
1.2;./00723Q<.//
0N.6764J
P40
>,LE
H>L?QE,LAkK
=235O0KL

IO/./
./0NJ50
0O2P
5O45
=439
2<
5O/
./0123D73;
1457/350
O46/
S23573N/D
52
./J410/L


I4g/352;/5O/.:5O/0/./0NJ500N;;/055O4532411.24SO:73SJND73;4;;./0076/SO/=25O/.419:
=232SJ234J435782D9f52T7343D5.4301J435:O401.2DNS/D407;37<7S43573S7D/3S/2<J23;Q5/.=GWM
73=435J/S/JJJ9=1O2=4:43D73D7S45/5O451457/3504./.4./J97</6/.SN./DLION0:326/J
5O/.41/N57S411.24SO/04./3//D/D










 

!"#$
%

&'()*(+&)*
,
./0/0 2345678
9:;<9=;>9
2345678?9@A?=<B
C2345678D
?E
<
>FG;H
IF=B?><9?F>
FJ
IK;=F9K;:<LM
<>N
9K;
5O70P
=F>FIHF><H
<>9?BFNMQ
:?9@A?=<B/

R>
<
LK<E;
RR
9:?<H
FJ
23456
<HF>;
?>
:;H<LE;N
<>N
:;J:<I9F:M
>F>7STUVWXYZ[
HM=LKF=<EQ
23456
L:FN@I;N
<
,]^
:;ELF>E;
:<9;Q
<>N
<
_,^
:;ELF>E;
:<9;
?>
L<9?;>9E`?9K
:;J:<I9F:M
N?E;<E;
Ca@9?;::;b
;9
<HQ
E@B=?99;ND
C.]D/
cNN?9?F><HHMQ
NFE;7<Nd@E9;N
23456K<E
L:FN@I;N
<
,e^
L:Ff:;EE?F>7J:;;
E@:G?G<H
<9
eg
=F>9KE
?>
L<9?;>9E
`?9K
L:;G?F@EHM
@>9:;<9;N<ff:;EE?G;
h7I;HH
HM=LKF=<E
C@>L@BH?EK;N
N<9<DQ
<>N
<
i0^
IF=LH;9;
:;=?EE?F>
:<9;
C._D/
8;I;>9;G?N;>I;
E@ff;E9E
9K<9
:?9@A?=<B
=<M
?>I:;<E;
9K;
;JJ?I<IM
FJ
IK;=F9K;:<LM/

5b@Ib=<>
;9<H9:;<9;N
]P
L<9?;>9E
`?9K
:?9@A?=<B
<>N
5643
<>N
FB9<?>;N
<>
FG;:<HH
:;ELF>E;
:<9;
FJ
i_^
FJ`K?IK__^
`;:;
IF=LH;9;
C.jD/

4J
g
L<9?;>9E
?>
9K?E
9:?<H
`KF
<IK?;G;N
58
<>N
K<N
L:;9:;<9=;>9
;G?N;>I;
FJ
<
h5k70
9:<>EHFI<9?F>
BM
358Q
,
K<N
>F
;G?N;>I;
LFE979:;<9=;>9
FJ
9K;
h5k70IHF>;
BM
358Q
<
:;E@H9
9K<9
?E
:<:;HM
<IK?;G;N
`?9K
5643
<HF>;/
l@:9K;:=F:;Q
?>
eP
L<9?;>9E`?9K
<ff:;EE?G;
h7I;HH
HM=LKF=<E
9:;<9;N
`?9K
:?9@A?=<B
<>N
5643Q
ie^
:;ELF>N;N
<>Nje^`;:;
IF=LH;9;/

8;I;>9HMQ
`;
K<G;
9:;<9;N
j
L<9?;>9E
`?9K
:;H<LE;N
<>N
:;J:<I9F:M
m6k
`?9K2345678
<>N
K<G;
FBE;:G;N
<
K?fK
:<9;
FJ
:;ELF>E;
CN<9<
9FF
;<:HMD/

nK;:;
?E
<HEF
L:;IH?>?I<H
;G?N;>I;
9K<9
:?9@A?=<B
<>N
IK;=F9K;:<LM
<:;
EM>;:f?E9?I/

h<E;N
F>
9K;E;
J?>N?>fEQ
`;L:Fd;I9
9K<9
2345678
I<>
<IK?;G;
<9
H;<E9
gP^
58o58@
?>
L:;G?F@EHM
@>9:;<9;N
L<9?;>9E
`?9K=<>9H;
I;HH
HM=LKF=<E/


./0/e RN?F9ML;
p<II?>;
q9@N?;E?>;AL;:?=;>9<H
<>?=<HE
<>N
L<9?;>9E
K<G;
N;=F>E9:<9;N
9K;
@9?H?9M
FJ
9K;
Rf
?N?F9ML;
<E
<
9@=F:7EL;I?J?I
<>9?f;>
JF:
9K;
9:;<9=;>9
FJ
h7I;HH
HM=LKF=<
C.,D
/
2?E;>
<>N
IF7`F:r;:E
J?:E9
N;=F>E9:<9;N
9K<9
<I9?G;
?==@>?b<9?F>
<f<?>E9
?N?F9ML?I
N;9;:=?><>9E
F>
=<H?f><>9
h
I;HHE
L:FN@I;N:;E?E9<>I;
9F
9@=F:
f:F`9K
?>
EM>f;>;?I
=?I;
C.gD/
q?>I;
9K<9
9?=;Q
9K;
LK;>F=;>F>
FJ
?N?F9ML;7EL;I?J?I
9@=F:
:;E?E9<>I;Q
<E
`;HH
<E
EL;I?J?I
<>9?79@=F:
9K;:<LM
<f<?>E9
;E9<BH?EK;N
9@=F:EQK<E
B;;>
:;L:FN@I;N
?>
<
>@=B;:
FJ
<>?=<H
=FN;HE
C.i70_D/
nK;E;
:;E@H9EQ
9<r;>
9Ff;9K;:QL:FG?N;N
9K;
:<9?F><H;
JF:
9;E9?>f
<@9FHFfF@E
9@=F:7N;:?G;N
?N?F9ML?I
E@:J<I;
Rf
CRND
<E
stuvwsxvytXz
{|szzXYv}
sVsXY[t
uy~sY
7I;HH
HM=LKF=<

R><E;:?;E
FJ
H<BF:<9F:M
<>N
IH?>?I<H
E9@N?;EQ
`<r
<9
;9/
K<G;
EKF`>
9K;
J;<E?B?H?9M
FJ
<>
?N?F9ML;G<II?>;
E9:<9;fM
C0j70iD/
5H?>?I<H
;AL;:?;>I;
BM
9K;
`<r
H<BF:<9F:M
:;G;<H;N
9K;
?>N@I9?F>FJ
L<:9?I@H<:HM
LF9;>9
<>9?7?N?F9ML?I
?==@>?9M
BM
9K;
<NN?9?F>
FJ
J:;;
a75ql
9F
9K;
RN7k6JF:=@H<9?F>
<E
<>
<Nd@G<>9/
l@:9K;:=F:;Q
9K?E
;JJ;I9
`<E
N;L;>N;>9
F>
9K;
E;H;I9?G;
<I9?G<9?F>FJ
9K;
n7I;HH
<:=
FJ
9K;
?==@>;
:;ELF>E;/
8;E@H9E
?>
<
E@BE;@;>9Q
H<:f;:
IH?>?I<H
9:?<H
FJRNG<II?><9?F>
?>7L<9?;>9E
`?9K
JFHH?I@H<:
HM=LKF=<
:;I;?G?>f
E9<>N<:N
NFE;
IK;=F9K;:<LM
Cij757P.eeD
K<G;
IF>J?:=;N
9K;
LF9;>IM
FJ
9K?E
IM9Fr?>;
<Nd@G<>9
?>
K@=<>E/

qL;I?J?I<HHMQ
]0
L:;G?F@EHM
@>9:;<9;N
L<9?;>9E
`?9K
JFHH?I@H<:
HM=LKF=<
K<G;
J?:E9
B;;>
9:;<9;N
`?9K
=FN?J?;N
3:Fc52
IK;=F9K;:<LM
9F
?>N@I;
<
=?>?=<H
:;E?N@<H
N?E;<E;
E9<9;
CIF=LH;9;
F:
L<:9?<H
:;=?EE?F>D/

n`;>9M
L<9?;>9E
K<G;
E@BE;@;>9HM
:;I;?G;N
<
E;:?;E
FJ
J?G;
=F>9KHM
E@BI@9<>;F@E
G<II?><9?F>E
`?9K
<@9FHFfF@E
Rf7k6Q
9Ff;9K;:
`?9K
HFI<HHM
<N=?>?E9;:;N
J:;;
a75ql
CL<9?;>9E
<:;:<>NF=?b;N
9F
:;I;?G;
;?9K;:
_PP
F:
.PP
=Ifo=0DCePD/
R>
IF>9:<E9
9F
9K;
L:;G?F@E
E9@NMQ
HFI<H
:;<I9?F>EIK<:<I9;:?b;
BM
;:M9K;=<
<>N
?>N@:<9?F>
C<9
H;<E9
g
I=D
K<G;
B;;>
IF>E?E9;>9HM
FBE;:G;N<99K;G<II?><9?F>E?9;EFJ<HHL<9?;>9EQE9<:9?>f`?9K9K;E;IF>NG<II?><9?F>E?9;EFJ<HH
L<9?;>9EQE9<:9?>f`?9K9K;E;IF>NG<II?><9?F>?>9K;E;:?;E/nK;E;HFI<H:;<I9?F>E`;:;
E@BE;@;>9HM:;L:FN@I;N<9N?E9<>9E?9;EBM<IK<HH;>f;`?9K@>IF>d@f<9;N<@9FHFfF@ERf<HF>;
C`?9KF@9k6DQB@9>F9`?9Ka75ql<HF>;QE@ff;E9?>f9K<9<E?f>?J?I<>9IF=LF>;>9FJ9K?E










 

!"#$
%

&'()*(+&)*
,
./01230/40
54./67/5
8984307
7:/
8;72<292;0
=9>
=3
?4@/
2?
04A
1874/370
?2.B8<<C
7/07/5D
7:40
./01230/E80
01/64?46
?2.
7:/
4354@45;8<
45427C1/D
80
5/B2307.87/5
FC
<86G
2?
8
./867423
72
8
6237.2<D4027C1/HB876:/5D
=9>
I:/0/
/8.<C
./0;<70
1.2@45/
623@436439


/@45/36/
7:87
47
40
12004F</72
435;6/
8
01/64?46
4BB;3/
./01230/
8984307
8
0/<?H7;B2.
83749/3
835
7:87
JKHLMN
40
8
127/374BB;3/
074B;<837
43
:;B83
1874/370>

K2./2@/.D
LO,P
I
6/<<
./01230/0
72
8;72<292;0
7;B2.E/./
5/B2307.87/5
43
QRS
TUQVWXY
2?
1874/370
TZUY>

[34B12.7837
835
;3830E/./5
\;/07423
40
7:/
4B1867
2?
.47;A4B8F
23
7:/
9/3/.87423
2?
8
IH6/<<
./01230/72
7:/
45427C1/
@86643/>

I:40
40
2?
1.867468<
6<43468<
4B12.7836/
F/68;0/
2?
7:/
436./80439
;0/
2?
.47;A4B8F
E47:
6:/B27:/.81C
FC
7./87439
1:C0464830D
80
E/<<
80
2?
064/374?46
4B12.7836/>
N2.
@86643/0
E:46:
1.4B8.4<C
1.25;6/
83
8374F25C
./01230/D
7:/./
40
8
6236/.3
7:87
.47;A4B8FB8C
8F.2987/
7:/
4BB;32<29468<
./01230/>

]2E/@/.D
?2.
@86643/0
E:46:
9/3/.87/
8
IH6/<<./01230/D
0;6:
80
7:/
45427C1/
@86643/
43
7:/
1./0/37
07;5CD
./6/37
/@45/36/
0;99/070
7:87
.47;A4B8F62;<5
436./80/
7:/
IH6/<<
./01230/
72
7:/
@86643/>

^</9837
/A1/.4B/378<
/@45/36/
43
B46/:800:2E3
7:87
5/1</7439
7:/
:207
2?
_
6/<<0
B8C
867;8<<C
=`La^[M^
8374H7;B2.
4BB;347C
/<4647/5FC
@86643/0
TZWY>

M1/64?468<<CD
43
8
B;.43/
7;B2.
B25/<D
4BB;34b87423
E47:
4..85487/5
7;B2.6/<<0
1.25;6/5
23<C
8
:;B2.8<
./01230/
E:46:
E80
323H1.27/674@/>

]2E/@/.D
7:40
08B/
@8664387423
07.87/9C
43
_H6/<<
5/?464/37
B46/
T9/3/7468<<C
/3943//./5
G326GH2;7
B46/Y
1.25;6/5
127/37IH6/<<
B/5487/5
1.27/674@/
8374H7;B2.
4BB;347C>

I:/
6236<;0423
?.2B
7:/0/
/A1/.4B/370
E807:877:/
1./0/36/
2?
_
6/<<0
43
7:/
1.4B439
1:80/
./0;<70
43
5408F</5
LOcP
IH6/<<
:/<1
?2.
LO,PDLIdHB/5487/5
7;B2.
4BB;347C>


 

U>W>c M;BB8.C
=3<49:72?7:/0/
2F0/.@874230D
7:/
6;../37
1.27262<
E4<<
/@8<;87/
7:/
/??/67
2?
8374H45427C146
@8664387423
23
7:/
9/3/.87423
2?
8
I
6/<<HF80/5
@86643/
./01230/
8?7/.
7./87B/37
E47:
^fgL]Ha
6:/B27:/.81C
;0439
7E2
54??/./37
B/7:250
2?
45427C1/
402<87423
835
068</H;1>

I:/
6<43468<
/35124372?
7:/
7.48<
E4<<
F/
72
5/7/.B43/
4?
1874/370
23
7:40
7.48<
:8@/
87
</807
8
B/5483
fNM
2?
Zh
B237:0>L<43468<<CD
E/
623045/.
86:4/@439
8
fNM
2?
Zh
B237:0
72
./1./0/37
8
04934?46837
4B1.2@/B/37
2@/.
078358.5
7./87B/37
E:46:
:80
F//3
./12.7/5
72
1.25;6/
8
B/5483
fNM
2?
U,
B237:0877:/
<239/07>












 

!"#$
%

&'()*(+&)*
,
./12343532367
9::1::;1<6
9<=
1<>?22;1<6
12343532367
@>361>39
./A 12343532367
@>361>39
BCDCD FGHIJKLMG

BCDCDCD
NLKKJO
PLQRGMKLK
MS
TQGUIO
HOII
IVTWXMTQ
YHMGSLZTOP
LG
[Q\MZQUMZV
MS
]QUXMIMRV^C
_IQKULH
HOII
`QZLQGU
aLII
\O
OILRL\IOC

BCDCDCB
bRO
c
Dd
VOQZKC
BCDCDCe
]ZO`LMJKIV
JGUZOQUOP
aLUX
HVUMUMfLH
HXOTMUXOZQWVC
]QULOGUK
TQV
XQ`O
ZOHOL`OP
IMHQI
ZQPLQULMG
MZ
Q
KXMZU
HMJZKO
MS
KUOZMLPK
SMZ
HMGUZMI
MS
KVTWUMTKC

BCDCDCg
bII
KUQROK
MS
PLKOQKOC

BCDCDCh
[VTWX
GMPO
MS
c
B
HT
QHHOKKL\IO
SMZ
\LMWKViXQZ`OKU
MZ
j
DkkkilI
MS
HLZHJIQULGR
UJTMZ
HOIIK
LG
UXO
\IMMPC


BCDCDCm
nopq
WOZSMZTQGHO
KUQUJK
r
eC

BCDCDCs
bPOtJQUO
TQuMZ
MZRQG
SJGHULMG
YKOZJT
HZOQULGLGO
DCh
TRiPI
MZ
HZOQULGLGO
HIOQZQGHO
v
xy
z{|z}~
}{}}~


z|{
{



z|{
}~
}~
}
}{
KVGPZMTO
QK
POSLGOP
\V
j
dk
JGHMGuJRQUOP
bo
j
Dkkk
QGP
WIQUOIOUK
j
Dkkkkk^
JGIOKK
LTWQLZTOGU
PJO
UM
MZRQG
LG`MI`OTOGU
\V
IVTWXMTQC
BCDCDCd
M
QHUL`O
KVTWUMTQULH
LKHXOTLH
XOQZU
PLKOQKO
TVMHQZPLQI
LGSQZHULMG
MZ
HMGROKUL`O
XOQZU
SQLIJZO
aLUXLG
UXO
WQKU
VOQZC
FS
qb
LK
M\UQLGOP
UXO
[n
KXMJIP
OfHOOP
gkC
BCDCDC,
b\LILUV
UM
RL`O
LGSMZTOP
HMGKOGUC


BCDCB nfHIJKLMG

BCDCBCD
bGUL\MPLOK
UM
F
MZ
WZOKOGHO
MS
XOWQULULK
_
KJZSQHO
QGULROGC
BCDCBCB
]ZORGQGU
MZ
IQHUQULGRC

BCDCBCe
]ZLMZ
TQILRGQGHV
LG
WQKU
h
VOQZK
OfHOWU
KtJQTMJK
MZ
\QKQI
HOII
HQZHLGMTQ
MZ
HJZQUL`OIV
UZOQUOP
LG
KLUJ
MS
UXO
HOZ`LfC
BCDCBCg
FG`MI`OTOGU
MS
HOGUZQI
GOZ`MJK
KVKUOT
\V
IVTWXMTQC
./. :@>11<3<4
192 963?<
BCBCD oMTWIOUO
LKUMZV
QGP
]XVKLHQI
OfQTLGQULMGC
BCBCB o_o
PLSSOZOGULQI
]N
]NN
¡qpN
¡q]N
[¢
QI£QILGO
WXMKWXQUQKO
\LILZJ\LG
QI\JTLG
HQIHLJT
]XMKWXQUO
JZLH
QHLP
HZOQULGLGO
YBg
XMJZ
HZOQULGLGO
HIOQZQGHO
LS
KOZJT
HZOQULGLGO
j
DCh
TRiPI^
OIOHUZMIVUOK
JZLGQIVKLKC

BCBCe F
QGUL\MPV
QGP
XOWQULULK
_
KJZSQHO
QGULROGC

BCBCg oq
YJZLGO^
LG
aMTOG
MS
HXLIP\OQZLGR
WMUOGULQIC
BCBCh nIOHUZMHQZPLMRZQTC
BCBCm ¡UQRLGR¤oXOKUf¥ZQVoNKHQGMSHXOKUQ\PMTOGQGPWOI`LKHMIMGMKHMWVLSGMU
WOZSMZTOPLGWZO`LMJKBTMGUXK¡]noNRQIILJTQKLGPLHQUOPC










 

!"#$
%

&'()*(+&)*
,-
/0/01 3456
78
596
:;<=5>
?;9@A;>4
BCAD
@EAF:FGE
5H
@:C9C@5::E
C96C@5A460

IJK MNOPQRMSRPTU
WMTXNYZMNQ
[;ADF>C\46
HA5]]
<;HA
>4GCHA4>
59
4:CGC=:4
@596C65A4
BCAD
^7_
749A>5:
`4GCHA>5ACF9
a]]C@4
b7`ac
BCADC9/dDF;>H
F]
HCG9C9G
@F9H49A0

[
>4GCHA>5ACF9
e:CGC=C:CAE
7D4@f:CHA
]>F<
AD4
B4=
HCA4
gDAA?hiiDF<40@@>0@59@4>0GFjiC9A>5i4:CGC=C:CAEiB4:@F<40DA<c
<;HA
=4
@F<?:4A46
596
H49A
jC5
49@>E?A464<5C:
AFh

^7_
749A>5:
`4GCHA>5ACF9
a]]C@4
9@C@49A>5:>4GCHA>5ACF9k:l<5C:09CD0GFj0

[]A4>@F9]C><5ACF9
F]
4:CGC=C:CAE
5A
749A>5:
`4GCHA>5ACF9
a]]C@4m
7`a
HA5]]
BC::
@5::
?D5><5@E
AF
56jCH4AD4<
F]
AD4
5@@4?A59@4
F]
AD4
?5AC49A
F9
AD4
?>FAF@F:
?>CF>
AF
AD4
>4:45H4
F]
59E
C9j4HACG5ACF95:
5G49AH0

n4>C]C@5ACF9
F]
`4GCHA>5ACF9
BC::
=4
]F>B5>646
4:4@A>F9C@5::E
jC5
4k<5C:
AF
AD4>4H45>@D
A45<0
[
>4@F>64>
CH
5j5C:5=:4
6;>C9G
9F9kBF>fC9G
DF;>H0
KJQRZYo
PpWqNpNURSRPTU

KJr QRZYo
YNQPOU
s0,0, t;<<5>E
u5AC49AHBC::
>4@4Cj4
v
@E@:4H
F]
eua73k`0

[::
?5AC49AH
BC::
>4@4Cj4
C6CFAE?4
j5@@C94
>4G5>6:4HH
F]AD4C>>4H?F9H4
AF
eua73k`
;9:4HH
AD4E
>4w;C>4
9F9k?>FAF@F:
@D4<FAD4>5?E
F>
>56C5ACF9
=4AB449@F<?:4ACF9
F]
eua73k`
596
=4GC99C9G
F]
j5@@C95ACF90

_]
?5AC49AH
>4w;C>4
@D4<FAD4>5?E
6;>C9G
j5@@C95ACF9m
j5@@C95ACF9
BC::
=4
HAF??460
8D4
64@CHCF9
AF
=4GC9
9F9k
?>FAF@F:@D4<FAD4>5?E
F>
>56C5ACF9
BC::
=4
<564
=E
AD4
u_
=5H46
F9
GFF6
<46C@5:
?>5@AC@4x
G494>5::Em<5yF>
F>G59
HEHA4<
@F<?>F<CH4
F>
AD4
?>4H49@4
F]
HEHA4<C@
HE<?AF<H
5>4
>45HF9H
AF
=4GC9A>45A<49A0
n5@@C95ACF9
BC::
=4GC9
BD49
AD4
j5@@C94
CH
5j5C:5=:4
]F::FBC9G
5
<C9C<;<
F]
,/B44fH5]A4>
@F<?:4ACF9
F]
eua73k`0

eua73
z5EH
,k{
`CA;|C<5=
z5E
,
[6<C9CHA4>v@E@:4H
_6i}
_6i}
_6i}
_6i} _6i}
-
,/
,v
/-
/d
s/
M~~
X~
K
~~
eua73k`


4GC9H
eua73k`




e96H


8C<4
b44fHc
u>4k8>45A<49A



ej5:;5ACF9

s0,0/ eua73k`
[6<C9CHA>5ACF9
_9];HCF95:
5G49AH
5>4
56<C9CHA4>46
jC5
@49A>5:
j49F;H
5@@4HHm
596
@E@:4H
5>4
>4?45A46
4j4>E
/,
65EH0zFH4
56y;HA<49Ah
8F
?>FjC64
F?AC<5:
6FH4
C9A49HCAEm
6FH4H
BC::
=4
56y;HA46
=5H46
F9
AD4
:4j4:F]D4<5AF?FC4AC@
AF|C@CAE
5H
]F::FBHh

50^4;A>F?DC:

^56C>[^7F9?>4jCF;H@E@:4
zFH44j4:
{--i<<s
eH@5:5A4F94:4j4:










 

!"#$
%

&'()*(+&)*
,,
./001223
4
5
26789:626;<8
,
=>
?@7;A6
./001223
B
3
26789:626;<8
,
C6D9?6
>;6
E6F6E
GHIE7<6E6<8
=7DJ:
KE<8
>;
K:6FJ>98
?L?E6

M>86
N6F6E
B
5/O




=>
?@7;A6
.5/O




C6D9?6
>;6
E6F6E
=PQRS

,TRUVWCRTR=QV
XUVRM
P=
QYZ[R
YRRON\
[X[
Z]G><@9;7??6K<7GE6
;69<:>K6;J7
7;D
<@:>2G>?L<>K6;J7
>??9:^
986
<@6
E>_6:
>]
<@6
<_>
D>86
E6F6E:6D9?<J>;
>K<J>;8H
Z]
<@6
K7<J6;<
@78
6`<6;8JF6
G>;6
27::>_
J;F>EF626;<
7<
<@6
8<7:<
>]
<@6:7KL^<@6
:68K>;8JGE6
K@L8J?J7;
@78
<@6
>K<J>;
;><
<>
7<<6;97<6
D:9A
D>868
]>:
9;7??6K<7GE6
D9:7<J>;8>]
;69<:>K6;J7H

M>86
N6F6E
,S
M>`>:9GJ?J;S
,0
2A1251D7L
[Za
D7L8
,bc
def
@>9:8gH

R<>K>8JD6S
/0
2A1251D7L
[Za
D7L8
,bc
def
@>9:8gH
aJ;?:J8<J;6
0Hc
2A1251D7L
[Za
D7L8
,bc
def
@>9:8gH

[L?E>K@>8K@72JD6S
h/0
2A125
Za
D7L
/
7]<6:
J;]98J>;8H
I:6D;J8>;6
f0
2A1
25
IHPH
GJD
D7L8
,b/H
CJ<9`J27G
3h/
2A125
Za
D7L
,
J226DJ7<6EL
G6]>:6
J;]98J>;8H
jJEA:78<J2
300
kA1D7L
V[
D7L
f
<>
K>8<b;7DJ:
Ul[
m/^
0001223n
Q7GE6
>]
D>868
K6:
E6F6E
]>:
7Do98<6D
7A6;<8S













pqrst














pqrs
putvt
wvq
putv
xvyvzt

{|
 {}
 }
|
~



M>`>:9GJ?J;
d2A1251D7Lg
,0
 ,0
 ,0
 ,5
 ,cHc
 ,hH3
 50Hh
 5cH
R<>K>8JD6
d2A1251D7Lg
/0
 /0
 /0
 f0
 h5
fHc
 ,03Hh
,5cHc
[L?E>K@>8K@72JD6
d2A1251D7Lg
c0
f00
h/0
e00
,00
,5ef
,///
 ,ff
 R8?7E7<J>;
>;
89G8696;<
D>86
E6F6E8S
M>868
>]
D>`>:9GJ?J;^
6<>K>8JD6^
7;D
?L?E>K@>8K@72JD6
J;?:6786D
GL
50
>F6:
<@6
J226DJ7<6
K:6?6DJ;A
E6F6EH
 M>86
N6F6E
db,gd2A1251D7LgS
50
:6D9?<J>;
>]
?L?E>K@>8K@72JD6
7E>;6
]:>2
E6F6E
Z
d?L?E>K@>8K@72JD6
f00
2A125g
><@6:
D:9A
D>868
9;?@7;A6DH
 C6D9?<J>;
>;
89G8696;<
D>86
E6F6E8S
M>86
>]
?L?E>K@>8K@72JD6
:6D9?6D
GL
50
>F6:<@6J226DJ7<6K:6?6DJ;AE6F6EH
 M9:7<J>;>]<@6:7KLSI7<J6;<8_JEE:6?6JF6f?L?E68H










 

!"#$
%

&'()*(+&)*
,-
/01 3455678
4:;676<=>4=6?7
@A-A, CDEEFGH
IJHKDJDLFMG
NOMPFQQHJHGL
RHLSMPT
MQ
FPFMLUKH
FTMVDLFMG
DGP
TEDVHWXK
OFVV
YH
HRKVMUHP
FG
LSH
ZDEEFGH
RDGXQDELXJH
KJMEHTTA

NSH
QFJTL
,@
KDLFHGLT
OFVV
JHEHFZH
ZDEEFGH
KJMPXEHP
YU
LSH
TMRDLFE
SUYJFPF[DLFMG
LHESGF\XH
]DEEJXDV
EMRKVHLHP^
DGP
LSH
THEMGP
,@
KDLFHGLT
OFVV
JHEHFZH
ZDEEFGH
KJMPXEHPYU
LSH
JHEMRYFGDGL
RHLSMPA


@A-A- CDEEFGH
_PRFGFTLJDLFMG
IDLFHGLTOFVV
JHEHFZH
D
THJFHT
MQ
`
aPbcde
ZDEEFGDLFMGT
fgA`
Rh
LXRMJWPHJFZHP
ah
EMGiXhDLHP
LM
cdejYHhFGGFGh
,-
OHHkT
]MJ
DL
TXES
VDLHJ
LFRHl
XK
LM
,-
RMGLSTl
LSDL
LSH
aP
ZDEEFGH
YHEMRHT
DZDFVDYVH^DQLHJ
EMRKVHLFMG
]FAHA
PHTFhGDLHP
DT
PDU
-,
MQ
VDTL
EUEVH^
MQ
mInoeWp
MG
LSH
TESHPXVH
MXLVFGHPFG
LSFT
THELFMGA

aQ
KDLFHGLT
SDZH
KJMhJHTTFZH
PFTHDTH
LSDL
JH\XFJHT
ESHRMLSHJDKU
LJHDLRHGLYHQMJH
MJ
OSFVH
JHEHFZFGh
ZDEEFGDLFMGl
ZDEEFGDLFMG
OFVV
HFLSHJ
GML
YHhFG
MJ
OFVV
YH
TLMKKHPA
@A-A@ qESHPXVH
aPbcdeZDEEFGH
DGP
rsWoqt
OFVV
YH
DPRFGFTLHJHP
TXYEXLDGHMXTVU
MG
LSH
QMVVMOFGh
TESHPXVHu
v wDU
gu

 

aPWcde
gA`
Rh
TAEA

v wDUT
gl
,l
-l
@
 
rsWoqt
,gg
xhbR-bP
TAEA

aGiHELFMGTFLHT
DJH
JMLDLHP
YHLOHHG
XKKHJ
DGP
VMOHJ
HyLJHRFLFHTA

mDES
PMTH
MQ
ZDEEFGH
MJ
rsW
oqtFTTKVFL
H\XDVVU
YHLOHHG
LSH
LOM
XKKHJ
MJ
VMOHJ
HyLJHRFLFHTA
rsWoqt
FGiHELFMG
FT
LM
YH
hFZHGFGEVMTH
KJMyFRFLU
]z
`
ER^
LM
LSH
aPbcde
FGiHELFMG
TFLHA

eMOHZHJl
FQ
VMEDV
JHDELFMGT
LM
rsWoqtDJH
THZHJHl
rsWoqt
FGiHELFMGT
RDU
YH
hFZHG
HVTHOSHJHA

IDLFHGLT
OFVV
YH
MYTHJZHP
FG
LSHEVFGFEQMJ
LOM
SMXJT
QMVVMOFGh
aPWcde
DGPbMJ
rsWoqt
DPRFGFTLJDLFMG
OFLS
ZFLDV
TFhGT
LDkHG
YHQMJHFGiHELFMG
DGP
HZHJU
@g
RFGXLHTA
{MGWTLHJMFPDV
DGLFWFGQVDRRDLMJU
PJXhT
DGPbMJ
TLHJMFPT
TSMXVPYHDZMFPHPA
|TH
VURKSMRD
ZDEEFGH
ZFLDV
TFhG
TSHHLA
_GU
VMEDV
TkFG
JHDELFMGT
OFVV
YH
EDJHQXVVUGMLHP
DGP
TEMJHP
QMJ
HJULSHRDl
FGPXJDLFMGl
KDFG
DGP
PFTJXKLFMG
MQ
LSH
YDJJFHJ
TXJQDEHA
}HOFVVMGVU
QMVVMO
JHDELFMGT
y
~
PDUT
OSFVH
KDLFHGLT
DJH
DL
{aeA
aQ
DGU
KDLFHGL
SDT
D
JHDELFMG
TXhhHTLFZH
MQ
THGTFLF[DLFMGl
LSH
ZDEEFGH
RDU
YH
TKVFL
FGLM
FLT
EMRKMGHGL
KDJLT
TKHEFQFEDVVUl
LSH
KDLFHGLOFVV
YH
LHTLHP
OFLS
aPWcde
DVMGH
DGP
LSHG
rsWoqt
DVMGHA
NMyFEFLFHT
OFVV
YH
hJDPHP
DEEMJPFGhLM
LSH
{oa
oNo
ZHJTFMG
-Ag
DL
SLLKubbELHKAFGQMAGFSAhMZA
/0/ =>84=;87=
;?:6654=6?7<
@A@A, mInoeWp
v mInoe
PMTH
JHPXELFMGTu
_PiXTLRHGLT
YDTHP
MG
GDPFJ
DT
MXLVFGHP
FG
qHELFMG
/001A

_PiXTLRHGL
YDTHP
MG
PDU
,
EMXGLTu
aQ
LSH
_{o
z
,gggbRR@MJ
KVDLHVHLT
z
`c
MG
PDU
MGH
MQ
LSH
GHyL
EUEVHl
LJHDLRHGL
TSMXVP
YH
PHVDUHP
YU
XK
LM
,
OHHk
XGLFV
JHEMZHJU
DYMZH
LSHTH
VHZHVT
OFLS
LJHDLRHGL
DL
LSH
VDTL
DPRFGFTLHJHP
PMTH
VHZHVA
aQ
LJHDLRHGL
FT
PHQHJJHP
PXH
LM
VMO
_{ol
QFVhJDTLFR
@ggxhbPDU
RDU
YH
DPRFGFTLHJHP
GMLH
LSDL
QFVhJDTLFR
TSMXVP
YH
TLMKKHP
DL
VHDTL
-~
SMXJT
YHQMJH
JHTLDJLFGh
mInoeA
aQ
LSH
EMXGLT
PM
GML
JHEMZHJ
YU
,
OHHkl
JHPXEH
mInoe
YU
MGH
PMTH
VHZHV
OSHG
EMXGLT
JHEMZHJA

eMOHZHJlFQLSHPHVDUHPJHEMZHJUFTQHVLLMYHTHEMGPDJULMYMGHRDJJMOPFTHDTHlLSH
KDLFHGLRDUYHLJHDLHPOFLSJHPXEHPEMXGLTDLLSHPFTEJHLFMGMQLSHKJFGEFKDV
FGZHTLFhDLMJA










 

!"#$
%

&'()*(+&)*
,-
/ 1234526789
:2;<
<==<>3?
@=
A23452678
67B
8<
2C=4?2@C
A73<
A<D73<;
7C;
67B
8<
A<;4><;
8B
?D@E<A
7;62C2?3A732@C
@A
FA<6<;2>732@CG
HI4?J
;@?<
A<;4>32@C?
@=
A23452678
E2DD
C@3
8<
67;<G
123452678
E2DD
8<
;2?>@C32C4<;
=@A
3I<
;4A732@C
@=
3I<
>B>D<
2C
F732<C3?
E23I
KA7;<
L
7DD<AK2>
A<7>32@C?G

M3
3I<
;2?>A<32@C
@=
3I<
NOJ
A23452678
67B
8<
7;62C2?3<A<;
@C
3I<
=@DD@E2CK
>B>D<?
4?2CK
?D@E<A
2C=4?2@C
A73<?
7C;
FA<3A<736<C3
E23I
8<C7;ABD
7C;
FA<;C2?@C<
4?2CK
?37C;7A;
6<;2>7D
FA7>32><G


/ OD<4?9
MDD
F732<C3?
?I@4D;
A<><2P<
?3@@D
?@=3<C<A?
7?
2C;2>73<;
3@
FA<P<C3
>@C?32F732@C
;4A2CK
QNRSTU1G
R>>7?2@C7DDBJ
?B6F3@6732>
2D<4?
67B
@>>4A
7C;
3I2?
?I@4D;
8<
3A<73<;
E23I
7
P2C>A2?32C<
;@?<
A<;4>32@CG
V<>74?<
3I<
;<KA<<
@=
2D<4?
67B
P7AB
7C;
8<
7==<>3<;
8B
>@6@A82;
<P<C3?J
;@?<
A<;4>32@C?
E2DD
8<
87?<;
@C
K@@;
6<;2>7D
FA7>32><G

W<C<A7DDBJ
7
;@?<
A<;4>32@C
@=
XYZ
E2DD
A<?4D3
2C
78A@K732@C
@=
3I<
2D<4?G

HI<
P2C>A2?32C<
;@?<
67B
8<
2C>A<7?<;
87>[
3@
=4DD
;@?<
2=
?B6F3@6?
@=
2D<4?
;@
C@3
@>>4A
=@DD@E2CK
7
;@?<
A<;4>32@CJ
87?<;
@C
K@@;
6<;2>7D
FA7>32><G

/ \<4A@D@K2>7D
3@52>23B9


H@52>23B
WA7;<
]2C>A2?32C<
^@?<

:<C?@AB

-
L
_YZ

Y`Z


a@3@A
X
-
_YZ

`Z

-G-GX WaUS:b
/ b<P<A9
WA7;<
,U-
=<P<Ac>I2DD?
7??@>273<;
E23I
P7>>2C<
7C;c@A
WaUS:b
7;62C2?3A732@C
2?
3A<73<;
E23I
7><3762C@FI<C
7C;c@A
6<F<A2;2C<G
b@A
KA7;<
L
=<P<A
4CA<?F@C?2P<
3@
M><3762C@FI<CJ
I@D;
WaUS:b
4C32D
d
KA7;<
XJ
7C;
A<?37A3
73
Y`Z
@=
@A2K2C7D
;@?<
=@A
A<672C;<A
@=
2Ce<>32@C?G


/ \<4A@D@K2>
3@52>23B9
b@A
KA7;<
XU-J
I@D;
3A<736<C3
4C32D
?B6F3@6?
A<?@DP<;J
7C;
3I<C
A<?37A3
73
Y`Z
@=
@A2K2C7D
;@?<
=@A
A<672C;<A
@=
2Ce<>32@C?G

O=
3@52>23B
A<>4A?
@A
F<A?2?3?J
@AKA7;<
L
3@52>23B
@>>4A?J
WaUS:b
E2DD
8<
;2?>@C32C4<;G


/ S7A;27>
3@52>23B9
b@A
f
KA7;<
-
D2[<DB
7??@>273<;
E23I
WaUS:bJ
;2?>@C32C4<
WaUS:bG


/ W7?3A@2C3<?32C7D9
b@A
MgHcM:H
h
,`
5
C@A67DJ
I@D;
WaUS:b
4C32D
d
Y
5
C@A67DJ
7C;
3I<C
A<?37A3
73
Y`Z
@=
@A2K2C7D
;@?<
=@A
A<672C;<A
@=
;@?<?G
b@A
KA7;<
-
P@6232CK
i4CA<?F@C?2P<
3@
3I<A7FBjJ
I@D;
WaUS:b
4C32D
d
KA7;<
X
7C;
3I<C
A<?37A3
73
Y`Z
@=
@A2K2C7D
;@?<
=@A
A<672C;<A
@=
;@?<?G

klm op
rstuv
wxyztys{opr
-GLG, NA<UHA<736<C3

-GLG,G,
HE<C3B
62DD2D23<A?
@=
?<A46
=@A
?3@A7K<G
-GLG,GX
|47C323732P<
2664C@KD@84D2CJ
?<A46
FA@3<2C
<D<>3A@FI@A<?2?G
-GLG,G- gB6FI@FI<A<?2?9,5,`,`DB6FI@>B3<?G:<C;3@^AG}@FFJSD2C2>7DO664C@D@KB
:<AP2><?J\SOUbS1^SJbA<;<A2>[Ja^GHI<?<?76FD<?E2DD8<4?<;=@A87?<D2C<
?34;2<?@=HU><DDA<?F@C?<3@O;G










 

!"#$
%

&'()*(+&)*
,-
/0-0,0-
23456
7859:;<
=6856
>5
>6?@>4?A>B
@CC
9@>8?A>:
43:>
3AD?6E5
@
7859:;
5F
@
GC8A8G@CC;
8AH5CH?D
C;49I
A5D?
>5
965H8D?
4@>?68@C
F56
8D85>;9?
H@GG8A?
3AC?::
>3456
G?CC:
@H@8C@7C?
7;
@9I?6?:8:0

2I?
7859:;
:I53CD
7?
@>
C?@:>
J
G4
:K3@6?
8A
:8L?0

M5A?
4@665N
7859:;0
O8H?
GG
5F
4@665N
N8CC
7?
@:986@>?D
8A>5
P0Q
4C
5F
=OR
F56
=ST
@A@C;:8:0
UI?A
95::87C?B
OVSW
N8CC
7?
D5A?
5A
>I?
4@665N0


/0-0,0Q
OVSW
5F
9?689I?6@C
7C55D
F56
D8:?@:?
D?>?G>85A<
:?AD
JP
GG
8A
E6??A
>59:0
/0-0,0X
Y;49I5G;>?
:37:?>
@A@C;:8:Z
=6?<>6?@>4?A>
57>@8A
X
GG
E6??A
>59
>37?
F56
OVSW
>5
M8CC
[599
/0-0J \368AE
]=^SR<T
S;GC?:
/0-0J0,
]@GI
G;GC?
_D@;
,`Z
=I;:8G@C
?a@4B
SMSbD8FF?6?A>8@CB
?C?G>65C;>?:B
C8H?6
F3AG>85AB
Y\R0




/0-0J0J
VCC
>6?@>4?A>
N??c:Z
SMSbD8FF?6?A>8@C
>N8G?
N??cC;0

/0-0J0/
]AD
5F
G;GC?
-
@AD
XZ
UI5C?
75D;
S2
:G@A:0

W=]S2
E@CC834B
G5C5A5:G59;

@AD
75A?
4@665N
7859:;
8F
95:8>8H?
5A
C@:>
?a@40
O56
G@:?:
8A
NI8GI
>I?
8AH?:>8E@>56:
:>65AEC;
:3:9?G>
6?:8D3@C
D8:?@:?
_?0E0
@7D548A@C
4@::?:
8:
E@CC834
@H8D`B
84@E8AE<
E38D?D
A??DC?
7859:;
4@;
7?
9?6F564?D0
/0-0J0-
=I@64@G5c8A?>8G:
5F
?>595:8D?B
D5a56378G8A
@AD
H8AG68:>8A?
N8CC
7?
D6@NA
5A
@CC
G;GC?:
8A
NI8GI
:@49C8AE
G@A
7?
57>@8A?D0

\6@N
Q
GG
E6??A
>59
>37?
@>
>I?
F5CC5N8AE
>84?:
5A
?@GI
G;GC?Z
284?
P
_7@:?C8A?`d
284?
JJ
I536:
_D6@N
J
>37?:`d
efgh
jk
lmnop
qrost
u
vnwhpxy

zh{r
vnwhp
vm
|o
}os{~
sfpp
swmosvmo
f{
,/S,,0

/0-0J0Q
Y;49I5G;>?
:37:?>
@A@C;:8:Z
S;GC?
X
\J,
57>@8A
X
GG
E6??A
>59
>37?
F56
OVSW
>5
M8CC
[599

/0-0J0X
OVSW
5F
9?689I?6@C
7C55D
F56
D8:?@:?
D?>?G>85A
@F>?6
G;GC?
-
@AD
@F>?6
G;GC?
X
8F
95:8>8H?
5A
G;GC?
-<
:?AD
JP
GG
8A
E6??A
>59:0
/0-0/ \368AE
@GG8A?
26?@>4?A>
/0-0/0,
^7>@8A
844?D8@>?C;
96?<
_N8>I8A
-
N??c:
5F
:>@6>8AE
H@GG8A@>85A:`
@AD
-
N??c:
95:><H@GG8A?
_@F>?6
Q
H@GG8A?
>6?@>4?A>:`
>3456
4?@:36?4?A>:
@AD
:>@E8AE
D8:?@:?
:8>?:
_S2`
@AD
E@CC834b=]2
8F
95:8>8H?
5A
C@:>
?a@40

O56
G@:?:
8A
NI8GI
>I?
8AH?:>8E@>56:
:>65AEC;
:3:9?G>
6?:8D3@C
D8:?@:?
_?0E0
@7D548A@C
4@::?:
8:
E@CC834
@H8D`B
84@E?<E38D?D
A??DC?
7859:;
4@;
7?
9?6F564?D0
/0-0/0J
Y;49I5G;>?
:37:?>
@A@C;:8:Z
=6?
@AD
95:><H@GG8A?
>6?@>4?A>
57>@8A
X
GG
E6??A
>59
>37?
F56
OVSW
>5
M8CC
[5990
/0-0/0/
=2B
=22B
V
@AD
J<48G65EC573C8A
5A
D@;
P
5F
?@GI
8443A8L@>85AZ
/0-0/0-
O8H?
>8E?6
>59
>37?:
5F

9?689I?6@C
7C55D
_XP<,JPGG
8A
=OR`
F56
:?634
@AD
C;49I5G;>?
96?9@6@>85AB
6?:9?G>8H?C;B
F56
>I?
SC8A8G@C
443A5C5E;
W?6H8G?
5A
D@;
P
5F
?@GI
>I?
F86:>
8443A8L@>85AB
@AD
J
>8E?6
>59
>37?:
5A
D@;
P
5F
:37:?K3?A>
8443A8L@>85A:0
/0-0/0Q Wc8AM859:;@>>I?D8:G6?>85A5F>I?=68AG89@CAH?:>8E@>560^7>@8AA?@69C@AA?D
8443A8L@>85A:8>?5AD@;P5FF86:>8443A8L@>85A_7@:?C8A?:@49C?`@AD@E@8A5A










 

!"#$
%

&'()*(+&)*
,-
/012
,3
43
56
7
58
9::;<9=0>95<
7
0>
29>?
58
?61>@?:0
0</A56
9</;60>95<B
CD9<
E95F21
<5>
6?G;96?/
856
?H9I9E9H9>1B
7BJB7BK
M9<?
<??/H?
02F960>95<
56
N56?
E95F21
58
0<
?<H06I?/
H1:F@
<5/?
/609<9<I
>@?
O0NN9<0>95<
29>?2
:01
E?
F?6856:?/
>5
5E>09<
H1:F@5N1>?2
856
9<
O9>65
022012B
MPQ
56
N56?
E95F21
58
H1:F@
<5/?
<5>
6?G;96?/
856
?H9I9E9H9>1B

7BJB7BR
MQSC
58
F?69F@?60H
EH55/
856
/92?02?
/?>?N>95<
F6?
0</
F52>
O0NN9<?T
2?</
4U
NN
9<
I6??<
>5F2B

7BJB7BV
SWS
X9>@
/988?6?<>90H
0</
S@?:
4U
5<
Y01
U3
,3
43
7
58
?0N@
9::;<9=0>95<B

7BJB7BZ
[::;<?
2>;/9?2
5<
F?69F@?60H
EH55/
0>
?0N@
F52>TO0NN9<?
85HH5XT;FT
2?</
KU
NN
9<
\M]
0</
CC^
>;E?2B

7BJBJ \52>T^@?60F1
_O0H;0>95<2

7BJBJB,
M5HH5X9<I
>@?
H02>
9::;<9=0>95<3
6?2>0I?
0HH
29>?2
58
/92?02?
E1
S^
2N0<2
G
7
:5<>@2
`
J3
G
K
:5<>@2
`
J
0</
1?06H1
>@?6?08>?6B

7BJBJB4
C>;/9?2
0>
?0N@
85HH5XT;F
O929>a
]IE3
]S^3
bWS3
0</
/988?6?<>90H3
Ccd^3
0HD0H9<?
F@52F@0>02?3
eY]B
Pd^_a

^@?2?
:01
E?
/5<?
H?22
86?G;?<>H1
0>
>@?
/92N6?>95<
58
>@?
9<O?2>9I0>56B
fgh jklmnklo
qrk
knsrtou
qkrs
vkrmrjru
mwnkovx
oyz
rqq{|m}zx
jklmnklo
7B-B, S69>?690
856
~?:5O0H
865:
\65>5N5H
^@?60F1
 S5:FH?>95<
58
F65>5N5H
>6?0>:?<>
 [<0E9H9>1
>5
>5H?60>?
>@?60F1
56
8?H>







 \0>9?<>
O5H;<>061
X9>@/60X0H
 [<2>9>;>95<
58
56
6?G;96?:?<>
856
<5<TF65>5N5H
N@?:5>@?60F1
7B-B4 d88
C>;/1
S69>?690
 \0>9?<>
/5?2
<5>
85HH5X
>@?
9<2>6;N>95<2
I9O?<
E1
>@?
2>;/1
>?0:
 \0>9?<>
O5H;<>061
X9>@/60X0H
 Y?0>@
7B-B7 d88
\65>5N5H
^@?60F1
0</
d88TC>;/1
\65N?/;6?
Q;>@569=?/
2>088
:;2>
<5>981
S?<>60H
~?I92>60>95<
d889N?
S~d
X@?<
0
2;E?N>
92
>0D?<
588
F65>5N5H>@?60F1
0</
X@?<
0
2;E?N>
92
>0D?<
588T2>;/1B
Q
\06>9N9F0<>
C>0>;2
F/0>?2
M56:
865:
>@?X?E29>?
@>>FaAA@5:?BNN6BN0<N?6BI5OA9<>60A?H9I9E9H9>1AX?HN5:?B@>:
:09<
F0I?
:;2>
E?
N5:FH?>?/
0</
2?<>
O90
?<N61F>?/
?:09H
>5a

PS[
S?<>60H
~?I92>60>95<
d889N?
<N9N?<>60H6?I92>60>95<TH:09HB<9@BI5OB
g|}vvrkmltn
jokn

g vyn}srjx|ml|lkrtnjl
QHHF0>9?<>2X9HH6?N?9O?F65F@1H0`92/;69<I_\dS]T~B^69:?>@5F69:A2;H80:?>@5`0=5H?[YC










 

!"#$
%

&'()*(+&)*
,-
/01234567
897::
;6<=:;>83?:
4@A=
:@;9
B::C
3=
D7:5:77:40
EFF:7G3;
D@83:<8=
H@A
7:;:3?:
3<9@F:4
D:<8@H343<:
IJJ
HG
6<;:
@
H6<890

KLM OPQRS
UVWXW
WVYZSRQ[
\]V]U[
^
RYUV_
/@83:<8=B389
93G9
8>H67
2>74:<
H@A
2:
87:@8:4
B389
@FF6D>73<6F
-JJHG
D7367
86
;A;F:
,
`/1abc
d56FF6B:4
2A
IJJ
HG
4@3FA
567
>D
86
e
4@A=0
b6=D38@F3f@836<
B389
@GG7:==3?:
gh
9A47@836<
@<4
>73<@7A@FC@F3f@836<
H@A
2:
>=:40
iLjXRWk[]XQ[Y
]RUU[]OXRY
YRO[lE=
65
EH:<4H:<8
mn
<6
=@HDF:=
@7:
2:3<G
D76=D:;83?:FA
;6FF:;8:4
567
893=
D7686;6Fo
96B:?:7n@<@FA=:=
65
D7:?36>=FA
;6FF:;8:4
=@HDF:=
@7:
6<G63<G0

p:;836<=
iL^L^ciL^Lq
2:F6B
7:D7:=:<889:
673G3<@F
;6FF:;836<
3<567H@836<
@<4
@<@FA=:=
6<
89:
=@HDF:=
@<4
@7:
7:8@3<:4
9:7:
56793=8673;@F
D>7D6=:=o
p:;836<
iL^Lr
7:D7:=:<8=
<:B
@<@FA=:=0

g<
@443836<n
=>2s:;8=
H@A
2:
7:;6<=:<8:4n
35
7:t>37:4n
86
@FF6B
89:
6<G63<G
>=:
65
89:37
=@HDF:=
567
5>8>7:
7:=:@7;9
@<@FA=:=n
3<;F>43<GG:<:83;
8:=83<G0


iL^ ]RSS[UuOXv[
WOPZX[W
w0,0, mAHD9
y64:
b@7?:=8z{36D=A
mAHD9<64:
236D=3:=
B3FF
2:
43?34:4
@DD76|3H@8:FA
@=
56FF6B=}

~@
1<:ct>@78:7
65
89:
=D:;3H:<
B3FF2:=:<8
3<
=@F3<:
67
H:43@
86
70
`F@3<:
@55:n
b:H@86D@896F6GA
p:;836<n
m@267@867A
65
/@896F6GAn
86
2:
D76;:==:4
567
76>83<:
93=86F6GA
@<4
567
3HH><6D9:<68AD3;
;9@7@;8:73f@836<
~30:0
H6<68AD3;
9:@?A
@<4
F3G98
;9@3<
:|D7:==36<o
~2
1<:ct>@78:7
65
89:
=D:;3H:<
B3FF
2:
=:<8
3<
;6F4=@F3<:
67
H:43@
86
70
p8@>48
567
@<@FA=3=
65
;yE
H3;76@77@A
@<4o
~;
1<:c9@F5
65
89:
=D:;3H:<B3F










cadan
B9:7:
38
B3FF2:@==3G<:4
@
><3t>:
@;;:==36<
<>H2:70
/76;:==3<G
3<86
@
=3<GF:c;:FF
=>=D:<=36<
@<4
 ¡


 ¢




w0,0£ /:73D9:7@F
{F664
b@7?:=83<G
g<D@83:<8=
B389
@4:t>@8:
;37;>F@83<G
8>H67
;:FF=
~¤
wJJ
;:FF=z¥F
H@A
9@?:
8>H67
;:FF=
9@7?:=8:4
2A@D9:7:=3=
86
628@3<
¦
wJJ
|
,J-
8>H67
;:FF=
567
D764>;836<
65
?@;;3<:0
E
=H@FF
@F3t>68
~§
,J
|
,J-;:FF=B3FF
2:
@<@FAf:4
2A
Eap
@<4
;A86F6GA
86
;6<537H
D7:=:<;:
65
8>H67
;:FF=0


a6FF:;836<
65
FAHD96;A8:=
~¤
£
|
,J-zCG
2A
@D9:7:=3=
B3FF
@F=6
2:
D:7567H:4
D7367
86
2:G3<<3<G
`/1abcd
@<4
D7367
86
2:G3<<3<G
?@;;3<:
567
3HH><6F6G3;@F
@==@A=0

g5
@<
@D9:7:=3=
3=
46<:
D7:c
`/1abcd
567
;6FF:;836<
65
8>H67
;:FF=n
893=
B3FF
@F=6
=>553;:
567
;6FF:;836<
65
FAHD96;A8:=
567
¨


©








cadan
B9:7:
89:A
B3FF2:@==3G<:4
@
><3t>:
@;;:==36<
<>H2:70
/76;:==3<G
@<4
;7A6D7:=:7?@836<
B3FF
2:
D:7567H:4
2A70ªB@


w0,0I {F664
@<4
{6<:
«@776B
p@HDF:=
128@3<D7:c
@<4
D6=8c?@;;3<:
~B3893<
¬
B::C=
><3F@8:7@F
26<:
H@776B
236D=A
@<4
@=D37@8:
567
@==:==H:<8
65
H3<3H@F
7:=34>@F
43=:@=:
2A
D;70
3?:
;;
65
H@776B
B3FF
2:
@=D37@8:4
3<86
J0w
HF
65
/b567/ad
@<@FA=3=0

EFF
D:73D9:7@F
2F664
@<4
26<:
H@776B
@=D37@8:
=@HDF:=
B3FF
2:
=:<8
3<
@<
:|D:438:4H@<<:7
86
aF3<3;@F
gHH><6F6GA
p:7?3;:=n
yagcada0

­3G:7
86D
8>2:=
B3FF
2:
=D><
46B<@<4=:7>H43?34:43<86,HF@F3t>68=567576f:<=867@G:0/:73D9:7@F2F664H6<6<>;F:@7
;:FF=~/{«aB3FF2:3=6F@8:4D73678657::f3<G2A3;6FFc9AD@t>:;:<8735>G@836<>=3<G=8@<4@74
D7686;6F=0










 

!"#$
%

&'()*(+&)*
,-
/0,01 3445446578
9:
;66<75
=<7>8?97
@A6BC9>A85
4<D458
E7EFA4?4
GHI
E7J
KI>5FF4L
M?FF
D5
E445445J
DA
=3NO
E8
8C5
:9FF9M?7P
8?65
B9?784Q,0RS5ITRUNVIWX
Y0
R948ITRUNVIW
GNA>F5
Z
[Y,LX
\0
RS5I]E>>?75X
10
R948I^E>>?750

O57JZ>>?7
_S557
K9B
GO9J?<6
V5BES?7L
89
H?FF
`9BB
G\a,Ib1ZI,1c,L
E4
9<8F?75J
ED9^50


/0,0/ 344EA
:9S
O5S<6
378?I;J?98AB?>
378?D9JA
;7EJ?S5>8
57dA65IF?7e5J
?66<79ED49SD578
E44EA
GT@;O3Lf
BS5I?66<75
E7J
CAB5SI?66<75
45S<64E6BF54
:S96
5E>C
BE8?578
M?FF
D5
J?F<85J
9^5S
M5FF4
9:
E
6?>S98?85S
BFE85
8CE8
ES5
>9E85J
M?8C5?8C5S
E<89F9P9<4
?66<79PF9D<F?7
?J?98AB5
9S
E
BE75F
9:
?498AB5I6E8>C5J
C<6E7
8<69S
?66<79PF9D<F?74
9:
<7S5FE85J
?J?98AB50

Y-
H9<7J
E78?D9JA
?4
J585>85J
M?8C
C9S45SEJ?4C
B5S9g?JE45IP9E8
E78?C<6E7
F?PC8I>CE?7
E78?D9J?54
J?S5>85J
EPE?748
8C5
F?PC8
>CE?7
798
BS54578
?7
8C5?66<79PF9D<F?7
?J?98AB5
GNEF8EP
FED9SE89S?54f
O9<8C
OE7
=SE7>?4>9L0
/0,0Z 344EA
:9S
;J?98AB5IOB5>?:?>
RS9F?:5SE8?^5
W54B9745
hC57:5E4?DF5f
:S54C
RHiN
M?FF
D5
<45J
97
8C5
4E65
JEA
8C5A
ES5
9D8E?75J
:9S
E7EFA4?40

Y-

O89S5J:S9d57
RHiN
M?FF
D5
E^E?FEDF5
E4
E
DE>eI<B0
RHiN
M?FF
D5
ME4C5J
E7J
BFE85J
E8
E
>97>578SE8?97
9:
1
g
,a/
jkllm
okp
qkll
rs
tmjuvkwm
xuyrzrky
{|l}kjjuwm
xkyr|x
~t{
qr

B5S>578C<6E7
3H
45S<6
G;i[iI,
B5S>578
3HL0
`@Vf
E<89F9P9<4
;66<79PF9D<F?7
?J?98AB5f
9S
EBE75F9:?498AB5I6E8>C5J
?66<79PF9D<F?74
9:
?SS5F5^E78
?J?98AB54
E8
>97>578SE8?974
9:
a
89
,aa
PB5S6?FF?F?85S
?7
;i[iI,
B5S>578
3H
BS5BESE8?97
M?FF
D5
EJJ5J
?7
8S?BF?>E850
3:85S
8C5
>5FF4
ES5?7><DE85J
:9S
8CS55
JEA4
E8
\-9N
?7
E7
E8694BC5S5
>978E?7?7P
/
B5S>578
>ESD97
J?9g?J5f
8C5A
M?FFD58SE74:5SS5J
89
E
BS5BESE8?97
9:
;i[i
E7J
/
B5S>578
:58EFI>EF:
45S<6
>978E?7?7P
S5>96D?7E78
?785SF5<e?7IY
G\a

B5S
6?FF?F?85SL0
KC5
BFE854
M?FF
8C57
D5
?7><DE85J
:9S
8M9
JEA4
E7JB<F45J
:9S
,Z
89
Ya
C9<S4
M?8C
\VIFED5F5J
8CA6?J?75
G,
N?
B5S
M5FFL0

[E8E
ES5
5gBS5445J
E4
65E7GOTiL
>9<784
B5S
6?7<85
9:

\V8CA6?J?75
?7>9SB9SE8?970
;7?8?EF
:?^5IJEA
><F8<S54
9:
RHiN4548EDF?4C5J
E4
J54>S?D5J
ED9^5
M?FF
D5
5gBE7J5J
?7
;i[iI/
B5S>578
:58EFI>EF:
45S<6
>978E?7?7P
?785SF5<e?7IY
G\a
6FL0
VES^5485J
>5FF4
M?FF
D5
S5BFE>5J
?7
;i[iI,
B5S>578
3H
>978E?7?7P
E<89F9P9<4
?66<79PF9D<F?7
?J?98AB5
E7J
:S54C
?SSEJ?E85J
G/aaa
WL
E<89F9P9<4
RHiN4G1
g
,a/
>5FF4
B5S
M5FFL
E4
E78?P57IBS54578?7P
>5FF4
:9S
:?^5
JEA4f
D5:9S5
B<F4?7P
M?8C

\V8CA6?J?750
/0,0- [5:?7?8?97
9:
E
R94?8?^5
;J?98AB5
KIN5FF
W54B9745
RS9>5J<S54
E7J
J5:?7?8?974
E4
9<8F?75J
DA
H57JE7J?
58
EF
G\aL0




/0,0b [585>8?7P
i?7?6EF
W54?J<EF
[?45E45
GiW[L
/0,0b0,
WE8?97EF5
:9S
iW[
E445446578
{kkjrs
rsrxl
kmry|l
{rmkmk
~{
js
}k

ouqkpz|l
uul
u
xusrup
orksmw
S54B9745
89
8S5E86578
E7J
5ESFA
J585>8?97
9:
S5FEB450


;8?49:
S545ES>C
?785S548
89
J585S6?75
?:
>?S><FE8?7P
8<69S
[3
D5:9S5f
J<S?7P
9S
E:85S
8C5SEBA
?4BS5J?>8?^5
9:
F97PI85S6
J?45E45I:S55
4<S^?^EF0
3JEB8?^5
H?985>C79F9P?54
N9SB
M?FF
E44544
MC58C5S
?66<75
S5B5S89?S5
JE8E
G50P0f
HI>5FF
?66<79PF9D<F?7
S5>5B89S
45<57>54L
:S96
8C5
V<6E7
iE85S?EF
>E7
D5
<45J
E4
D?96ESe5S4
8CE8
>9SS5FE85
M?8C
J?45E45I:S55
4<S^?^EF0
3JEB8?^5
H?985>C79F9P?54
N9SB
M?FF
<45
E
BS9BS?58ESA
658C9Jf
;66<75
N5FF
W5>5B89S
O5<57>?7PG;NWOLBFE8:9S6f:9SE6BF?:A?7PE7JE7EFAd?7P?66<75>5FFS5>5B89S45<57>54f
EFF9M?7P<7BS5>5J5785J4574?8?^?8AE7J4B5>?:?>?8A0[E8E:S965gB5S?65784>97J<>85JDA
3JEB8?^5H?985>C79F9P?54fN9SB0<4?7P8C5C<6E76E85S?EFM?FFD5BS9^?J5J89N;E7J4<>C










 

!"#$
%

&'()*(+&)*
,-
/01023456/7/
89
:/021657
;6417<=>4?4@67A
B432
14
CBD
E09
87
FA7/
89
CBD
G43
0>9
2F324A7H
IH,H-HJ
L0E2?7A
14
87
A7>1
14
:/021657
;6417<=>4?4@67A
B4/7/M
N?6>O7/P

G34Q7>
43
G43E0?6>
G6R7/
0>/
2030GG6>
7E87//7/
NSSTUP
=FE0>
16AAF7
0>/
A73FE0>/V43
2?0AE0
A0E2?7A
0>/
/010
G34E
A7?7<1
20167>1A
W6??
87
A7>1M
6G
0506?08?7H

IH,H-HX
L=6226>@
6>G43E0164>
Y>?9<4/7/
N?6>O7/P
A0E2?7A
W6??
87
A=037/
0A
/7A<3687/
87?4WZ
A77
L7<164>
[\][][
G43
234<7AA
4G
A0E2?7
<4/6>@M
0>/
A0E2?7
37^F7A1
6>A13F<164>AH

_=7
A0E2?7A
0>/
/010
W6??
87
A1437/6>
1=7
B?6>6<0?
LF22431
`084301439M
`76/4A
;64E7/6<0?
a7A703<=M
D><H
0>/
A7>1
6>
801<=7A
14
:/021657
;6417<=>4?4@67A
B432
01
1=7
0//37AA
?6A17/
87?4Wb


:/021657
;6417<=>4?4@67A
B432H
,II,
U0A1?0O7
:57
U
LF617
Jcc
L7011?7
d:
e-,cJ
f]g ijklmn
ipqrjsnt

prjuvwxs
jxy
ywilqiwpwqx
:??A27<6E7>A
48106>7/
6>
1=7
23414<4?
037
FA7/
0A
/7G6>7/
6>
1=7
23414<4?H

L0E2?7A
W6??
87
43/737/6>
BaDL
0>/
130<O7/
1=34F@=
0
B?6>6<0?
_360?
z010
{0>0@7E7>1
A9A17EH

L=4F?/
0
BaDL
A<377>>41
87
0506?08?7M
1=7
BaDL
/4W>16E7
234<7/F37A
W6??
87
G4??4W7/H

L0E2?7A
W6??
>41
87
A7>14F1A6/7
CD|
W61=4F1
Da;
>416G6<0164>
0>/
0>
7R7<F17/
{_:H
IHJH, T34<7/F37A
G43
A1437/
A27<6E7>A
L77L7<164>
[\][][
G43
6>G43E0164>H


IHJHJ L1F/9
B4E2?7164>M
SF1F37
}A7
0>/
L0E2?7
z7A13F<164>
_=7A1F/9W6??
37E06>
427>
A4
?4>@
0A
A0E2?7
43
/010
0>0?9A6A
<4>16>F7AH

S4??4W6>@
<4E2?7164>
4G1=72?0>>7/
0>0?9A7AM
A0E2?7A
W6??
37E06>
6>
A1430@7
0A
/7106?7/
08457H
_6AAF7A27<6E7>A
0>/
/73657/
16AAF7
?9A017AM
aC:
0>/
zC:
<4??7<17/
6>
1=7
<4F3A7
4G
1=6A
37A703<=234~7<1
E09
87
80>O7/
0>/
FA7/
6>
1=7
GF1F37
14
6>57A16@017
>7W
A<67>16G6<
^F7A164>A
37?017/141=6A
A1F/9
1=01
037
>41
7R237AA?9
A1017/
6>
1=7
237A7>1
23414<4?H
|4W7573M
1=6A
37A703<=
E094>?987
/4>7
6G
1=7
36AOA
4G
1=7
>7W
^F7A164>A
0>/
1=7
23424A7/
37A703<=
=057
F>/73@4>7
234A27<1657
Da;
37567W
0>/
0223450?H
DG
>7W
36AOA
037
0AA4<6017/
W61=
1=7
37A703<=
1=7
T36><620?
D>57A16@0143
EFA1
0E7>/
1=7
23414<4?
0>/
48106>
6>G43E7/
<4>A7>1
G34E
0??
37A703<=
AF8~7<1AH
DGM010>916E7M
0
20167>1
W61=/30WA
G34E
1=7
A1F/9
0>/
/47A
>41
W6A=
G43
1=763
7R6A16>@
A0E2?7A
14
87F16?6Q7/M
1=7
6>/656/F0?
EFA1
23456/7
0
W36117>
37^F7A1H
S4??4W6>@
37<7621
4G
1=6A
37^F7A1M
/010
W6??877R<?F/7/
G34E
GF1F37
/6A1368F164>AM
8F1
/010
1=01
=057
0?370/9
877>
/6A1368F17/
G43
0223457/37A703<=
FA7
W6??
>41
87
08?7
14
87
37136757/Z
0//6164>0??9M
1=7
A0E2?7A
W6??
87
/7A13497/H

_=7TDW6??
37<43/
0>9
?4AA
43
F>0>16<62017/
/7A13F<164>
4G
A0E2?7A
0A
0
/7560164>H
a724316>@
W6??
872731=737^F637E7>1A
4G
A7<164>
HJH

f]\ snxnpwusnxqkwu
jxjmiwi
IHXH, z7A<362164>4G1=7A<4274G@7>716<V@7>4E6<0>0?9A6A










 

!"#$
%

&'()*(+&)*
,-
/012345620
62
078
12193:8:;
25<=19
>825=8
?5@9A
B8
12193C8A
D5<
?5=41<6:52
E607
5078<
08:062>
F8G>G;?12?8<
>825=8HG
IGJGK M8:?<640652
5D
75E
4<6N1?3
12A
?52D6A820619603
5D
=8A6?19
62D5<=10652OB6595>6?19
:48?6=82:
E699
B8
=1P6=6C8A
Q52D6A820619603
D5<
>82806?
:1=498:
E699
B8
=16201628A
1:
A8:?<6B8A
FR8?0652
STUTVTW
12A
UWTUTUHG

X21AA60652;
1
Q8<06D6?108
5D
Q52D6A820619603
71:
B882
5B01628A
D5<
076:
:0@A3G
IGJGJ Y121>8=820
5D
Z8:@90:
R@B[8?0:E699
B8
?5201?08A
6D
1
?9626?1993
1?06521B98
>828
N1<6120
6:
A6:?5N8<8AG

Q9626?1993
1?06521B98
D62A62>:
D5<
076:
:0@A3
1<8
A8D628A
1:
A6:5<A8<:
14481<62>
62
078
/=8<6?12
Q5998>8
5D
Y8A6?19\82806?:
12A
\825=6?:
<8?5==82A10652:
D5<
078
<80@<2
5D
62?6A82019
D62A62>:
0710
6:
?@<<82010078
06=8
5D
4<6=1<3
12193:6:G
F/
96:0
5D
?@<<820
>@6A89628:
6:
=16201628A
52
078
QQZ
620<1280]7004:]OO??<5AG?12?8<G>5NO?52D9@82?8OA6:4913OQQZQZ^OX2?6A82019_`62A62>:_a6:0:HG
IGJGb \82806?
Q5@2:8962>
R@B[8?0:E699
B8
?5201?08A
E607
1
<8c@8:0
05
4<5N6A8
1
B955A
:1=498
05
B8
:820
05
1
QaX/
?8<06D68A91B5<105<3G

XD
078
<8:81<?7
D62A62>:
1<8
N8<6D68A
62
078
QaX/
?8<06D68A
91B;
078
:@B[8?0
E699B85DD8<8A
078
5445<0@2603
05
?5=8
05
dXe
05
71N8
>82806?
8A@?10652
12A
?5@2:8962>
05
8P49162076:
<8:@90f
10
078
06=8
5D
123
:@?7
8N820F:H;
078:8
1?06N6068:
E699
B8
D@2A8A
B3
078
dQXOQQZ62
?52:6A8<10652
5D
078
:48?6D6?
?6<?@=:012?8:G

XD
078
:@B[8?0
A58:
250
E120
05
?5=8
05dXe;1<8D8<<19
05
1
95?19
>82806?
781907?1<8
4<5N6A8<
E699
B8
4<5N6A8A
F10
0786<
8P482:8HG
g76:6:078
5293
06=8
A@<62>
078
?5@<:8
5D
078
:0@A3
0710
62?6A82019
D62A62>:
E699
B8
<80@<28AG
d5
6208<<5>10652:
<8>1<A62>
?9626?1993
1?06521B98
D62A62>:
E699
B8
=1A8
1D08<
078
4<6=1<3
12193:6:G
hTjklk
noppqnlros
ksj
qtkpuklros

hTU jklk
noppqnlros
g78vXE699
B8
<8:452:6B98
D5<
5N8<:8862>
820<3
5D
A101
6205
12
62w75@:8
41::E5<A
4<508?08A
898?0<526?:3:08=
MQR
?9626?19
0<619:
A101B1:8
12A
82:@<62>
A101
1??@<1?3;
?52:6:082?3
12A
06=89628::G
g78
4<62?6419
62N8:06>105<;
1::5?6108
62N8:06>105<:O<8:81<?7
2@<:8:
12AO5<
1
?520<1?08A
A101=121>8<
E699
1::6:0
E607
078
A101
=121>8=820
8DD5<0:G

/99
A101
5B01628A
A@<62>
078
?52A@?0
5D0784<505?59
E699
B8
x840
62
:8?@<8
280E5<x
A<6N8:
5<
62
144<5N8A
1908<2106N8
:608:
0710
?5=493
E607dXe:8?@<603
:012A1<A:G
v<6=1<3
12A
D6219
12193C8A
A101
E699
71N8
6A8206D68<:
:5
0710
<8:81<?7A101
?12
B8
100<6B@08A
05
12
62A6N6A@19
7@=12
:@B[8?0
41<06?64120G
/99/y:;62?9@A62>
?9626?1993
:6>26D6?120
1B25<=19
D62A62>:
52
91B5<105<3
8N19@10652:;
<8>1<A98::
5D:8N8<603;
E699
B8
D5995E8A
@2069
<80@<2
05
B1:89628
5<
:01B696C10652
5D
8N820G
R8<65@:
1AN8<:8
8N820:0710
5??@<
=5<8
0712
Jz
A13:
1D08<
078
91:0
1A=626:0<10652
5D
62N8:06>1065219
1>820O6208<N820652
12A
71N8
12
100<6B@0652
5D
10
981:0
45::6B93
<89108A
05
078
1>820O6208<N820652
:75@9AB8<8?5<A8A
12A
<845<08AG
/21B25<=19
91B5<105<3
N19@8
E699
5293
B8
?52:6A8<8A
12
/y
6D
078
91B5<105<3
1B25<=19603
6:
?71<1?08<6C8AB31235D078D5995E62>]
{ Z8:@90:62A6:?52062@10652D<5=078:0@A3










 

!"#$
%

&'()*(+&)*
,-
/ 123224563789
:67;
5<6=653<
26>=2
4?
2@AB74A2

/ C8DE6?82
7?837A8=7
4?
3=@
47;8?
7;8?3B8E765
6=78?F8=764=
/ 123224563789
:67;
9837;
4?
3=47;8?
28?64E2
39F8?28
8F8=7G
6=5<E96=>
;42B673<6H3764=I

/ 12JE9>89
K@
7;8
1=F8276>374?
74
K8
4L
26>=6L653=7
5<6=653<
6AB357
/ 1L3=@
3K=4?A3<
<3K4?374?@
?82E<7
62
54=2698?89
5<6=653<<@
26>=6L653=7G
7;8
6=F8276>374?
:6<<
B?4F698
MNOPQRS
PUVWO
OXN
PYOQVZ
OP[NZ
\QOX
]NS^NYO
OV
OXN
ONSO
M]W_
PZM
PUVWO
OXN
^POQNZO`S
4E754A8I
abcefghicj
klemncilngo
p373
:6<<
K8
274?89
3554?96=>
74
qqrG
spt
?8>E<3764=2
3=9
u1q
1=7?3AE?3<
C854?92
C878=764=
r5;89E<8
32
3BB<653K<8I

veggelcnghlimhweb
ef
cxhxo
r;4E<9
:8
K854A8
3:3?8
7;37
3
A3J4?
K?835;
6=
4E?
B<3=
74
B?47857
2EKJ85754=L698=763<67@
3=9
7?63<
9373
;32
455E??89G
7;62
:6<<
K8
?8B4?789
8yB896764E2<@
B8?
?8DE6?8A8=72
6=
285764=
z{|{}{
~{| 

v
I,I 8=4A65
p373
r;3?6=>
<3=
=<6=89>8=4A65
9373
:6<<
K8
98B426789
6=
BEK<65
>8=4A65
9373K3282
2E5;
32
9K3
6=
54AB<63=58
:67;
7;8
u1q
8=4A65
p373
r;3?6=>
4<65@I
~{ aa
a
s?4A7;81=78?=3764=3<
4?2;4B
74
r73=93?96H8
C82B4=28
?678?63
L4?
=4=VM_[QZ`S
@AB;4A32I
C82B4=282
AE27
<327
L4?
37
<8327

:882
4LL
?82B8576F8
7?837A8=7
6I8I
B427q
C3=9B42719
6AAE=6H3764=I

/ 4AB<878
?82B4=28
C
4AB<878
9623BB83?3=58
4L
3<<
9878573K<8
5<6=653<
3=9
?3964>?3B;65
8F698=58
4L
9628328
3=9
9623BB83?3=58
4L
3<<
9628328?8<3789
2@AB74A2
6L
B?828=7
K8L4?8
7;8?3B@G
3=9
=4?A3<6H3764=
4L
7;428
K645;8A653<
3K=4?A3<67682
8I>I
pq
98L6=678<@
3226>=3K<8
74
7;8
<@AB;4A3I

t<<
<@AB;
=4982
AE27
;3F8
?8>?82289
74
=4?A3<
26H8

I
5A
6=
>?837827
963A878?
6L
 
I
5A
K8L4?8
7;8?3B@I

?8F64E2<@
6=F4<F89
=4982
7;37
:8?8
I
74
I
5A
6=
>?837827
963A878?
AE27
;3F8
985?83289
74


5A
4?
K@
A4?8
7;3=
¡¢
6=
7;8
2EA
4L
7;8
B?49E572
4L
7;8
>?837827
963A878?2
rpI
rB<88=G
6L
54=2698?89
74
K8
8=<3?>8
K8L4?8
7;8?3B@G
AE27
;3F8
?8>?82289
6=
26H8
3=9
=47
K8
B3<B3K<8
4=
B;@2653<
8y3A6=3764=I

£;8
K4=8
A3??4:
AE27
2;4:
=4
8F698=58
4L
9628328
K@
;6274<4>@I

s<4:
5@74A87?65G
A4<85E<3?
4?
5@74>8=8765
27E9682
:6<<
=47
K8
E289
74
9878?A6=8
?82B4=28I


/ 4AB<878
?82B4=28
E=54=L6?A89
CE
t2
B8?
C
5?678?63
8y58B7
7;37
6L
3
?8269E3<
=498
62 
I
5AG
67
AE27
;3F8
?8>?82289
K@
 
¡¢
6=
rpI

@AB;45@78
3>>?8>3782
:67;6=
7;8
K4=8
A3??4:
AE27
K8
=8>376F8
L4?
¤58<<
A3?8?2
8I>I
,I
/ 3?763<
?82B4=28
¥
-¢
985?83289
6=
rp
4L

<3?>827
94A6=3=7
=4982
4?
=493<
A32282I
u4
6=5?8328
6=
26H8
4L
=4982G
<6F8?
4?
2B<88=
3=9
=4
=8:
26782
4L
9628328I

rB<8=65
3=9
;8B3765
=49E<82
AE27
?8>?822
K@
¥
-¢
6=
7;8
rpI

¤4=8
A3??4:
62
6??8<8F3=7
L4?
9878?A6=3764=4L3CI
/ ?4>?8226F89628328¥-¢6=5?8328L?4A=396?6=7;8rp4L3=@B?8F64E2<@6=F4<F89
=4984?7;83BB83?3=584L3=@=8:<8264=I










 

!"#$
%

&'()*(+&)*
,-
/ 123456
7896396:
;6<8=67
39
5699
2>3=
3
?@
4A2
=B2
CDBED6998F6
7896396G

HIJ LMNOPOLQ
PSOLTSOU

V>6WXYXBZZB=
VB[8\82]
XD826D83
F6D98B=
,G^
_855
46
A967
<BD
2B[8\82]
3=7
37F6D96
6F6=2
D6CBD28=EG`
\BC]
B<
2>6
XVX
F6D98B=
,G^
\3=
46
7B_=5B3767
<DBZ
>22C:aa\26C:8=<BG=8>GEBFG

bIcOdSTeMSLOcf
STghOSTiTcLjklULU
Ucl
jUmTLQ
iMcOLMSOcf
enUc
bIo lTmOcOLOMcj
?56396D6<6D
2B
76<8=828B=9
CDBF8767
8=
?B58\]
p^-:
@6CBD28=E
@6963D\>
qF6=29
<BA=7
>6D6G
bIr MdjSe
MmmOPT
Mm
PMienOUcPT
Ucl
LSUOcOcf
k

OSs
STeMSLOcf
tG,G- q[C678267
@6CBD28=E

?56396D6<6D
2B
2>6
D6CBD28=E
D6uA8D6Z6=29
8=
?B58\]
p^-:
@6CBD28=E
@6963D\>
qF6=29
3=7
?B58\]
p^,WB=vXBZC583=\6
wAZ3=
1A4x6\29
@6963D\>
<BA=7
>6D6G

tG,G, Y@y
@6uA8D6Z6=29
<BD
?Y
@6CBD28=E
32
XB=28=A8=E
@6F86_
?56396D6<6D
2B
2>6
D6CBD28=E
D6uA8D6Z6=29
8=
?B58\]
p^-:
@6CBD28=E
@6963D\>
qF6=29
<BA=7
>6D6G

bIz cPO
PnOcOPUn
lOSTPLMS
STeMSLOcf


?DB456Z96[C67828BA95]
D6CBD267
2B
2>6
{w1@?aY@y
8=
8@Y1
_855
359B
46
D6CBD267
2B
2>6
WXY
X58=8\35;8D6\2BDG

`
96C3D326
9A4Z8998B=
89
=B2
=6\6993D]
39
D6CBD29
8=
8@Y1
_855
46
3F3853456
2B
2>6X58=8\35
;8D6\2BDG
Y=377828B=
2B
2>B96
D6CBD29|
355
7632>9
2>32
B\\AD
_82>8=
}^
73]9
3<26D
D6\68F8=E
3
D6963D\>
8=26DF6=28B=
9>BA57
46
D6CBD267
F83
6Z385
2B
2>6
X58=8\35
;8D6\2BD
A=5699
2>6]
3D6
7A6
2B
CDBED6998F6
7896396G


VBD6CBD22>696
7632>9|
C56396
96=7
3=
6Z385
769\D848=E
2>6
\8D\AZ923=\69
B<
2>6
7632>
2B
;DG
;3>A232WXYXX@~`Z385G=8>GEBF
_82>8=
B=6
4A98=699
73]
B<
563D=8=E
B<
2>6
7632>G
bIJ Ocl
jeMcjMS
STeMSLOcf
PSOLTSOU
@6CBD28=EB<
`7F6D96
qF6=29
2B
XVq?
>39
=B2
466=
D6uA8D67
98=\6
^a^a,^^|
39
2>6
CDB2B\B5
_39\BZC56267
_82>
XVq?
B=
2>32
7326G


bI lULU
Ucl
jUmTLQ
iMcOLMSOcf
enUc
tGG- ?D8=\8C35
Y=F6928E32BDa@6963D\>
V63Z
`557323_855
46
\B556\267
8=
3
28Z65]
Z3==6D
3=7
D6F86_67
4]
2>6
CD8=\8C35
8=F6928E32BD
BD
3
5637
399B\83268=F6928E32BDG

qF6=29
Z6628=E
D6uA8D6Z6=29
<BD
6[C678267
D6CBD28=E
39
769\D8467
8=
96\28B=bIrIo_855469A4Z82267_82>8=2>63CCDBCD832628Z658=69G
tGG, 1CB=9BD
V>8992A7]_39ZB=82BD674]2>6X58=8\35;323C73261]926ZX;1F6D98B=-G-A=285










 

!"#$
%

&'()*(+&)*
,,
./0.10,..2
3456
745
89:7:;:<
3=>
;:?8<575@
3A74
BCDEF
GHJKLKMJKMNLO
NQRJMSTULKMQRJ
C4A>A>=>7V@W
A6756@5@
7:
89:XA@5
=
>?=<<
75>7
:Y
=
7459=85V7A;
>79=75ZW
A6
=
@A>5=>5
3A74
95;:Z6A[5@
8::9
:V7;:?5>F
C45
89A?=9W
:\]5;7AX5>
:Y
74A>
>7V@W
=95
7:
Y:9?
=6
5>7A?=75
:Y
745
89:Z95>>A:6^Y955
>V9XAX=<
_E`ab
A6
8=7A567>
795=75@
3A74
DEcBd^e
=6@
_A@A:7W85
X=;;A65b
\5ZA66A6ZY9:?
745
>7=97
:Y
;45?:7459=8WF
C4A>>7V@W
3A<<
95fVA95
=
?=gA?V?
:Y
,2
8=7A567>
7:
=@@95>>
745
89A6;A8=<
:\]5;7AX5>
8:>5@
\W
745
89:7:;:<FD>7A?=75>
:Y
?5@A=6
E`a
9=6Z5
Y9:?
h
7:
ij
?:674>
Y:9
;:?\A6=7A:6
;45?:7459=8Wk
=6@A>i2F,
?:674>
Y:9
9A7VgA?=\
=6@
BdcE
;45?:7459=8WF

l5
=95
=A?A6Z
7:
@5?:6>79=75k
3A74A6=>?=<<
>A6Z<5
=9?
>7V@Wk
3457459
745
;:?\A6=7A:6
:Y
DEcBd^e
=6@
A@A:7W85
X=;;A65
?=W@5?:6>79=75
=
8:7567A=<<W
>V859A:9
:V7;:?5
7:
:7459
7459=85V7A;
=889:=;45>
3A74
=
7=9Z57
?5@A=6E`a
:Y
m2
?:674>F



n5;=V>5=
Y:9?=<
73:^>7=Z5
@5>AZ6
3A<<
6:7
\5
89=;7A;=<
3A74
m2
?:674>
=>
745
7A?5
=7
34A;4
745
?=A656@8:A67
A>
5X=<V=75@k
74A>
>7V@W
3A<<
V>5
=
>A6Z<5
>7=Z5
84=>5
oo
@5>AZ6
A6
:9@59
7:
5>7A?=75
7456V?\59
:Y
8=7A567>
7:
56759
A67:
745
5X=<V=7A:6
:Y
E`a
=>
Y:<<:3>F
o7
3A<<
\5
@5>A9=\<5
AY
/.p
:Y8=7A567>
=95
=\<5
7:
4=X5
=
E`a
5fV=<
7:
:9
Z95=759
74=6
m2
?:674>
_8iqF/.bF

nW
;:679=>7k
AY
:6<W,/p=;4A5X5
m2
?:674
E`a
_8.q.F,/bk
7456
74A>
A>
6:
\57759
74=6
745
\5>7
74=7
3:V<@
4=X5
\5565g85;75@
Y9:?
=
;:4:97
795=75@
:6
:7459
79A=<>k
34A;4
4=X5
=
?5@A=6
E`a
:Y
V8
7:
=889:gA?=75<W
ih
?:674>
_5g85;75@
E`a
3:V<@
\5
,/p
=7
m2
?:674>
AY
?5@A=6
3595
ih
?:674>k
=>>V?A6Z=6
5g8:6567A=<
>V9XAX=<
@A>79A\V7A:6bF
lA74
=<84=q.Fi.
=6@
\57=q.Fi.k
,2
8=7A567>
3A<<
\5567595@F

oY
i.r0,2
4=X5
m2
?:674
E`ak
74A>
3A<<
\5
@5>A9=\<5
A6
:9@59
7:
>4:3
;:6>A>756;W
3A74=?5@A=6
:Y
m2
?:674>
E`a
_mmbF
B:6YA@56;5
A6759X=<>
=\:V7
745
m2^?:674
E`a
8:A67
3A<<
=<>:\5;:6>79V;75@F
s
j/p
:65^>A@5@
;:6YA@56;5
\:V6@
\565=74
i.0,2
5g756@>
@:363=9@
7:
,mpt74V>k
AY
i.0,2
8=7A567>
=95
:\>59X5@
7:
4=X5
m2
?:674
E`ak
7456
74595
A>
=
j/p
;4=6;5
74=7
74579V589:8:97A:6
3A74
m2
?:674
E`a
5g;55@>
,mpF
o6:9@597:
89:XA@5
=
>7:88A6Z
9V<5
\=>5@
:6
E`ak
A6
745
=\>56;5
:Y
=
Y:9?=<
73:^>7=Z5
@5>AZ6k
745
Y:<<:3A6Z3A<<
\5
V>5@u

sY759
745
>7V@W
4=>
\556
:856
=6@
4=>
=;;9V5@
8=7A567>
Y:9
m2
?:674>k
745v=8<=6^w5A59
;V9X5
Y:9
E`a
3A<<
\5
;:6>79V;75@k
=6@
745
ih
?:674
E`a
5>7A?=75
3A<<
\5
;=<;V<=75@k
=<:6Z
3A74
A7>
>7=6@=9@
@5XA=7A:6F
oY
745
ih
?:674
5>7A?=75
?A6V>
:65
>7=6@=9@
@5XA=7A:6A6;<V@5>
/.p
E`ak
7456
=;;9V=<
3A<<
>7:8k
\5;=V>5
74A>
3A<<
A6@A;=75
;:6>A>756;W
3A74
7458:7567A=<<W
5g85;75@
?5@A=6
E`a
:Y
/.p
=7
ih
?:674>F
o7A>4W8:745>A[5@
74=7
=
Y=;7:9
34A;4
?=W
Z95=7<W
A6Y<V56;5
745
@V9=7A:6
:Y
E`a
3A<<
\5
89:@V;7A:6
:Y
=6
A??V65
95>8:6>5F

C45
A??V65
95>8:6>5
3A<<
\5
@5YA65@
=>
895XA:V><W
8V\<A>45@,xF

s
89A:9
>7V@W
:Y
A@A:7W85
X=;;A65
>4:35@
=
j/p
Y95fV56;W
:Y
A??V65
95>8:6>5
A6
8=7A567>3A74
Y:<<A;V<=9
<W?84:?=
795=75@
3A74
E9:wsBD
;45?:7459=8W,xF

d:35X59k
745
A?8=;7
:YDEcBd
;45?:7459=8Wk
?=67<5
;5<<
4A>7:<:ZW
=6@0:9
9A7VgA?=\
:6
745
Y95fV56;W
:Y
=
8:>A7AX5
A??V6595>8:6>5
A>
;V99567<W
V6y6:36F
o6
:9@59
7:
=<<:3
745
79A=<
7:
56@
=;;9V=<
:Y
8=7A567>
89A:9
7:7458<=665@
=;;9V=<
A6
745
5X567
74=7
745
A??V65
95>8:6>5
9=75
A>
<:359
74=6
5g85;75@k
35
8<=6
7:V>5=65=9<W
>7:88A6Z
9V<5
Y:9
A??V65
95>8:6>5>F

oY
745
:\>59X5@
A??V65
95>8:6>5
9=75
A>
?V;4<5>>74=6
x.p
=7
=6
5=9<W
8:A67k
35
8<=6
7:
95^5X=<V=75
745
79A=<
@5>AZ6F

`:9
74A>
8V98:>5k
353A<<5?8<:W=>A?8<5:65^>7=Z5>7:88A6Z9V<5=>Y:<<:3>Fs889:gA?=75<Wi/8=7A567>3A<<\5
569:<<5@A6:9@597:5g85;77:4=X5i.34:3:V<@\5795=75@3A74DEcBd^e=6@95;5AX5745YV<<
X=;;A65FoY1r0i.5g4A\A7=6A??V6595>8:6>5k7456=;;9V=<3A<<89:;55@V67A<74595=95,2










 

!"#$
%

&'()*(+&)*
,-
/012341524
67837
16
533
193
:0;421<83
6=
>?@
05
835A72B38C
61937D253E
D219
F
16
-
2::<43
735/6453524
GF
/0123415
D96
90H3
A6:/I3138
0II
H0AA24012645E
19373
25
64IJ
0
GK
/76B0B2I21J
6=
6B537H24;5<A9
0
7073
6<1A6:3
2=
193
17<3
735/6453
/76/671264
D373
LFKM
N=
1925
D373
16
90//34E
0AA7<0ID6<I8
B3
5<5/34838
<412I
04
3H0I<01264
6=
193
2::<46I6;2A0I
048
AI242A0I
348/62415
25
<483710O34M

P4IJ
2=
19373
D05
83:645170138
:3721
24
A64124<24;
193
1720IE
5<A9
05
=0H670BI3
AI242A0I735<I15
67
24=67:01264
5<;;35124;
1901
193
A96534
2::<43
735/6453
0550J5
86
461
73=I3A1
3==2A0AJED6<I8
0AA7<0I
B3
736/3438M

Q925
3H0I<01264
D6<I8
B3
8643
24
A645<I101264
D219
193
NRS96I837M

TMUMV
 N1
25
0412A2/0138
1901
,
J3075
6=
0AA7<0I
D2II
B3
73W<2738
24
67837
16
34137
</
16,V/0123415
6416
1925
1720IM
X053864193
0B6H3
3512:0135
048
055<:/12645E
</
16
,TK
6=
3413738
/0123415
:0J
461
90H3
73A32H380II
6=
19327
H0AA243
17301:3415
8<3
16
8253053
/76;7355264M
Y
5<B531
040IJ525
3H0I<0124;
>?@0:64;
/0123415
D96
73A32H38
0II
H0AA243
17301:3415
D2II
B3
/37=67:38
16
0772H3
01
04
3512:0136=
/6134120I
B343=21
6=
H0AA243
24
1925
5<B531M


Z[]^__`a^b`cdef
`hbffifjck
Z[l i`cfbd`_k
cb`jkmfb
`hbffifjcn


ad^efkc
djcfbj`cd^j`_
Q9373250o013720I5
Q7045=37
Y;733:341
poQYq
D219
X26H351
N41374012640IE
N4AM
`r
st
`uvwxuvwy
jz
y{|r
ic`

|r
ws
}sw~v
}|x[

MGMG YAA67824;
16
193
137:5
6=
193
oQY
 `r
st
`uvwxuvwy
jz
y{|r
rvy|sw
|r
ws
}sw~v
v}vwy[
dy
|r
v|w~
vy
ts
{|rys|}
srvr[
a|svry
|r
ws
}sw~v
|ws}vx
|w
y{v
ryx
y{vvtsv
y{v
s}}sysr
}|ryvx
v}s
xs
wsy
{v
vrr
ys
w
xy
s
ru}vr[
X26H351
D2II
90H3
0AA355
16
193










 ¡¢
£¤¤

¤¤

433838
16
5<//671
193
73;251701264
6=
193
Y;341
pN8¥¦§¨
©0AA243q
BJ
193
?SY
24
1925
8253053M
?<71937:673E
X26H351
D2II
B3
/76H2838
50=31J
8010
;34370138
=76:
193
<53
6=
193
Y;341
pN8¥¦§¨
©0AA243q
1901
25
24
193
/655355264
048
A64176I
6=
RN¨
05
433838
16
££¤
ª
«¬­
®¤¯
¤°¤¤¢

¤


¤±



²
¤
<53
=67
73;<I0167J
=2I24;5
64IJM

 ³I242A0I
S010
048
735<I15
<4837
R³N
>7616A6I
´
FF³FG--
:0J
B3
<538
BJ
X26H351
24
6B102424;
?SY
0//76H0I
=67
193
A6::37A20I
:07O3124;
6=
Y;341
pN8¥¦§¨
©0AA243q
/768<A15M

 X26H351
0AA355
16
048
73H23D
6=
N83412=20BI3
>72H013
N4=67:01264
pN>Nq
590II
B3
64IJ
=67
645213
W<0I21J
0<82124;M
X26H351
D2II
73A32H3
N>N
64IJ
=67
/<7/6535
6=
50125=J24;
?SY
67
¤ª
ªª
ª¤¢
£¤®
µ²¶

±¤

ª
££¤
8273A1IJ
73I0138
16
6B102424;
73;<I0167J
0//76H0I
6=
Y;341
pN8¥¦§¨
©0AA243qM
X26H351
25
/7692B2138
=76:
0AA355E
73H23DE
73A32/1E
67
<53
6=
5<A9
24=67:01264
=67
61937
/<7/6535M

 N=193
S010
B324;
/76H2838
25
A6838E
193
>76H2837
pR³Nq
D2II
461
73I3053E
048
193
X26H351
D2II
461
73W<351E
193
O3J
16
193
A683M
X26H351
D2II
461
A6410A1
67
:0O3
04J
3==671
16
283412=J
2482H28<0I5
D96
073
67
:0J
B3
193
56<7A35
6=
S010
D2196<1
5/3A2=2A
D721134
0//76H0I
=76:
>76H2837M










 

!"#$
%

&'()*(+&)*
,-
/010, 3456786
95:4;<76=45
:4;
>?@A45@=BC?
D7;6=?@
76
E=4F?@6
956?;576=457CG
9580
HI
KL
HMNOPMNOQ
RS
QTNIN
UKVVWXKYWQKYI
WYN
OK
VKOZNY
[O\KV\NP
[O
QTN
IQ]P^_
`T[I
[OLKYMWQ[KO
[I
XN[OZ
aNbQ
LKY
T[IQKY[UWV
b]YbKINI_
37;C4@
c0
d7564@G
De0f0
d;0
gD
D;4hi86
f?F?C4A<?56
75h
>?jiC764;k
l::7=;@

E=4F?@6
956?;576=457CG
9580
m,-
d4i6e
nkh?
D7;o
lF?
di=6?
mpq
r7<A7G
cs
mmtqt
uuu0788?56=705?6
f7F=h
v4@?;
f=;?864;
4:
s?j7C
l::7=;@
m,-
d0
nkh?
D7;o
lF?0
di=6?
mpq
r7<A7
cs
mmtqt
w<7=Cx
f<4@?;y788?56=705?6
z_{ }H`~H
`HR~
H~~}~R`


HH`~
`~
re?vrl
u=6e
lh7A6=F?
E=46?8e54C4j=?@
34;A
e7@
B??5
:iCCk
??8i6?h
64
7CC4u
6e?
@7<AC?@
h?@8;=B?h=5
d?86=45
__
64
B?
@e=AA?h
64
lh7A6=F?
E=46?8e54C4j=?@G
34;A0
_}HR
~`
`~`R

_H`RH~

~`
~~`R
45
 ¡¢£¤¢¥
¥¦¦§¨©
¥  
ª¥¨§
¥
§§ª«

¬§­§ª®
¢¥ §
¥ª§
¢ª§
 ?Ck
6e75
:?<7C?@64
B?
7::?86?h
75h
6e=@
u=CC
B?
;?:C?86?h
=5
6e?
j?5h?;
h=@6;=Bi6=45
4:
4i;
87@?@0

¯?
e7F?
@?C?86?h<756C?
8?CC
Ck<Ae4<7@
:4;
=58Ci@=45
=5
6e=@
6;=7C
B?87i@?
6e?k
7;?
845@=h?;?h
64
B?
=58i;7BC?u=6e
8e?<46e?;7Ak0

rei@G
6e?k
u4iCh
A46?56=7CCk
B?5?:=6
:;4<
6e?
i@?
4:
7
54F?C
8e?<46e?;7Ak
;?j=<?5
C=o?
wD°3n>0

lhh=6=457CCkG
6e?
6?@6=5j
4:
7
54F?C
F788=576=45
7AA;478e
64A46?56=7CCk
@6=<iC76?
75
=<<i5?
;?786=45
7j7=5@6
6e?
Ck<Ae4<7
84iCh
;?@iC6
=5
75
=<A;4F?h
8C=5=87C4i684<?0

D76=?56@
i5h?;
6e?
7j?
4:
1±
7;?
?8Cih?h
B?87i@?
<756C?
8?CC
Ck<Ae4<7
=@
;7;?=5k4i5j
A76=?56@G
75h
6e?
=58Ci@=45
4:
75
4887@=457C
k4i5j?;
A76=?56
u=CC
546
A;4F=h?
j?5?;7C=²7BC?
=5:4;<76=45
6e76
u4iCh
³i@6=:k
6e?=;
=58Ci@=45
45
6e=@
Ae7@?
9
@6ihk0
lhh=6=457CCkG
A76=?56@u=6e
n9g
=5:?86=45
u=CC
B?
?8Cih?h
hi?
64
6e?
@?F?;?
=<<i54@iAA;?@@=45
4:
6e=@
6e?;7AkG75h
A;?j5756
4;
5i;@=5j
<46e?;@
7;?
?8Cih?h
B?87i@?
4:
6e?
A46?56=7C
6?;764j?5=8
?::?86@4:6e?;7Ak0
_{H`H`R

~`
RH~
`
~
R~R`
lhiC6@i57BC?
64
j=F?
845@?56
u?;?
?8Cih?h
:;4<
?5;4CC=5j
=5
6e?
A;46484C0

n4u?F?;G
;?
845@?56<7k
B?
5?8?@@7;k
75h
6e?;?
=@
7
A4@@=B=C=6kG
6e4ije
i5C=o?CkG
6e76
@iB³?86@
84iCh
B?84<?
h?8=@=457CCk
=<A7=;?h0
c4;
6e=@
;?7@45
75h
B?87i@?
6e?;?
=@
7
A;4@A?86
4:
h=;?86
B?5?:=6
:;4<
;?@?7;8eA7;6=8=A76=45
´d?86=45
_µ¶G
7CC
@iB³?86@
u=CC
B?
4::?;?h
6e?
4AA4;6i5=6k
64
:=CC
=5
6e?=;
¬¤§¦ªª§§¥ª¨¤¥¨¥ª§®¥¥¥·¸©©·©§§¨¢¥§ª©¤§¹º»¼­¥¨§
f=;?86=F?:4;n?7C6e37;?75hv?h=87C½§§¥ª¨¤¾¥ª©¨£¥©¿¦ª¢©¤¥©¥©¤§ª£§ª¨¥
<7o?h?8=@=45@7B4i66e?=;<?h=87C87;?=56e??F?566e766e?kB?84<?=587A78=676?h4;










 

!"#$
%

&'()*(+&)*
,-
/0123435678
39:;3<6=
=><321
4?6
/0><@6
0A
4?6
@4>=8B
C046D
E?6
FG
0<
HG
I377
/024;/4
4?6
CGJ
HK3734840L02@624
H@@6@@9624
E6;9
MHLHEN
A0<
65;7>;4302
;@
266=6=
A0<
4?6
A0770I321D
;2
32=6:62=624
;@@6@@9624
0A
I?64?6<
;2
32=353=>;7
?;@
4?6
/;:;/348
40
:<053=6
/02@624O
;@@3@4;2/6
323=6243A8321
;2=
;@@6@@321
;2
;::<0:<3;46
@><<01;46
I?62
32=3/;46=O
;2=P0<
;2
;@@6@@9624
0A
4?6
/;:;/34840
;::0324
;
@><<01;46B

Q0<
4?0@6
@>KR6/4@
4?;4
K6/096
32/;:;/34;46=
;2=
=0
204
?;56
:<6S=646<9326=
@>K@434>46
=6/3@302
9;T6<U
4?6
:<0/6=><6@
=6@/<3K6=
32

CGJJVFF
WXF
YZ[
A0<
;::0324321
;
@><<01;46
=6/3@302
9;T6<
A0<
;=>74
@>KR6/4@
I?0
;<6
M;N
=6/3@302;778
39:;3<6=U
;2=
MKN
I?0
=0
204
?;56
;
761;7
1>;<=3;2
0<
=><;K76
:0I6<
0A
;440<268U
I377K6A0770I6=B
\]^_abcdecfghi
hk
laiakgfm
cin
ogmpmqngmrhskhofm
F;43624@9;8
0K4;32
=3<6/4
K626A34
A<09
4<6;49624
I34?
[FXLJSVU
;
<613962
I?3/?
32/7>=6@
202S6t:6<39624;7
/84040t3/
;1624@
;2=
<34>t39;KB
E?6
<3@T@
;2=
K626A34@
0A
[FXLJSV
;<6
/09:;<;K76
40
@4;2=;<=
4<6;49624
;::<0;/?6@B

F;43624@
9;8
;7@0
:046243;778
K626A34
A<09
4?6
3=3048:65;//326B
G4
3@
:0@@3K76
K>4
>2T20I2
3A
026
46/?23u>6
A0<
3=3048:6
3@07;4302
;2=
@/;76S>:
3@@>:6<30<
40
4?6
04?6<
026B

V3@T@
0A
3=3048:6
5;//326
G
:<6530>@
4<3;7@
?;56
K662
=>6
40
;=9323@4<;4302@
0A
vwSLWQ
I34?
0//;@302;7
A656<U
/?377@
;2=
K0=8
;/?6@B

H74?0>1?
34
3@
:0@@3K76
40?;56;73A6S4?<6;462321
;776<13/
<6;/4302U
4?3@
?;@
204
K662
0K@6<56=
32
:<6530>@
4<3;7@B
GA
4?3@
;::<0;/?3@
6AA6/4356U
:;43624@
9;8
K6
=3<6/478
K626A346=B

E?6:046243;7
<3@T@
0A
162643/
46@4321
;<6
;@
0>47326=
32
4?6
32A0<96=
/02@624
=0/>9624
M32/7>=6=P<653@6=
I34?
H962=9624
xNB

E?3@
@4>=8
?;@
;
L6<43A3/;46
0A
L02A3=6243;7348U
I?3/?
yz{|}|z
|z}
z}zy

yz
z}zyz}
{z

y}
}

z
A0</6=40=3@/70@6
4?6
3=624348
0<
;28
32A0<9;4302
/0776/46=
32
4?3@
@4>=8
32
;28
761;7
:<0/66=321@
;44?6A6=6<;7U
@4;46U
0<
70/;7
76567U
<61;<=76@@
0A
I?64?6<
4?68
;<6
/<3932;7U
;=9323@4<;4356U
0<
7613@7;4356
:<0/66=321@B
J0I656<U
4?6
:;43624
0<
4?6
<6@6;</?6<
9;8
/?00@6
40
507>24;<378
=3@/70@64?6
:<046/46=
32A0<9;4302
>2=6<
/6<4;32
/3</>9@4;2/6@B
Q><4?6<90<6U
A6=6<;7
;162/36@
zz
|z}
z}
z
{z
}z}
}y
}


zz}

32A0<9;4302
A0<
;2
;>=34
0<
:<01<;9
65;7>;4302
0<
;2
QH
<6u>6@4
>2=6<
4?6
Q00=U
<>1
;2=
L0@9643/@
H/4B
E?6
L6<43A3/;46
0A
L02A3=6243;7348
I377
204
:<046/4
;1;32@4
4?6
<6u>3<6=
<6:0<4321
K8?0@:34;7
@4;AA
0A
32A0<9;4302
02
@>@:6/46=
/?37=
;K>@6U
<6:0<4;K76
/099>23/;K76
=3@6;@6@U
;2=P0<:0@@3K76
4?<6;4
0A
?;<9
40
@67A
0<
04?6<@B
E?6
:<0/6=><6@
3250756=
32
4?3@
:<040/07U
I34?
4?63<;4462=;24
<3@T@
;2=
=3@/09A0<4@
;2=
:046243;7
K626A34@
I377
K6
/;<6A>778
6t:7;326=
40
4?6
:;43624B
\]^ogmpqlaiakgf
cicdmgm
F;43624@0A462
K626A34
A<09
;=9323@4<;4302
0A
LJXF
;2=
;<6
73T678
40
=6<356
K626A34
A<09
[FXLJSVU
I?3/?
/024;32@
4?6
@;96
;1624@B

F;43624@
9;8
;7@0
K626A34
A<09
4?6
;==34302
0A
4?6
3=3048:65;//326B

H
/7323/;7
4<3;7
0A
3=3048:6
5;//326
32
A0773/>7;<
/6246<
/677
789:?09;@
@>116@4@
4?;4349;8
@439>7;46
399>26S96=3;46=
/76;<78
0A
93239;7
<6@3=>;7
=3@6;@6
;@
;@@6@@6=
K8
FLV
A0<4?6YZSY
4<;2@70/;4302B

GA
4?6
3=3048:6
5;//326
3@
;K76
40
@439>7;46
399>26S96=3;46=
4>90<
/76;<;2/6U
4?3@
I377
K6
;
9;R0<
;2=
39:0<4;24
@46:
32
90<6
6AA6/435678
4<6;4321
789:?09;@B
E?>@U
4?6T20I76=16
4?;4
I377
K6
1;326=
A<09
4?3@
4<3;7
3@
:046243;778
39:0<4;24
;2=
9;8
K6
0A
=3<6/4
K626A3440:;43624@B

v35624?6:<0@:6/40A=3<6/4K626A34U4?3@@;96<3@T@PK626A34@;2;78@3@;::736@;7@040;=>74@I?0
9;8K6/096>2;K7640/02@624=><321:;<43/3:;4302B










 

!"#$
%

&'()*(+&)*
,-
/0124567869
;<54877
=6>
>54?@869=9A56
BCDEFGHIJECKHCL
MNOO
PH
EPLQNCHI
NC
QOO
RQLNHCLK
EC
LSNK
LFNQOT

USHFH
MNOO
PH
CE
GNCEFK
HCFEOOHI
V
WXYHQFKEOI
KE
LSQL
QKKHCL
NK
ZCCHJHKKQFYT

USH
NCDEFGHI
JECKHCL
JECLQNCK
QOO
HOHGHCLK
FH[ZNFHI
DEFJECKHCLT

BC
QIINLNEC\
LSH
]FNCJNRQO
BC^HKLN_QLEF
EF
SNK
IHKN_CHH
MNOO
RFE^NIH
EFQO
JECKHCL
QCI
MNOOPHQ^QNOQPOH
LE
QCKMHF
QOO
RQLNHCL
[ZHKLNECKT

W`TaTWUHOHRSECH
FHcJECKHCL
USHNCDEFGHI
JECKHCL
IEJZGHCL
MNOO
PH
KHCL
LE
LSH
KZPdHJLT

eC
HfROQCQLNEC
ED
LSH
KLZIY
MNOO
PH
RFE^NIHIE^HF
LSH
LHOHRSECH
QDLHF
LSH
KZPdHJL
SQK
SQI
LSH
ERREFLZCNLY
LE
FHQI
LSH
JECKHCL
DEFGT

USHKZPdHJL
MNOO
KN_C
QCI
IQLH
LSH
NCDEFGHI
JECKHCLT

USHEFN_NCQO
NCDEFGHI
JECKHCL
IEJZGHCL
MNOO
PH
KHCL
PQJg
LE
LSH
JECKHCLNC_
NC^HKLN_QLEF
MSE
MNOOKN_CQCI
IQLH
LSH
JECKHCL
DEFG
MNLS
LSH
IQLH
LSH
JECKHCL
MQK
EPLQNCHI
^NQ
LHOHRSECHT


hjkllmnonpkqnr
pstm
uvll
wn
xnqkxynr
zv{
|{vl
jsx
q}n
~kwnpq~
xnpsxr~
USHNCDEFGHI
JECKHCL
RFEJHKK
MNOO
PH
IEJZGHCLHI
NC
LSH
GHINJQO
FHJEFIT

//1;=<@=48?9A4=
A65<@=9A56
//1/8;54<A9?A@=
WWTWTWYJOERSERSQGNIH
EGGHFJNQO
RSQFGQJY
KZRROY
MNOO
PH
ZKHIT

e^QNOQPOH
NC
MSNLH
JFYKLQOONCH
DEFGZOQLNEC
DEF
NCLFQ^HCEZK
NCdHJLNEC\
NC
^NQOK
JECLQNCNC_
W``
G_\
,``
G_\
a``
G_\
O
_G\
QCI
,
_GT
eOO
RFHRQFQLNECK
QFH
KLQPOH
QL
FEEG
LHGRHFQLZFH
CEL
LE
HfJHHI
`
T
HJECKLNLZLH
MNLS
QRRFERFNQLH
QGEZCLKED
KLHFNOH
MQLHF
LE
RFEIZJH
Q
DNCQO
JECJHCLFQLNEC
ED
,`
G_GOT
NKJQFI
KEOZLNEC
QDLHF
,
SEZFKQLFEEG
LHGRHFQLZFHT
LQPOH
ZR
LE
-
IQYK
ND
FHDFN_HFQLHI
,c
X
T
eIGNCNKLHF
B
NC
W``
`TQO
E^HF
Wa
GNCT
UEfNJNLNHK
GYHOEKZRRFHKKNEC\
CQZKHQ
QCI
^EGNLNC_\
SHGEFFSQ_NJ
JYKLNLNK\QOERHJNQT
YKLNLNK
JQC
PH
OQF_HOY
RFH^HCLHI
PY
GQNCLQNCNC_
Q
_EEI
KLQLH
ED
SYIFQLNEC
QCI
_EEIZFNCH
DOEM
IZFNC_
QCI
QDLHF
IFZ_
QIGNCNKLFQLNEC
ZKNC_
LSH
DEOOEMNC_

 ¡¢¡£¤

eOORQLNHCLK
KSEZOI
FHJHN^HI
CEFGQO
KQONCH
QL
LSH
DEOOEMNC_
^EOZGHK
PQKHI
EC
JYJOERSEKRSQGNIH
IEKHOH^HOK
QCI
FQLHK
MNLS
SQOD
_N^HC
PHDEFH
QCI
SQOD
_N^HC
QDLHF
LSH
JYJOERSEKRSQGNIH
NCdHJLNECT


¥ ¦H^HOK
Wc,

W
ONLHF

§
``ca``
JJSF
¥ ¦H^HOK
ca

,
ONLHF

§
``ca``
JJSF
¥ ¦H^HOK
¨
-

,Ta
ONLHF

§
``ca``
JJSF
WWTWT,EfEFZPNJNC
EGGHFJNQO
RSQFGQJY
KZRROY
MNOO
PH
ZKHIT

e^QNOQPOH
NC
W`\
,`\
a`\
QCI
Wa`
G_
^NQOK
MNLS
a`
G_\W``G_\
QCI
,a`
G_
ED
OQJLEKH\
FHKRHJLN^HOY©
LSH
LSFHH
IEKQ_H
KLFHC_LSK
QFH
FHJECKLNLZLHI
MNLS,GO\

GO\
W`
GOT
QCI
`
GO
ED
CEFGQO
KQONCH
EF
KLHFNOH
MQLHF
DEF
NCdHJLNEC\
FHKRHJLN^HOY\
_N^NC_QDNCQO
IFZ_
JECJHCLFQLNEC
ED
a
G_GOT
HJECKLNLZLHI
KEOZLNEC
NK
KLQPOH
DEF
,
SEZFK
QL
FEEGLHGRHFQLZFH
QCI
DEF
X
SEZFK
ZCIHF
FHDFN_HFQLNEC
QCI
KSEZOI
PH
RFELHJLHI
DFEG
KZCON_SLT
UEfNJNLNHK
ªYHOEKZRRFHKKNEC\
KLEGQLNLNK\
QOERHJNQ\
CQZKHQ
QCI
^EGNLNC_\
QCI
QJZLH
QCI
JSFECNJ
JQFINQJLEfNJNLY\
GQCNDHKLHI
QK
QFFSYLSGNQK
EF
Q
JEC_HKLN^H
JQFINEGYERQLSY\
LSH
OQLLHF
ZCJEGGECQLLELQOJZGZOQLN^HIEKHKOHKKLSQCa``G_G,TUSHIFZ_JQZKHKOEJQOCHJFEKNKND
NCDNOLFQLHINCLEKZPJZLQCHEZKLNKKZHT










 

!"#$
%

&'()*(+&)*
,-
//0/01345674895:
;<==:764>?
@A>7=>6B
8C@@?B
D4??
E:
C8:F0

GH>4?>E?:
45
I
=JK
,
=JK
>5F
L
=J
H4>?
84M:80
N>6A
=?6<59>458
I
=J
<O
H456748945:K
/PP
=J
=>5549<?K
/01
=J
=:9AB?@>7>E:5K
>5F
P0,
=J
@7<@B?@>7>E:50
Q7CJ
8A<C?F
E:
89<7:F
>9
,RST;
>5F
8A<C?F
E:
@7<9:69:F
O7<=
?4JA90
U<V46494:8W
@:74@A:7>?
5:C7<@>9ABK
>C9<5<=46
5:C7<@>9ABK
>?<@:64>0
X<6>?
5:67<848
4O
45Y:69:F
8CE6C9>5:<C8?B0
//0/0ZN9<@<84F:
;<==:764>?
@A>7=>6B
8C@@?B
D4??
E:
C8:F0

GH>4?>E?:
>8
>
6<56:597>9:
O<7
@>7:59:7>?
C8:
45
/PP
=JH4>?8[:>6A
=?
6<59>458
,P
=J
:9<@<84F:K
,
=J
649746
>64FK
1P
=J
E:5MB?
>?6<A<?K
SP
=J
@<?B8<7E>9:
SPK
\LP
=J
<O
@<?B:9AB?:5:
J?B6<?
1PPK
>5F
1P0L]
>?6<A<?0
Q7CJ
8A<C?F
E:
F4?C9:F
E:O<7:>F=454897>94<5
45
QL^
<7
5<7=>?
8>?45:0
U<V46494:8W
=B:?<8C@@7:884<5K
5>C8:>K
H<=4945JK
>5>@AB?>6946
7:>694<58K
>?<@:64>K
>5F
AB@<9:584<5
4O
45OC84<5
48
9<<
7>@4F0
_ GQ`IaIbUcGUIda
de
3Ia;cIbUaNfQdgdchiI;IafNUdjdbIQN0
b9>E4?49B
89CF4:8
6<5FC69:F
EB
9A:
jA>7=>6:C946>?
Q:H:?<@=:59
b:7H46:K
jA>7=>6B
Q:@>79=:59K
aIk
;?4546>?
;:59:7K
A>H:
F:=<5897>9:F
9A>9
>F=4V9C7:8
<O
H456748945:K
F<V<7CE4645K
>5F
:9<@<84F:
45
P0l]
b<F4C=
;A?<74F:
I5Y:694<5K
hbj
>9
6<56:597>94<58K
7:8@:694H:?BK
<O
/K
,L
>5F
/,L
=6Jf=XR
/0ZK
1L
>5F
/-L
=6Jf=X[
,K
LP
>5F
,LP
=6Jf=X[
>5F
,0SK
-P
>5F
1LP
=6Jf=X
>7:
89>E?:
O<7
>9
?:>89
1\
A<C78
>9
7<<=
9:=@:7>9C7:
DA:5
@7<9:69:F
O7<=
?4JA90
G?8<
>F=4V9C7:8
6<59>4545J
H456748945:K
F<V<7CE4645
>5F
:9<@<84F:
6<56:597>94<58
<O/0\K
ZP
>5F
,PP
=6Jf=X
>7:
89>E?:
O<7
>9
?:>89
1P
A<C78
>9
1,
F:J7::8
;0
I5
9A48
89CFBK
UkN
QGIXm
QdbN
n40:0
,Z
A<C7
8C@@?Bo
<O
H456748945:K
F<V<7CE4645
>5F
:9<@<84F:
D4??
E:>F=4V:F
9<J:9A:7
45
LPP
=X
<O
P0l]
b<F4C=
;A?<74F:0
I5Y:694<5
>5F
F:?4H:7:F
D49A
>
8C49>E?:
45OC84<5
@C=@
9A7<CJA
>
6:597>?
H:5<C8
>66:88
F:H46:0
UA:
E>J
D4??
E:
:V6A>5J:F
F>4?B
O<7
:>6A
<O
9A:
O<C7
F>B8
9<
6<=@?:9:
9A:
l\
A<C7
45OC84<50
;B6?<@A<8@A>=4F:
D4??
E:
F4?C9:F
45
/PP
=X
<O
QL^
<7
ab
>5F
45OC84<5
<H:7
/L
=45C9:80
j>94:598
D4??
E:
45897C69:F
9<
F745p
>5
>F:qC>9:
>=<C59
<O
O?C4F8
>5F
:=@9B
9A:47
E?>FF:78
O7:qC:59?B
FC745J
6B6?<@A<8@A>=4F:
>F=454897>94<50
//0/0Lj7:F548<5:
;<==:764>?
@A>7=>6B
8C@@?B
D4??
E:
C8:F0

GH>4?>E?:
45
>
?>7J:
5C=E:7
<O
<7>?
F<8>J:
897:5J9A8
456?CF45J@4??8
>5F
?4qC4F
O<7=C?>94<580
U>E?:98
8A<C?F
E:
89<7:F
45
D:??R6?<8:F
6<59>45:78
>9
9:=@:7>9C7:8
E:9D::5
/LR1PT;0
U<V46494:8W
@7<V4=>?
=C86?:
D:>p5:88K
J?C6<8:
459<?:7>56:K
9A45545J<O
8p45K
7:F48974EC94<5
<O
E<FB
O>9K
;C8A45J<4F
O>64:8K
4==C5<8C@@7:884<5K
>5F
@7<@:5849B
9<
J>897<459:8945>?
C?6:7>94<50
//0/0\c49CV4=>E
;<==:764>?
@A>7=>6B
8C@@?B
D4??
E:
C8:F0

c49CV4=>E
48
@7<H4F:F
/P
=?
n/PP
=Jo
>5F
LP
=?
nLPP=Jo@A>7=>6:C946>?
J7>F:
J?>88
H4>?8
>9
>
6<56:597>94<5
<O
/P
=J
<O
@7<9:45
@:7
=?0
b9<7>J:W
c49CV4=>E
O<7
6?4546>?
C8:
8A<C?F
E:
89<7:F
45
>
8:6C7:
7:O74J:7>9<7
>9
,
9<
S
T;0
c:6<58949C94<5
>5FQ4?C94<5W
UA:
>594E<FB
8A<C?F
E:
F4?C9:F
459<
>
O45>?
H<?C=:
<O
P0l]
8<F4C=
6A?<74F:
<7
L]
F:V97<8:45
D>9:7
O<7
O45>?
6<56:597>94<5
<O
/RZ
=Jf=?0
;>C94<5
8A<C?F
E:
9>p:5
FC745J
9A:
@7:@>7>94<5
<O
9A:
F7CJK
>8
8A>p45J
6>5
6>C8:
>JJ7:J>94<5
>5F
@7:64@49>94<5
<O
9A:
>594E<FB0
c49CV4=>E8<?C94<58O<745OC84<5>7:89>E?:>9,RSF:J7::8;n1\RZ\F:J7::8eoO<7,ZA<C78>5F
>97<<=9:=@:7>9C7:O<7>5>FF494<5>?/,A<C780GF=454897>94<5Wc49CV4=>ED4??E:>F=45489:7:F
>8>54597>H:5<C845OC84<5>91-L=Jf=,
<5F>B/<O:>6A6B6?:<ONjd;k4==:F4>9:?B@74<79<










 

!"#$
%

&'()*(+&)*
,-
/012/34/56
/01
786927582
56
:01;5/0143<=>
?7/9@7;3A
786927582
B7CC
A1
3D;7872/141D
/5
<3/718/2
783859/<3/718/
:C787:
21//78E>
F43C
<41G;1D7:3/758
H,
/3AC1/2
56
3:1/3;785<018
38D
IJGKJJ
;E
D7<0180=D43;781
0=D45:0C547D1L
B7CC
A1
3D;7872/141D
MJ
/5
NJ
;789/12
<4754
/5
2/34/78E
13:0
7869275856
47/9@7;3A>
O
<147<0143C
54
:18/43C
78/43P18592
C781
B7CC
A1
12/3AC7201D>
Q9478E
/01
47/9@7;3A78692758R
/01
<3/718/S
2
P7/3C
27E82
HAC55D
<4122941R
<9C21R
412<743/758R
/1;<143/941L
2059CDA1;587/541D
1P14=
KI
;789/12
/7;12
T
54
98/7C
2/3AC1
38D
/018
0594C=
98/7C
/01
78692758
72
D72:58/7891D>
OP37C3AC1
3/
/01
A1D27D1
<4754
/5
47/9@7;3A
3D;7872/43/758
B7CC
A1
1<781<04781
654
29A:9/381592
78U1:/758R
D7<0180=D43;781
0=D45:0C547D1
654
78/43P18592
78U1:/758R
38D
41292:7/3/758
1V97<;18/
654
/01
1;14E18:=
;383E1;18/
56
383<0=C3:/57D
413:/7582>
W01
787/73C
D52143/13/
/01
/7;1
56
/01
6742/
47/9@7;3A
78692758
2059CD
A1
IJ;EX04
654
/01
6742/
0594>
Y6
85
/5@7:7/=722118R
/01
D521
43/1
;3=
A1
12:3C3/1D
E43D93CC=
HIJ
;EX04
78:41;18/2
3/
MJ
;789/1
78/14P3C2L/5
3
;3@7;9;
56
TJJ
;EX04>
Y6
/01
6742/
D521
56
47/9@7;3A
72
B1CC
/5C143/1DR
/01
2/34/78E
6C5BG43/1654
/01
3D;7872/43/758
56
29A21V918/
D5212
B7CC
A1
KJJ
;EX04
/018
78:41321D
E43D93CC=
HKJJ;EX04
78:41;18/2
3/
MJ
;789/1
78/14P3C2L
85/
/5
1@:11D
TJJ
;EX04>
ZO[WYF\]
QF
\FW
OQ^Y\Y_W`?
O_
O\
Y\W?Oa`\F[_
b[_c
F?
dFe[_>
W5@7:7/712]
Z5;;58
/5@7:7/712
78:C9D161P14R
:07CC2R
839213R
32/01873R
013D3:01R
38E751D1;3R
<4947/92
38D
4320>
e19f5<1873
5::942783<<45@7;3/1C=
KJg
A9/
E43D1
M
54
T
819/45<1873
72
98:5;;58>
c=<5/182758
5::9441D
78KJg56<3/718/2
D9478E
47/9@7;3A
78692758R
38D
2147592
A458:052<32;
38D
94/7:3473
3225:73/1D
B7/047/9@7;3A
78692758
13:0
5::9441D
78
61B14
/038
KJg
56
<3/718/2>
e122
:5;;58
/5@7:7/712
78:C9D13AD5;783C
<378R
P5;7/78ER
/045;A5:=/5<1873R
381;73R
;=3CE73R
34/043CE73R
D7hh78122R
38D
40787/72>
KK>K>ik7CE432/7;
H\19<5E18lL
Z5;;14:73C
<034;3:=
29<<C=
B7CC
A1
921D>

Y/
72
<45P7D1D
78
/B5
P73C
27h12
56
MJJ
38D
TIJ
mEX;e>Y/
2059CD
A1
2/541D
3/
,G-S
Z
HD5
85/
6411h1L
38D
72
2/3AC1
654
3/
C132/
Y
=134
3/
/072
/1;<143/941>
W5@7:7/712]
?341
383<0=C3:/7:
413:/7582
B7/0
/01
6742/
D521n
A581
<378
3/
27/12
56
3:/7P1;3445B
B7/0
:58/7891D
3D;7872/43/758>
e5:3C
413:/7582
3/
78U1:/758
27/12>
Z582/7/9/7583C
2=;</5;2R
78:41321D
3Cf3C781
<052<03/321R
eQcR
947:
3:7Dn
B5421878E
56
<41G1@72/78E
786C3;;3/54=
:58D7/7582>
KK>K>-YDGoec
a3::781
YD75/=<1<45/178
645;
/01
78D7P7D93C
d
:1CC
C=;<05;32
B7CC
A1
5A/3781D
9278E
/B5
D7661418/
;1/05D2>W01
6742/
KM
<3/718/2
H3::493C
:5;<C1/1DL
B7CC
41:17P1
P3::781
;38963:/941D
B7/0
7D75/=<1725C3/1D
9278E
3
25;3/7:
0=A47D5;3
/1:087V91>

W01
21:58D
KM
<3/718/2
B7CC
41:17P1
P3::781;38963:/941D
B7/0
7D75/=<1
;38963:/941D
B7/0
7D75/=<1
725C3/1D
A=
41:5;A7838/
/1:087V912>

YD75/=<1
725C3/1D
A=
17/014
/1:087V91
B7CC
A1
:5P3C18/C=
:59<C1D
/5
f1=05C1
C7;<1/
01;5:=3878
HoecL
9278E
/01
7D18/7:3C
/1:087V912
38D
:58/43:/54>

OCC
P3::7812
B7CC
A1
<45D9:1D
3::54D78E/5
p55D
^38963:/9478E
b43:/7:12
2/38D34D2
38D
/12/1D
654
2/147C7/=R
18D5/5@78
:58/3;783/758R
38D
E18143C
2361/=
<4754
/5
7/2
921
78
38=
<3/718/>

W01
<41<343/758
38D
V93C7/=
:58/45CXV93C7/=
3229438:1
/12/78E
56
/01
YDGoec
:58U9E3/1
B7CC
A1
<14654;1D
A=
W_Y
q32078E/58
98D14QZ_X\ZY
:58/43:/>

W01
Y\Q
654
/01
YDGoec
P3::781
B7CC
A1
01CD
A=
/01
Q49E
?1E9C3/54=
O663742_1:/758R
ZW`b>
c5B
_9<<C71D]
k54;9C3/1D
<45D9:/
654
29A:9/381592
3D;7872/43/758
:58/3782J>I
;E
76
YD
38D
oec
13:0
<14
;C
56
854;3C
23C781>

YDGoec
B7CC
A1
29<<C71D
32
3
K
;C
P73C>
r _/543E1Gb4754/53D;7872/43/758RYDGoecB7CCA12/541D3/G,J5Z>










 

!"#$
%

&'()*(+&)*
,-
/ 123454678974:5
;
<5=
:>
7?=
>:@@:A45B
45C=674B97:86
A4@@
D=
9C94@9D@=
>:8
C9EE45=
F8=F98974:5G
H86I
JA9KL
M4@6:5
:8
N:A@=8I

1>7=8
7?9A45B
952
B=57@=
9B47974:5L
7?=
C49@
E:57=576
6?:O@2
D=
289A5
OF
O645B
95
PQRB9OB=
5==2@=
:5
9
6S845B=I

1>7=8
7?=
=5748=
E:57=576
?9C=
D==5
289A5
OFL
9
,TRB9OB=
5==2@=
>:8
45U=E74:5
39S
8=F@9E=
7?=
PQRB9OB=
5==2@=I
V?46
F8:E=2O8=
46
43F:87957
7:
=56O8=
7?97
9@@
F9874EO@97=6
W5:839@
E:3F:5=576
:>
7?46
C9EE45=X
98=
:D7945=2
>8:3
7?=
C49@I
/ V:Y4E47S
R
V:Y4E474=6
2=6E84D=2
A47?
Z2RJ[\
C9EE45=
923454678974:5
45E@O2=
@:E9@
647=
8=9E74:56
W=8S7?=39L
452O8974:5L
6A=@@45B
952
7=52=85=66XL
>=C=8L
E?4@@6L
896?L
3S9@B496
952
987?89@B49I

]4@2
=@=C974:56
45
E8=974545=
F?:6F?:K4596=
W^_JX
?9C=
D==5
:D6=8C=2I
PPIPI-`]R^aN
Wa98B893:6743G
ba^
cdPef-Tg
hhRZbH
,de,X
/ a:O8E=
952
_?9839E:@:BS
R
V?=
`]R^aN
7:
D=
O6=2
45
7?46
67O2S
46
B@SE:6S@97=2L
8=E:3D45957
?O395
`]R^aNI

V?46
`]R^aN
46
95
9@7=8=2
>:83
:>
7?=
5974C=
3:@=EO@=g
7?=
F:6474:5
,e
98B4545=
?96
D==5
8=F@9E=2
A47?
9
@=OE45=
7:
>9E4@4797=
=YF8=664:5
:>
7?=
F8:7=45
45
S=967
Wa9EE?98:3SE=6
E=8=C4649=XI
/ N:83O@974:5
952
a79D4@47S
R
V?=
`]R^aN
46
>:83O@97=2
96
9
A?47=
@S:F?4@4i=2
E9K=
952
46
F8:C42=2
45
C49@6
E:5794545B
Tjj
kB
:>
7?=
`]R^aN
F8:7=45
96
A=@@
96
PjIj
3B
:>
6OE8:6=L
ljIj
3B
:>
395547:@L
952
PI,
3B
:>
V846
WV843=7?9345=XI
V:
F8=F98=
9
C49@
:>
`]R^aN
>:8
248=E7
6ODEO795=:O6
O6=L
96=F74E9@@S
45U=E7
PIj
3@
:>
a7=84@=
M97=8
>:8
Z5U=E74:5L
ma_L
457:
7?=
C49@
7:
2466:@C=
7?=
@S:F?4@4i=2
E9K=I

V?=
24@O=57
6?:O@2
D=
248=E7=2
9B94567
7?=
642=
:>
7?=
C49@
7:
9C:42
=YE=66
>:9345BI
1C:42
C4B:8:O6
9B47974:5
:>
7?=
C49@g
2:
5:7
6?9K=I

V?46
S4=@26
9
6:@O74:5
E:5794545B
Tjj
kBn3@I

V?=
O58=E:56747O7=2
397=849@
6?:O@2
D=
K=F7
8=>84B=897=2
97
,RQ:^
952
46
679D@=
>:8
97
@=967
=4B?7==5
3:57?6I

<5E=
8=E:56747O7=2L
7?=
6:@O74:5
46
679D@=
>:8
97
@=967
,l
?:O86
97
,RQ:^
:8
97
PQR,T:^I

h=E9O6=
7?=
F8:2OE7
2:=6
5:7
E:57945
9
F8=6=8C974C=L
C49@6
6?:O@2
D=
78=97=2
96
O547R2:6=
E:57945=86g
8=E:56747O7=2
6:@O74:5
6?:O@2
D=
?=@2
97
,RQ:^
952
246E982=2
9>7=8
5:
3:8=
7?95
64Y
?:O86I

H:
5:7
>8==i=
`]R^aNI
/ aOFF@4=8
R
]95O>9E7O8=2
DS
Z33O5=YI

M4@@
D=
F8:C42=2
DS
^Vo_I
/ p:O7=
:>
123454678974:5
R
V?=
9FF8:F8497=
7:79@
2:6=
46
A47?289A5
457:
952
92345467=8=2
>8:3
9
F@9674E
7OD=8EO@45
6S845B=I

V?=
`]R^aN
A4@@
D=
45U=E7=2
6ODEO795=:O6@S
96
E@:6=
96F:664D@=
7:
7?=
Z2RJ[\
45U=E74:5
647=I

1@@
`]R^aN
2:6=6
>:8
=9E?
F974=57
A4@@
D=
92345467=8=2
DS
7?=
5O8645B
679>>
45
7?=
:O7F974=57
O547I
/ V:Y4E47S
R
V:Y4E474=6
2=6E84D=2
45
F974=576
8=E=4C45B
`]R^aN
45E@O2=G
N=C=8L
E?4@@6L
249F?:8=646L
3S9@B496L
>974BO=L
39@946=L
?=929E?=L
24ii45=66L
2S6F5=9L
D8:5E?:6F963L
F@=O89@
=>>O64:5L
95:8=Y49L
4524B=674:5L
59O6=9L
C:34745BL
24988?=9L
45U=E74:5
647=
7=52=85=66L
O874E9849L
896?L
F8O847O6L
?SF=86=56474C47S
8=9E74:5L
D:5=
F945L
7?8:3D:=3D:@4E
=C=576L
F?@=D4746L
?SF:7=564:5L
F=84F?=89@
=2=39L
@=OK:ES7:646L
7?8:3D:ES7:646
:8
7?8:3D:ES7:F=549L
?=F974E
=5iS3=
9D5:839@474=6L
952
D4@48OD45
=@=C974:5I
V?=
>4867
923454678974:5
:>
`]R^aN
?96
F8:C:K=2
9
6S528:3=
:>
2S6F5=9
952
?SF:7=564:5
A47?45
7A:
?:O86
9>7=8
`]R^aN
45U=E74:5
45
9
645B@=
F974=57
8=E=4C45B
S=967R2=84C=2
`]R^aNg
7?467SF=:>8=9E74:5?963:8=>8=qO=57@SD==5:D6=8C=245F974=5768=E=4C45B`]R^aN
F8:2OE=245oIE:@4I<5=8=F:87:>9C96EO@98@=9KR@4K=6S528:3=:EEO8845B9>7=8
9O7:@:B:O6D:5=3988:A78956F@957459F974=578=E=4C45BE:5745O:O6Zr45>O64:5:>`]R
^aN?96D==58=E:82=2I










 

!"#$
%

&'()*(+&)*
,-
/013454346748

:;=>?@>ABCDE>D
F
FG
HDI?JKE>
L
-;M
NKAJO>
P>OO
OQIRSTIKU
HA
>AJ?JQ
PTI>@
TV
KE>;
WOTTX
YZM
[[Y,U[[\[G
:\\]
^;_?@S>D`
aM
NKAJO>UP>OO
OQIRSTIKM
bOK@@?V?PKJ?TA
KAX
JS>DKR>CJ?P
?IRO?PKJ?TA@;
HAAKO@
TV
cAPTOTEQ
Z
deCRRO;
]fM
g,gUg,\G
:\\]
,;HDI?JKE>
LcM
NKAKE>I>AJ
TV
IKAJO>
P>OO
OQIRSTIK;
cAPTOTEQ
O^M
[\UggG
:\\Y
[;h?JJKOCEK
eG
W?iA>A@
aG
j>TXTDTk?P
aG
>J
KOM

bO?A?PKO
KAKOQ@?@
TV
]Z-
PK@>@
?A
JlT
JD?KO@
TV
JS>
mCDTR>KA
cDEKA?nKJ?TA
VTD
JS>
`>@>KDPS
KAX
jD>KJI>AJ
TV
bKAP>D
oQIRSTIK
bTTR>DKJ?k>
pDTCR
eCBJQR>
KPPTDX?AE
JT
JS>
`>k?@>X
mCDTR>KAUHI>D?PKA
bOK@@?V?PKJ?TA
TV
oQIRST?X
q>TROK@I@M

H
PTIRKD?@TA
l?JS
JS>
=TDr?AE
_TDICOKJ?TA;
WOTTX
YZM[,gYU[,]ZG
:\\];
g;j>TXTDTk?P
aG
h?JJKOCEK
eG
sOC?AUq>O>ITA@
LG
>J
KOM
mVV?PKPQ
TV
VTCD
X?VV>D>AJ
D>E?I>A@
?A
][
IKAJO>
P>OO
OQIRSTIK
PK@>@M
bO?A?PTRKJSTOTE?P
PTIRKD?@TA
l?JS
[\Y
TJS>D
ATAUtuvwxyz{|
OQIRSTIK
@CBJQR>@;
L
bO?A
cAPTO
:,M
^Y:\U^Y^]G
:\\g;

];~>OX>D@
pHG
sOC?AUq>O>IKA@
LbG
F>
WT>D
bLG
>J
KOM
NKAJO>
P>OO
OQIRSTIKM
H
hTRCOKJ?TAU
WK@>XbO?A?PKO
eJCXQ;
L
bO?A
cAPTO
:[M
:^]\U:^Z[G
:\\];

Z;?XX>IKAA
=G
AJ>DSKOJ
NG
>DDIKAA
`G
>J
KOM
NKAJO>
P>OO
OQIRSTIK@
SKk>
ITD>
l?X>@RD>KX
X?@>K@>
KAX
@OTl>D
D>@RTA@>
JT
PS>ITJS>DKRQ
PTIRKD>X
l?JS
VTOO?PO>
P>AJ>D
OQIRSTIK@M
`>@COJ@
TV
K
RDT@R>PJ?k>
PTIRKDKJ?k>
KAKOQ@?@
TV
JS>
p>DIKA
OTlUEDKX>
OQIRSTIK
@JCXQ
EDTCR;
L
bO?A
cAPTO
:]M
:\^^U:\,-G
:\\Y;

Y;eKIKSK
G
FCITAJ>J
bG
s>JJ>D>D
qG
>J
KOM
NKAJO>
P>OO
OQIRSTIKM
H
D>JDT@R>PJ?k>
@JCXQ
TV
:^:PK@>@;
o>Cr>I?K
O^M:^Y:U:^Y:G
:\\Y;

\;CPPKmG
_TAJKAKG
eG
`TEE>DT
mG
>J
KOM
jD>KJI>AJ
KAX
RDTEAT@?@
TV
P>AJDTPQJ?P
dIKAJO>
P>OOf
OQIRSTIKM
H
D>JDT@R>PJ?k>
KAKOQ@?@
TV
^]
RKJ?>AJ@
JD>KJ>X
?A
TA>
?A@J?JCJ?TA;

o>Cr
oQIRSTIK
:,M:-gU::-G
:\\[;
:-;HDI?JKE>
LG
>J
KO
djS>
ATAUtuvwxyz{|
u
||yyyuz
u

yzy
>kKOCKJ?TA
TV
JS>
aAJ>DAKJ?TAKO
oQIRSTIK
eJCXQ
pDTCR
POK@@?V?PKJ?TA
TV
ATAUtuvwxyz{|
OQIRSTIK;
WOTTX
Y\M,\-\U,\:YG
:\\Z;
::;sSTCD?
a_G
`TIKEC>DK
LG
sKAJKDi?KA
G
>J
KOM
QR>DUb~HF
KAX
S?ESUXT@>
I>JSTJD>KJ>PQJKDKB?A>
VTOOTl>X
BQ
@J>IUP>OO
JDKA@ROKAJKJ?TAM
HA
KPJ?k>
D>E?I>A
VTD
KEED>@@?k>
IKAJO>UP>OO
OQIRSTIK;

L
bO?A
cAPTO
:]M,Y-,U,Y-\G
:\\Y;
:^;_D>>XIKA
HeG
q>CB>DJ
FG
pD?BB>A
LpG
>J
KOM
?ESUXT@>
PS>ITDKX?TJS>DKRQ
KAX
KAJ?UWUP>OO
ITATPOTAKO
KAJ?BTXQURCDE>X
KCJTOTETC@
BTA>
IKDDTl
JDKA@ROKAJKJ?TA
?A
IKAJO>UP>OO
OQIRSTIK
qT
>k?X>AP>
VTD
OTAEUJ>DI
D>I?@@?TA;
L
bO?A
cAPTO
:]M,UgG
:\\Y;

:,;TlKDX
cG
pD?BB>A
LG
q>CB>DE
FG
>J
KOM
`?JCKAbch
?AXCPJ?TA
JS>DKRQ
?A
A>lOQ
X?KEAT@>X
RKJ?>AJ@
l?JS
IKAJO>
P>OO
OQIRSTIK;
hDTP
HI
eTP
>I>
\[MKB@DJ
^Y-[G
:\\\;
:[;=?O@TA
=G
WDQKAJ
pG
WKJ>@G
eG
>J
KOM
mhcb
PS>ITJS>DKRQM
jT?P?JQ
KAX
>VV?PKPQ
?A
D>OKR@>X
KAX
D>VDKPJTDQ
ATAUtuvwxyz{|
u

yz
zu

  
:g;=?O@TA
=G
pDT@@BKDX
NoG
HOkKD>n
NG
>J
KOM
FT@>U>@PKOKJ?AE
mhcb
PS>ITJS>DKRQ
?A
RD>k?TC@OQ
CAJD>KJ>X
OKDE>
P>OO
OQIRSTIK;
hDTP
HI
eTP
cAPTO
:ZM]gG
:\\Y

:];bDCPnIKA
NeG
pD?OOTUoTR>n
HLG
=S?J>
bHG
>J
KOM
jD>KJI>AJ
TV
RKJ?>AJ@
l?JS
OTlUEDKX>
WU
P>OOOQIRSTIK
l?JS
JS>
PTIB?AKJ?TA
TV
PS?I>D?P
KAJ?UbF^-
ITATPOTAKO
KAJ?BTXQ
KAX
bch
PS>ITJS>DKRQ;
L
bO?A
cAPTO
:ZM^]YG:\\\
:Z;eJ>k>A@TApjGeJ>k>A@TA_sMHAJ?BTXQJTITO>PCOKDOQX>V?A>XKAJ?E>APTAV?A>XJTKJCITD
P>OO@CDVKP>;qKJCD>:\ZgG^g[MZ:[U]










 

!"#$
%

&'()*(+&)*
,-
-/0234353678
29
:35;6
<=>
?@AB3CC@6;DE3F;
86A3GBH3;5
AB
A7;
E3I86HDG36H36I
53A;5
BJ
CK;EBC8
L4BA;3650

M4BN
=8AE
?N8H
2N3
O2?
P/>,-,QD,-,R9
-ST-
-S0UB4I;65;6
V9
W8@H;468NF
W9
<866;5A8H
X>

YCC@63Z8A3B6
[3A7
A7;
E3I7A
N7836
86H
A7;
\]
HBC836
BJ
A7;
35BEBIB@5
CK;EBC8
L4BA;36
,-R
3673G3A5
I4B[A7
BJ
CB@5;
LE85C8NKABC8
^_M`D,-R0

2N86H
U
YCC@6BE
-->aSD,R9
-S/Q
aQ0b8E;K^U9
W;G;E
<^9
]K6N7
cW>

YH3BAKL;D5L;N3J3N
A4865LE86A8A3B6
4;535A86N;
AB
^_M`D
,-R>?G4BI8A3B6
GK
LB5AD3CC@63Z8A3B6
A7KC;NABCK0

U
YCC@6BE
-aQ>-PaQD-Pad9
-ST/
a-0e43HI;5
2<>

M84A3N3L8A3B6
BJ
A7;
7@CB48E
3CC@6;
5K5A;C
36
A7;
CK;EBC8D5L;N3J3N
A4865LE86A8A3B6
4;535A86N;0

U
YCC@6BE
-a->dTSDd/,9
-ST/
aa0f4;;HC86
M^9
?@A4K
Uc9
VBF@H8
29
g3EE38C5
c`9
U4>

V@CB4
3CC@63AK
36H@N;H
GK
L4;3CC@63Z8A3B6
[3A7
e?]ehN
CB@5;
CK;EBC8
L4BA;360

U
=8AE
`86N;4
Y65A
RP>T,RDTdQ9
-STP
a,02@I8329
M8EC;4
bg9
V8E8E
=9
g3AZ
YM>
M4BA;NA3i;
86H
N;EE@E84
3CC@6;
4;5LB65;5
AB
3H3BAKL3N
H;A;4C3686A5
B6
N;EE5
J4BC
8
5LB6A86;B@5
EKCL7BC8
BJ
=jeh=jgf-
C3N;0

U
:kL
^;H
-dQ>-RdTD-RR/9
-STd
ad02A;i;65B6
fX9
WB4HB6
U>
YCC@63Z8A3B6
[3A7
3H3BAKL3N
3CC@6BIEBG@E36
L4BA;NA5
8I8365A
H;i;EBLC;6A
BJ
e
EKCL7BNKA3N
E;@F;C389
G@A
;C;4I36I
A@CB4
N;EE5
N86
;i8H;
86A3GBHK
8AA8NF
GKCBH@E8A3B60

U
YCC@6BE
-,Q>STQDST,9
-S/,
aR0X8C365F3
^29
X3A8C@48
X9
^8EB6;K
bW9
];iK
c>

YH3BAKL;
i8NN368A3B6
8I8365A
C@436;
e
N;EEEKCL7BC80

Y673G3A3B6
BJ
A@CB4
3CC@63AK
GK
J4;;
3H3BAKL;
L4BA;360

U
YCC@6BE
-,/>-a/SD-aSP9
-S/T
aP0X[8F]g9
`8CLG;EE
^U9
`Z;4[365F3
bX9
;A
8E>
Y6H@NA3B6
BJ
3CC@6;
4;5LB65;5
36
L8A3;6A5
[3A7e
N;EE
EKCL7BC8
8I8365A
A7;
5@4J8N;
3CC@6BIEBG@E36
3H3BAKL;
;kL4;55;H
GK
A7;34
A@CB450

=
:6IE
U
^;H
,aT>-aQSD-a-R9
-SSa
aT0X[8F]g9
lB@6I
<?9
M;6636IAB6
cg9
g;;F5
2g>
\8NN368A3B6
[3A7
5K6I;6;3N9
EKCL7BC8DH;43i;H
3CC@6BIEBG@E36
3H3BAKL;
NBCG36;H
[3A7
I486@EBNKA;hC8N4BL78I;
NBEB6KD5A3C@E8A36I
J8NAB4
L43C;5
C3N;
JB4
8
L4BA;NA3i;
VDN;EE
4;5LB65;0

M4BN
=8AE
?N8H
2N3
O2?S,>-QSTa9
-SSP
a/02A;4685
]9
U863F
U:9
b@JJ;K
M]9
;A
8E>

:84EK
4;5@EA5
BJ
8
NE363N8E
A438E
BJ
A7;48L;@A3N
i8NN368A3B6
[3A7
YI
3H3BAKL;
86A3I;6
JB4
H;
6BiB
JBEE3N@E84
EKCL7BC80
eEBBH
//m2@LLE
-n>PTa89
-SSP0
aS0e;6H86H3
^9
2A;4685
]9
c;K6BEH5
`g9
X[8F
]g>
Y6H@NA3B6
BJ
8@ABEBIB@5
EKCL7BC8D
5L;N3J3N
`b/o
V
N;EE5
GK
L8A3;6AD5L;N3J3N
i8NN368A3B6
8I8365A
JBEE3N@E84
EKCL7BC8
36
J345A
4;C3553B60

eEBBH
SQm2@LLE
-n>adS89
-SST
,Q0e;6H86H3
^9
WBNF;
`b9
XBG436
`e9
;A
8E>
`BCLE;A;
CBE;N@E84
4;C3553B65
36H@N;H
GK
L8A3;6AD5L;N3J3N
i8NN368A3B6
LE@5
I486@EBNKA;DCB6BNKA;
NBEB6KD5A3C@E8A36I
J8NAB4
8I8365A
EKCL7BC80
=8A@4;
^;H
R>--T-D--TT9
-SSS
,-0fB486U^9
cB78A36;4
?j29
`B3JJ3;4
e9
;A
8E>
^@EA3N;6A;4
L785;
YY
5A@HK
BJ
JE@H848G36;
L7B5L78A;
JB4
L8A3;6A5
[3A7
6;[EK
H38I6B5;H
EKCL7BLE85C8NKAB3H
EKCL7BC89
pqrstuvwxyz{v
}q~xyryrutzq
qus
zquwrtDN;EE
EKCL7BC80
U
`E36
_6NBE
-T>RdP9
-SSS

,a036;A8E09
=8A@4;
^;H
d>PaTDP,Q9
-SS/0
,,0V78EEMf
86H
23CB6
c^>
c;N;6A
H;i;EBLC;6A5
36
H;53I6
BJ
L785;
YY
NE363N8E
A438E50

36
V78EE
Mf;H0
c;N;6A
8Hi86N;5
36
NE363N8E
A438E
H;53I6
86H
868EK5350

XE@[;49
LL
dSDTa9
-SSR0










 

!"#$
%

&'()*(+&)*
,-
/01344567895:
/01/3445678<
/=

4>?957@>5:
A?>
:B?>57
:4598C56:
6?B5=DEE
DEFGHIJ
K1L
MIN
OINE
HJMINOPGHIJ
IJ
NEQRESG
PJT
RSE
IM
SGINET
SUEFHOEJSV


W,VWVWYUZENESHS
[NITRFGS\
]HSSRE\
PJT
DENRO
DUEFHOEJS
]ZE^_HJHFP_
DRUUING
`PaINPGINb\
`EHTIS
cHIOETHFP_
dESEPNFZ\
eJFV\
UNIFESSES
PJT
FNbIUNESENfES
SPOU_ESHJ
SRUUING
IM
edcgPUUNIfET\
h^e
F_HJHFP_
GNHP_SV

Y__
_PaINPGINb
UENSIJJE_
iHGZ
PFFESS
GI
UPGHEJGHJMINOPGHIJ
PJJRP__b
FIOU_EGE
GZE
hej
IJ_HJE
FIRNSE
HJ
[NIGEFGHIJ
IM
jROPJ
DRakEFGSV]ZE
_PaINPGINb
HS
^`eY
FENGHMHET
MIN
^lm
HOORJIUZEJIGbUHJn
PJT
P__
_PaINPGINb
PNEPS
IUENPGERJTEN
P
oRP_HGb
YSSRNPJFE
[_PJ
iHGZ
TIFROEJGET
DGPJTPNT
pUENPGHJn
[NIFETRNES
GZPG
PNE
NEfHEiETPJJRP__bV

`PaINPGINb
UENSIJJE_
PNE
PSSESSET
MIN
FIOUEGEJFb
UNHIN
GI
aEHJn
UENOHGGET
GIiINqiHGZ
UPGHEJG
SPOU_ESV

rMMINGS
GI
EJSRNE
UNIGEFGHIJ
IM
UPGHEJG
HJMINOPGHIJ
HJF_RTEs
t ]ZE
_PaINPGINb
HS
_IFPGET
HJ
P
FIJGNI__ET
PFFESS
aRH_THJn
PJT
_PaINPGINb
TIINS
PNE
qEUG
_IFqET
PG
P__
GHOESV
uHSHGINS
GI
GZE
_PaINPGINb
PNE
NEQRHNET
GI
aE
PFFIOUPJHET
ab
_PaINPGINb
SGPMM
PG
P__
GHOESV


t jPNT
FIUb
NEFINTS
IN
E_EFGNIJHF
FIUHES
IM
TIFROEJGS
FIJGPHJHJn
UPGHEJG
HJMINOPGHIJ
PNE
qEUG
HJ
GZE
_IFqET
_PaINPGINb
IN
IGZEN
FIJGNI__ET
PFFESS
_IFPGHIJSV



t YJ
E_EFGNIJHF
TPGPaPSE
HS
RSET
GI
SGINE
HJMINOPGHIJ
NE_PGET
GI
UPGHEJG
SPOU_ES
UNIFESSET
abGZE
_PaINPGINbV


v
]ZE
TPGPaPSE
NESHTES
IJ
P
TETHFPGET
UNInNPO
SENfEN
GZPG
HS
qEUG
HJ
P
FEJGNP_\
_IFqET
FIOURGEN
MPFH_HGbV


v
]ZE
MPFH_HGb
HS
SRUUINGET
ab
GiI
e]
SUEFHP_HSGS
iZI
OPHJGPHJ
RU
GI
TPGE
SEFRNHGb
MEPGRNES
HJF_RTHJn
fHNRS
PJT
MHNEiP__
UNIGEFGHIJV


v
[NInNPO
PFFESS
HS
_HOHGET
GI
SUEFHMHET
FIOURGENS
PS
TESHnJPGET
ab
GZE
_PaINPGINb
THNEFGINV

rPFZ
IM
GZESE
FIOURGENS
ZPS
P
UPSSiINT
NESGNHFGET
_InHJ
SFNEEJV


v
]ZE
TPGPaPSE
SPOU_E
EJGNb
UNInNPO
HGSE_M
HS
PFFESSET
GZNIRnZ
P
UPSSiINT
UNIGEFGET
EJGNb
SFNEEJV


v
]ZE
TPGPaPSE
UNInNPO
ZPS
THMMENEJG
_EfE_S
IM
PFFESS
PUUNIfP_
GI
_HOHG
RJPRGZINHwET
FZPJnES
GI
SUEFHOEJ
NEFINTS
PJT
GZE
UNInNPO
OPHJGPHJS
P
SPOU_E
ZHSGINbV


t xUIJ
SUEFHOEJ
NEFEHUG
EPFZ
SPOU_E
HS
PSSHnJET
P
RJHQRE\
SEQREJGHP_
_PaINPGINb
PFFESSHIJ
el
JROaENV

Y__
UNITRFGS
nEJENPGET
ab
GZE
_PaINPGINb
GZPG
iH__
aE
SGINET
EHGZEN
HJ
GZE
_PaINPGINb
MNEEwENS
IN
PG
P
FEJGNP_
NEUISHGINb
MPFH_HGb
PNE
HTEJGHMHET
ab
GZHS
PFFESSHIJ
elV
t cEnHJJHJn
pFGIaEN
W\
-yyz
HJfEJGINb
HJMINOPGHIJ
iH__
aE
SGINET
PG
GZE
fHP_
_EfE_
PJT
EPFZ
fHP_
iH__
aE
_PaE_ET
iHGZ
aIGZ
P
SPOU_E
el
PJT
P
fHP_
SEQREJFE
JROaENV


t uHP_
_PaE_S
TI
JIG
FIJGPHJ
PJb
UENSIJP_
HTEJGHMHEN
HJMINOPGHIJV



t DPOU_ES
PNE
SGINET
HJfEJGINHET
HJ
_IFqET
_PaINPGINb
MNEEwENS
PJT
PNE
NIRGHJE_b
GNPJSMENNET
GIGZE
h^eg{NETENHFq
NEUISHGINb
MPFH_HGHES
MIN
_IJn
GENO
SGINPnEV


t YFFESS
GI
SGINET
F_HJHFP_
SPOU_ES
HS
NESGNHFGETV

eJfESGHnPGINS
ESGPa_HSZ
SPOU_E
FI__EFGHIJS
|}~
|
~
}~

}
}


}


[NHJFHUP_
eJfESGHnPGIN\
SUEFHMHES
iZI
ZPS
PFFESS
GI
GZE
FI__EFGHIJV

cEnHJJHJn
pFGIaEN
W\
-yyzSUEFHMHFUENOHSSHIJSiH__aENEQRHNETGIfHEi\HJURGINiHGZTNPiSPOU_ESMNIOP
FI__EFGHIJV[NHINGIGZPGTPGESPOU_EHJURGiPSJIGNESGNHFGETPJTNESGNHFGHIJSiENE_HOHGET
GISUEFHOEJiHGZTNPiP_V










 

!"#$
%

&'()*(+&)*
,,
. 012345
6789:;1614
;5<=5>8>
>=?27885:
8@
133;@A5:
41?@;18@;B
>81CC
?B
1DB@D5
@895;
891D
895
;53@>78@;B
>@=;E5
E@:5
@6D5;
1;5
>=?27885:
8@
895
>@=;E5
E@:5
@6D5;
C@;
133;@A14F

G5H7DD7DH
IE8@?5;
JK
LMMN
895
;53@>78@;B
C1E7478B
6744
14>@
D@87CB
895
0@=;E5
O@:5
9@4:5;
@C1DB
>=?27885:
;5<=5>8>
C@;
>12345
6789:;1614F


. P87>
895
;5>3@D>7?7478B
@C
895
0@=;E5
O@:5
9@4:5;
Q895
ROP
S;7DE7314
PDA5>87H18@;T
8@
5D>=;5
8918
>12345>
;5<=5>85:
1D:
133;@A5:
C@;
6789:;1614
1;5
?57DH
=>5:
7D
1
21DD5;
E@D>7>85D8
6789
PUG
133;@A14F


V
W95
O47D7E14
0=33@;8
X1?@;18@;B
:@5>
35;C@;2
85>87DH
>5;A7E5>
8918
21B
?5
;5<=5>85:
?B
E47D7E14
7DA5>87H18@;>
7DE4=:7DHK
?=8
D@8
472785:
8@K
722=D@395D@8B37DH
?B
C4@6
EB8@258;B
1D:
EB8@Y7D5
85>87DH
=>7DH
ZXP0[
@;
2=487345\
3418C@;2>F


. ]95D
;5<=5>8>
1;5
>=?27885:
?B
895
ROP
7DA5>87H18@;
C@;
>97325D8
@C
>12345>
@=8>7:5
@C
895
RP^
78
7>
895
3@47EB
@C
895
41?@;18@;B
8@
;5<=5>8
:@E=25D8187@D
8918
1
_185;714
W;1D>C5;
[H;5525D8
7>
7D
341E5
8918
E@A5;>
895
>35E725D
8;1D>C5;F

W95
41?@;18@;B
:@5>
D@8
3;@A7:5
31875D8
7:5D87C75;
7DC@;2187@D
1>
31;8
@C
895
8;1D>C5;
3;@E5>>
?=8
21BK
18
895
:7>E;587@D
@C
895
ROP
7DA5>87H18@;K
H;@=3
>12345>
C;@2
7D:7A7:=14
31875D8>
695D
8918
7>
E;787E14
8@
895
85>87DH
3;@E5>>F



. W95
ROP
7DA5>87H18@;
;5>3@D>7?45
C@;
895
>12345
E@445E87@D
7>
;5>3@D>7?45
C@;
5D>=;7DH
133;@3;7185
PUG
133;@A14>
1;5
7D
341E5
1D:
8918
1
_185;714
W;1D>C5;
[H;5525D8
91>
?55D
5\5E=85:
3;7@;
8@
;5<=5>87DH
895
41?@;18@;B
8@
>973
>12345>
@=8>7:5
@C
895
RP^F


J,FJFLG4@@:>
C@;
S91;21E@Y7D587E
1D14B>7>
W95?4@@:
8918
61>
E@445E85:
C@;
S`
1D14B>7>
7>
E=;;5D84B
>8@;5:
1>
341>21
7D
>E;56aE1335:
3@4B3;@3B45D5
A714>
7D
1
abMcO
:5H;55
C;55d5;
697E9
7>
4@E185:
7D
1
E@22@D
C;55d5;
;@@2
7D
895
J] 41?1;51
@C
895
S5:718;7E
IDE@4@HB
G;1DE9F

W95
C;55d5;
85235;18=;5
7>
E@D87D=@=>4B
2@D78@;5:
C@;
efa
85235;18=;5
:7CC5;5DE5>
@C
JM
:5H;55>
OF

012345>
1;5
>8@;5:
?B
31875D8
7D78714>
1>65441>:185
1D:
8725
@C
>12345
7D
7D:7A7:=14
?@\5>
67897D
897>
C;55d5;F

U5E@;:>
@C
>12345>
>8@;5:1;5E1814@H=5:
7D
1
g74521Y5;
:181?1>5
697E9
7>
217D817D5:
?B
S91;21E@4@HB
1D:
Z\35;725D814
W95;135=87E>
;5>51;E9
D=;>5>
1D:
7>
31>>6@;:
3;@85E85:
>@
8918
@D4B
252?5;>
@C
895>5E87@D
91A5
1EE5>>
8@
31875D8
>12345
7DC@;2187@DF

U5>=48>
C;@2
895
1D14B>5>
@C
:;=H
45A54>
C;@2895>5
>12345>
1;5
217D817D5:
7D
1D
Z\E54
:181?1>5
217D817D5:
@D
1
31>>6@;:a3;@85E85:
E@23=85;7D
895
41?@;18@;B
@C
h;F
g;1DY
G147>F

G@89
E@23=85;>
E@D817D7DH
31875D8
>12345
7DC@;2187@D
1;5
?1EY5:
@D
1
;5H=41;
Q18
451>8
@D5
8725
35;
655YT
?1>7>F

RIWZiW95>5
1D14B>5>
1;5
D@
4@DH5;
@DH@7DHF

[EE@;:7DH4BK
h;F
G147>
D@
4@DH5;
7DA@4A5:
7D
895
>8=:Bj9@65A5;K
97>
D125
7>
;5817D5:
C@;
97>8@;7E14
;51>@D>F



ICF_001.pdf: 
MEDICAL RECORD 
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY 
• 
Adult Patient or 
• Parent, for Minor Patient 
INSTITUTE: 
National Cancer Institute 
STUDY NUMBER: 
00-C-0133 
PRINCIPAL INVESTIGATOR: 
Christopher Melani, M.D. 
STUDY TITLE:  
Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated 
Mantle Cell Lymphoma 
Continuing Review Approved by the IRB on 08/06/18 
Amendment Approved by the IRB on 07/25/18 (M) 
         Date Posted to Web:08/16/18   
Standard 
PATIENT IDENTIFICATION 
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY 
• 
Adult Patient or 
• Parent, for Minor Patient 
NIH-2514-1 (07-09) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent (1) 
 
 
INTRODUCTION 
We invite you to take part in a research study at the National Institutes of Health (NIH). 
First, we want you to know that: 
Taking part in NIH research is entirely voluntary.  
You may choose not to take part, or you may withdraw from the study at any time.  In 
either case, you will not lose any benefits to which you are otherwise entitled.  However, 
to receive care at the NIH, you must be taking part in a study or be under evaluation for 
study participation. 
You may receive no benefit from taking part.  The research may give us knowledge that 
may help people in the future. 
Second, some people have personal, religious or ethical beliefs that may limit the kinds of 
medical or research treatments they would want to receive (such as blood transfusions).  If you 
have such beliefs, please discuss them with your NIH doctors or research team before you agree 
to the study. 
Now we will describe this research study.  Before you decide to take part, please take as much 
time as you need to ask any questions and discuss this study with anyone at NIH, or with family, 
friends or your personal physician or other health professional.   
Why is this study being done? 
Mantle cell is a form of cancer of the white blood cells called lymphocytes.  In mantle cell, the 
abnormal lymphocytes multiply and accumulate in lymph nodes and elsewhere.  Standard 
treatment with chemotherapy can often control the mantle cell for a period but in most patients, 


MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 00-C-0133 
CONTINUATION: page 2 of 15 pages 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
the disease does not go entirely away or comes back.  In this study, we are testing a vaccine to 
determine if it can stimulate your own immune system to fight the cancer.  Experiments in the 
laboratory have shown that vaccines of this type work better if there is very little lymphoma 
present when the vaccine is given.  For this reason, we will first treat all patients with EPOCH 
chemotherapy and rituximab (called EPOCH-R). EPOCH (each letter stands for one of the drugs 
used in the combination) uses standard chemotherapy drugs and has been shown to have a high 
degree of effectiveness in lymphomas. Recent evidence indicates that the effects of 
chemotherapy may be improved by the use of a new drug called Rituximab.  Although rituximab 
is not an experimental drug, its use in this study is considered to be experimental because it is 
unproven if it will increase the effectiveness of EPOCH therapy.  Rituximab is a special kind of 
drug called an antibody, which binds to a specific molecule (called CD20) present on mantle cell 
lymphomas.  It is important to note that although the drugs in EPOCH-R are standard, we do not 
know how effective this combination will be in patients with mantle cell lymphoma.    
Why are you being asked to take part in this study?    
You have been invited to participate in this study because you have mantle cell lymphoma.  This 
is a clinical research study to test a new investigational approach using EPOCH-R chemotherapy 
and a vaccine directed against your lymphoma cells.   
Description of Research Study 
What will happen if you take part in this research study? 
Study Design 
The study is divided into 3 parts.  In the first part, you will undergo a series of tests to determine 
if you are eligible for the study and to determine the extent (called stage) of your lymphoma.  If 
you are found not to be eligible for the study, you will be referred back to your home physician.  
If you are eligible, we will ask you to undergo a procedure to obtain lymphoma cells for the 
vaccine and research tests.  A piece of lymphoma tissue to make the vaccine will be removed 
from places that are safe to biopsy.  Alternatively, it may be possible to obtain lymphoma cells 
from your blood by a procedure called apheresis or bone marrow.  These studies and procedures 
may take up to 4 weeks.  In the second part, you will receive a series of treatments with EPOCH-
R.  It usually takes 18 weeks to complete this part of the study.  In the third part, you will receive 
4 injections of vaccine administered 4 weeks apart, and a 5th injection 8 weeks after the 4th 
injection.  The vaccine treatments will begin around 3 months after you complete EPOCH-R, but 
in some cases it may be longer, depending on when the vaccine is ready.  After the vaccine 
treatments are completed, you will be followed in our clinic, every few months at first, and then 
less frequently if the lymphoma does not return. In some circumstances, it is possible you may 
not receive all or part of the vaccine treatments.  In approximately 10% of patients, it is not 
possible to make a vaccine, or rarely, a patient may have a severe reaction to a vaccine which 
would make it dangerous to continue.  In addition, if a patient’s lymphoma begins to grow before 
the vaccine treatments are completed and they need chemotherapy or radiation that are not part 


MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 00-C-0133 
CONTINUATION: page 3 of 15 pages 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
of this study, the vaccine will not be given.  We estimate that around one third of patients will 
not be able to complete the vaccine treatments for these reasons.   
EPOCH-R treatment 
Each chemotherapy treatment period is called a cycle.  The cycle is repeated every three weeks 
and the chemotherapy drugs are administered only during the first five days of every cycle.  
EPOCH-R consists of prednisone by mouth on days 1 to 5, and etoposide, doxorubicin, and 
vincristine as an infusion over days 1 to 5 (total of 96 hours), and cyclophosphamide on day 5 by 
vein.  You will receive the infused drugs as an outpatient through a lightweight, portable infusion 
pump, about the size of a portable tape recorder.  The pumps deliver the therapy through an 
intravenous catheter which is placed in your vein beforehand.  You will be taught about the use 
and care of the pump and what to do if it stops working.  The rituximab will be given by vein 
over several hours on day 1, immediately before the chemotherapy infusion begins, and the 
cyclophosphamide will be given by intravenous injection over about 15 minutes on day 5, 
immediately after the chemotherapy infusion is completed.  Each cycle lasts 3 weeks:  5 days of 
chemotherapy followed by 16 days of no chemotherapy.  You will receive 6 cycles of EPOCH-
R.  If your lymphoma grows, however, EPOCH-R will be discontinued.  Between cycles of 
treatment, we give another drug, G-CSF, to help your normal bone marrow cells recover from 
the chemotherapy and produce normal white cells.  You will be taught how to inject the G-CSF 
under your skin (like an insulin shot) each day beginning on day 6 of each cycle and continuing 
until recovery of the white blood cell count or until day 19 of each cycle.  If your white blood 
cell count is still very low on the day treatment is due to begin again, the chemotherapy may be 
delayed and the G-CSF restarted until recovery of the white count.  Because several of the 
chemotherapy drugs can lower your resistance to infection, you will receive an antibiotic called 
Bactrim for three days each week while you are on chemotherapy.  If you are allergic to this 
antibiotic, you will receive the drug, pentamidine, by inhalation once monthly. 
Vaccine treatment 
At least 3 months is necessary to produce the experimental customized vaccine from your 
lymphoma cells.  It is not always possible to successfully make a vaccine for every patient, so we 
cannot promise that you will receive a vaccine or that you will have any benefit from the vaccine 
if you do receive it.  The vaccine treatment is given in the clinic and you will be carefully 
observed.  To help the immune system respond to the vaccine, you will also receive daily 
injections of GM-CSF under the skin, beginning on the day of vaccination and for the three 
following days.  This drug is a naturally occurring protein in our own bodies which has been 
made into a drug.  The vaccine treatments (maximum of 5) will only be given if there are no 
serious side effects during previous vaccine treatments.  It is important that you not take steroid 
medications or drugs such as aspirin or ibuprofen during the period you are receiving the vaccine 
without consulting your NIH physicians, unless it is an emergency. 


MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 00-C-0133 
CONTINUATION: page 4 of 15 pages 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
Research tests 
Research studies will be performed on your blood, bone marrow, tumor tissue or other fluids to 
look at different genes and proteins that may be involved in the development of your lymphoma 
or the reaction of the immune system.  We will not examine mutations of normal genes from 
your tissue without obtaining additional permission from you.  It may be important to obtain 
repeat biopsies of tumor tissue after you have enrolled on the study.  Repeat biopsies requiring 
major surgery (e.g., in the chest or the abdomen) will not be performed for research purposes 
alone but only if absolutely necessary for your medical care.  You may decide not to have a 
biopsy for research purposes and this will not affect your eligibility for this study.  Blood 
samples of approximately 1 teaspoon in size may be drawn up to 5 times on each cycle of 
EPOCH-R to measure concentrations of chemotherapy drugs.  Up to 5 tablespoons of blood may 
also be drawn during each vaccination to measure the effects of the vaccine.  Additionally, a 
procedure called apheresis will be performed immediately before beginning EPOCH-R 
chemotherapy and again just before beginning the vaccine treatment to obtain cells for the study 
of your immune function and possibly for collection of tumor cells for the vaccine.  This 
procedure takes approximately 60 to 90 minutes and is performed in the NIH Department of 
Transfusion Medicine.  In this procedure, your blood will be filtered through a machine to 
remove the white cells, and your normal blood cells and platelets will be returned to you.  The 
progress of your response will be followed by CT scans of your body and blood tests.   
What tests will be done on my samples? 
Your blood and tissue that is collected will be used to look for specific changes in the DNA in 
tumors that could be used to develop new ways of diagnosing and treating cancer.   DNA (also 
called deoxyribonucleic acid) are the molecules inside cells that carry genetic information and 
pass it from one generation of cells to the next – like an instruction manual. Normal tissue 
contains the DNA (instructions) that you were born with, DNA in tumor cells has changed – or 
mutated – and we think that change in the DNA is what causes tumors to form and to grow, 
forming the cancer genome or DNA.  In order to determine which parts of the DNA have 
mutated, we will compare the DNA in your tumor cells to DNA from your normal cells.  When 
we are examining these pieces of your DNA, it is possible that we could identify possible 
changes in other parts of your DNA that are not related to this research.  These are known as 
“incidental medical findings”.  
These include:  
• Changes in genes that are related to diseases other than cancer  
• Changes in genes that are not known to cause any disease. These are known as normal 
variations.  
• Changes in genes that are new and of uncertain clinical importance. This means that we 
do not know if they could cause or contribute to a disease or if they are normal variations.  


MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 00-C-0133 
CONTINUATION: page 5 of 15 pages 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
However, the analyses that we perform in our laboratory are for research purposes only; they are 
not nearly as sensitive as the tests that are performed in a laboratory that is certified to perform 
genetic testing. Changes that we observe unrelated to our research may or may not be valid.  
Therefore, we do not plan to inform you of the results of testing on your tissue and blood that is 
performed in our research lab.  However, in the unlikely event that we discover a finding 
believed to be clinically important based on medical standards at the time we first analyze your 
results, we will contact you. This could be many years in the future.   We will ask you to have an 
additional tube of blood drawn to verify the findings we have seen in our lab. If the results are 
verified, you will be re-contacted and offered (at our expense) to have genetic education and 
counseling to explain the results.  If you do not want to come to NIH, we will help you find a 
local genetic healthcare provider who can explain it to you (at your expense). 
You should not assume that if you are not contacted, that you do not have any gene variants that 
might be related to a disease. 
Who else besides the investigators on this study will know the results of my sample testing? 
Once we obtain any of the samples listed above, the investigators take all your personal 
information off those samples and label them with a study code number.  Only the investigators 
on this study know who the sample came from.  The key linking your personal information with 
the code number is kept in a secure computer data base, with access only to key research staff 
who will be discussing this study with you.  Once the sample has been labeled with a code, it is 
sent to a variety of NIH laboratories for storage and testing.  No one testing your samples will be 
able to link the results to you personally.  Specimens obtained during your participation in this 
study may be sent for testing to investigators outside of NCI or the NIH.  All samples will be 
coded to protect your privacy and no personal information will be included.  Other investigators 
on this study will have access to limited clinical and biologic data such as age, gender and 
disease status. 
Your individual genomic data and health information will be put in a controlled-access database.  
This means that only researchers who apply for and get permission to use the information for a 
specific research project will be able to access the information.  Your genomic data and health 
information will not be labeled with your name or other information that could be used to 
identify you.  Researchers approved to access information in the database have agreed not to 
attempt to identify you. 
How long will your samples be stored? 
The samples collected during this study will be stored for as long as the study is open.  When this 
study is closed, we will keep the samples for future research. 
What happens after treatment is completed 
This depends on how you have responded to the therapy.  If all evidence of disease has 
disappeared, we will schedule periodic visits to the Clinical Center for follow-up examination 


MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 00-C-0133 
CONTINUATION: page 6 of 15 pages 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
and tests.  If the disease does not disappear entirely or if it should recur after having disappeared 
for a period of time, then you may need further therapy.  At that time you will be given the 
opportunity of participating in additional research protocols that may be appropriate for you.  If 
no such protocols are available, you will be returned to the care of your local physician.  It is 
important to stress that participation in this protocol does not constitute a promise of long-term 
medical care here at the Clinical Center.  It is conceivable that participation in this study may 
make you ineligible to participate in certain other research protocols because the requirements 
for entry onto these protocols may not allow patients who have already been treated with certain 
drugs or who have had certain side effects from previous treatment.  You may decide now not to 
receive treatment on this protocol, or you may choose at any point in time to stop the treatment 
and withdraw from the protocol; in either case you will be returned to the care of your referring 
physician.   
Risks or Discomforts of Participation 
In order to determine whether this study is suitable for you, a number of tests will have to be 
done.  This period of evaluation may take up to two weeks and is usually done on an outpatient 
basis.  Some or all of these tests will be repeated during and after the chemotherapy and vaccine 
at different times.  Depending on the tests you had before coming here, these may include blood 
and urine tests, studies of lung function, CAT or MRI scans, colonoscopy with biopsies, 
radioisotope scans, and biopsies of tumor tissue, bone marrow, liver, or other sites.  Biopsies 
will, when possible, be done under local anesthesia.  The risks associated with bone marrow 
biopsies include pain, bleeding, and local infection.  Risks of biopsies include pain, bleeding, 
infection, and the risks to the particular area undergoing surgery.  General anesthesia itself is 
generally very safe but has a very small risk of major complications such as heart attack or 
stroke.  The surgical and anesthetic risks will be explained to you in more detail at the time of 
surgery, if this is needed.  Risks of colonoscopy with biopsies include discomfort and bleeding 
from the rectum; rarely the colon may be punctured and if this occurs, it is serious and may 
require surgery.   A separate consent describing all of the complications and side effects of 
colonoscopy with biopsies will be obtained from you.   
In order to receive this therapy, you will need to have an intravenous catheter placed.  This 
catheter is usually placed in the arm, chest or neck area into a major vein inside your chest.  We 
usually remove the catheter after each cycle but on occasion it can be left in for several cycles.  
The catheter is necessary for infusion of chemotherapy and for the drawing of blood.  It is 
usually inserted under local anesthesia.  The risks associated with the procedure include pain, 
bleeding, infection, and puncture of the underlying lung.  Lung puncture can result in lung 
collapse, which might require that a chest tube be placed into the chest cavity (usually for a day 
or two) to help the lung reinflate.  The long-term risks of the catheter include infection and 
clotting of the vein in which the catheter sits.  If these occur, it may be necessary to remove the 
catheter.  These risks will be explained to you in more detail at the time of the insertion.  The 
apheresis requires the insertion of an intravenous line in to the arm or chest and peripheral blood 


MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 00-C-0133 
CONTINUATION: page 7 of 15 pages 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
will be removed and passed through an apheresis machine; this machine allows us to collect 
immune cells for research, and to return your own red blood cells and platelets back in your 
intravenous line.  In some patients, we may also collect tumor cells by apheresis to produce the 
vaccine. Serious reactions associated with apheresis are rare and generally mild.  They include 
pain and bruising at the insertion site of the intravenous line, and a temporary decrease in the 
platelet count and/or hemoglobin levels.  Fainting episodes related to needle insertion can occur, 
and skin tingling caused by low calcium levels can rarely occur.  During the leukopheresis, at 
least two apheresis nurses will be present, and a blood bank physician will be available in the 
clinic area where the procedure is performed.  For this study, the procedure will typically take 
about 60 to 90 minutes.  Side effects that have been observed with the drugs in this program 
when they are used individually include the following: 
• Doxorubicin may cause sore mouth, loss of hair, a fall in blood counts with increased risk 
of serious infection or internal bleeding, tissue damage if the drug contacts the skin, heart 
damage and, rarely, death due to heart failure.  However, the infusion method used in this 
study has been shown to reduce the risk of heart damage.  
• Cyclophosphamide may cause a fall in blood counts with increased risk of serious 
infection or bleeding, loss of hair, damage to the lining of the urinary bladder with 
painful and bloody urination, loss of function of the ovaries or testes, and nausea and 
vomiting.  Bladder irritation can be minimized by drinking at least two quarts of fluid 
each day. 
• Vincristine often causes numbness of the hands and feet after several cycles.  Rarely, 
patients may develop pain and/or weakness of the foot muscles.  Patients also may have 
constipation and medications will be given to reduce this.  In most instances, these 
symptoms resolve when the drug is stopped, but resolution of the numbness in the hands 
and feet may sometimes take months or even years.  The drug can also cause tissue 
damage if it contacts the skin.  
• Etoposide may cause nausea and vomiting, diarrhea, loss of hair, lowering of blood 
pressure during administration, mouth ulcers, and lowering of blood counts.  
• Rituximab commonly causes fever, chills, nausea, headache, swelling, itchiness and rash.  
Low white blood counts may occur but are less common. Occasionally patients have 
developed low blood pressure, wheezing and rashes during administration of rituximab.  
Less common toxicities are abdominal pain, vomiting, low platelets and red cells, muscle 
and joint pains, dizziness and runny nose.  Rarely, patients may die from the effects of 
rituximab due to an allergic reaction or lung problems.  
• Prednisone may cause ulceration in the stomach or bowel, increased blood pressure, high 
blood sugar (diabetes), increased risk of infection, a round appearance of your face, 
weight gain, change in mood, thinning of your bones with increase in the risk of fracture.  
It can also cause or worsen acne.  


MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 00-C-0133 
CONTINUATION: page 8 of 15 pages 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
• G-CSF can occasionally cause bone pain by stimulating normal bone marrow.  This stops 
when drug administration stops.  It has also been reported sometimes to cause skin rash, 
skin reddening around the injection site, muscle cramps, decreased platelets (not 
clinically significant), pain or numbness and tingling around the chin, worsening of 
certain pre-existing inflammatory conditions (such as psoriasis, eczema, or vasculitis), 
fever, body aches, and alterations in certain laboratory tests.  With prolonged 
administration G-CSF has been associated with hair thinning and enlargement of the 
spleen. 
• Vaccine treatment may produce some discomfort, such as redness, swelling and 
tenderness at the injection site.  Fever, chills, rash and flu-like symptoms may also occur.  
All of these are usually temporary.  Although very unlikely, it is possible that you could 
have a severe allergic reaction with shortness of breath and low blood pressure.   
• GM-CSF may cause fever, chills, sweating, muscle aches, tiredness, headache, dizziness, 
shortness of breath, fluid collection in the lining of the lung, lack of appetite, indigestion, 
nausea, vomiting, diarrhea, tenderness at the site of injection, hives, rash itching, allergic 
reactions, bone pain, clotting of blood vessels, low blood pressure, leg swelling, elevated 
white blood count, elevated platelet count, low platelet count, and abnormal blood tests of 
the liver.   
• Trimethoprim/sulfamethoxazole can cause a skin rash that goes away when the drug is 
stopped. Inhaled pentamidine can cause coughing, wheezing, and burning pain in the 
throat.  All of these symptoms usually go away shortly after the inhalation treatment is 
finished. 
It is important to emphasize that when you have a decreased white blood cell count from the 
EPOCH-R treatment, you are at risk of infection.  Such infections can be very serious and can 
even cause death if not quickly and properly treated.  Therefore, if you have a temperature 
greater than 38.3o C (101o F), you must call your doctor immediately.  Chemotherapy may also 
cause your platelets to fall; since platelets are the blood elements that permit blood to clot, this 
may place you at increased risk of serious bleeding.  It may be necessary to give you transfusions 
of platelets if your platelet counts reach very low levels.  There is a small chance that damage to 
the normal bone marrow may eventually result in bone marrow failure, leading to a serious 
shortage of one or more kinds of cells in the blood, or to leukemia.  Because this is a relatively 
new combination of drugs, it is always possible that unanticipated side effects may occur, 
including death. 
Many of the drugs used in this treatment program are toxic to the cells in the ovary and testicle 
and may produce sterility.  Recovery of normal fertility is not well studied although we know 
that some patients treated with this combination have remained fertile after the therapy has been 
completed.  For this reason, men who are about to receive this treatment should, if they wish to 
have children in the future, consider sperm banking before start of the treatment.  These drugs 
may also be very toxic to an unborn child.  Therefore, adequate birth control measures (such as 


MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 00-C-0133 
CONTINUATION: page 9 of 15 pages 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
the contraceptive pill, condoms, diaphragm with contraceptive foam or ointment, contraceptive 
sponge, etc.) should be used by participants or their sexual partners while receiving treatment on 
this study.  Women of childbearing age will have a pregnancy test, which must be negative at the 
time of study entry.  This test requires that blood be drawn from a vein one or two days prior to 
the study.  The results of the pregnancy test will be made available to you prior to the initiation 
of the study.  Your physicians will watch you closely for side effects and will stop treatment if 
any side effects become a serious threat to your life or well-being.  Your physicians will also 
stop the treatments if it becomes clear that the treatment is not successfully controlling your 
disease.  
Rarely, patients may develop a dangerous side effect from blood transfusions called graft versus 
host disease (GVH).  This disease is caused by white cells from the blood transfusion that can 
attack your normal tissues and cause death.  GVH is preventable by radiating the blood before 
you receive it.  It is important to emphasize that you will not receive any radiation from the 
blood and the radiation procedure done on the donated blood will not harm you.  If you require a 
blood transfusion at the NIH during this study, you will receive blood that has been radiated.  
However, if your local physician gives you a blood transfusion, it is important that you make 
sure the blood has been radiated. 
Psychological or Social Risks Associated with Loss of Privacy  
The following general points are indirectly related to your participation in the research study: 
1. Unanticipated medical information: During the course of this investigation, it is possible 
(although not likely) that we will obtain unanticipated information about your health or 
genetic background.   
2. Release of genetic information:   
• Your privacy is very important to us and we will use many safety measures to protect 
your privacy. However, in spite of all of the safety measures that we will use, we cannot 
guarantee that your identity will never become known. Although your genetic 
information is unique to you, you do share some genetic information with your children, 
parents, brothers, sisters, and other blood relatives. Consequently, it may be possible that 
genetic information from them could be used to help identify you. Similarly, it may be 
possible that genetic information from you could be used to help identify them.  
• While the controlled-access databases developed for this project will not contain 
information that is traditionally used to identify you, such as your name, address, 
telephone number, or social security number, people may develop ways in the future that 
would allow someone to link your genetic or medical information in our databases back 
to you. For example, someone could compare information in our databases with 
information from you (or a blood relative) in another database and be able to identify you 
(or your blood relative). It also is possible that there could be violations to the security of 


MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 00-C-0133 
CONTINUATION: page 10 of 15 pages 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
the computer systems used to store the codes linking your genetic and medical 
information to you. 
• Since some genetic variations can help to predict the future health problems of you and 
your relatives, this information might be of interest to health providers, life insurance 
companies, and others. Patterns of genetic variation also can be used by law enforcement 
agencies to identify a person or his/her blood relatives. Therefore, your genetic 
information potentially could be used in ways that could cause you or your family 
distress, such as by revealing that you (or a blood relative) carry a genetic disease. 
• There also may be other privacy risks that we have not foreseen. 
Since some genetic variations can help to predict future health problems for you and your 
relatives, this information might be of interest to health care providers, life insurance companies, 
and others.  However, Federal and State laws provide some protections against discrimination 
based on genetic information.  For example, the Genetic Information Nondiscrimination Act 
(GINA) makes it illegal for health insurance companies, group health plans, and most employers 
to discriminate against you based on your genetic information.  However, GINA does not 
prevent companies that sell life insurance, disability insurance, or long-term care insurance from 
using genetic information as a reason to deny coverage or set premiums.  GINA also does not 
apply to members of the United States military, individuals covered by the Indian Health 
Service, or veterans obtaining health care through the Veteran’s Administration.  Lastly, GINA 
does not forbid insurance medical underwriting based on your current health status though the 
Affordable Care Act limits consideration of pre-existing conditions by insurers. 
Potential Benefits of Participation 
Are there benefits to taking part in this study? 
Most patients will have tumor shrinkage with chemotherapy.  However, we do not know if the 
vaccine will be of benefit to you and do not know if you will be cured of your lymphoma.  It is 
also possible that you may not respond to any of this treatment. 
Alternative Approaches or Treatments  
What other choices do I have if I do not take part in this study? 
It should be emphasized that we do not know at this point whether the EPOCH-R and 
vaccination we propose to give you is superior, inferior, or equivalent to standard combination 
chemotherapy for your disease.  Alternative procedures that could be used to treat your disease 
include: 
• Other combination drug regimens and other schedules of the same drugs used in this 
study.  For example, a chemotherapy called CHOP given in the conventional manner 


MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 00-C-0133 
CONTINUATION: page 11 of 15 pages 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
would be suitable standard therapy for your condition.  You could also receive EPOCH-R 
as standard treatment.   
• Treatment with single drugs.  This is known to produce brief responses of a few months' 
duration in many patients but to have little beneficial effect in long-term control of the 
disease. 
• Radiation (X-ray) treatments.  This can stop tumor growth in particular locations, such as 
bone, abdomen, and other sites but is not successful in controlling the disease overall 
unless the disease is very localized at the start of therapy.  
• Surgery.  As with radiation, surgery can be successful in removing tumor from particular 
locations but cannot be used successfully to remove all lymphoma cells from the body, 
since the disease is almost always present in multiple locations.  Also, surgery cannot be 
used against tumor in some of the organs most commonly involved by lymphoma, such 
as the liver or the lungs. 
• Waiting, without active therapy.  Although a period of watchful waiting is appropriate 
treatment for some kinds of tumors, in lymphomas similar to yours the disease will often 
grow and spread rapidly if no treatment is administered. 
Research Subject’s Rights 
What are the costs of taking part in this study?  
If you choose to take part in the study, the following will apply, in keeping with the NIH policy: 
• You will receive study treatment at no charge to you. This may include surgery, 
medicines, laboratory testing, x-rays or scans done at the Clinical Center, National 
Institutes of Health (NIH), or arranged for you by the research team to be done outside 
the Clinical Center, NIH if the study related treatment is not available at the NIH.  
• There are limited funds available to cover the cost of some tests and procedures 
performed outside the Clinical Center, NIH.  You may have to pay for these costs if they 
are not covered by your insurance company. 
• Medicines that are not part of the study treatment will not be provided or paid for by the 
Clinical Center, NIH. 
• Once you have completed taking part in the study, medical care will no longer be 
provided by the Clinical Center, NIH 
Will your medical information be kept private?  
We will do our best to make sure that the personal information in your medical record will be 
kept private.  However, we cannot guarantee total privacy.  Organizations that may look at 
and/or copy your medical records for research, quality assurance, and data analysis include: 


MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 00-C-0133 
CONTINUATION: page 12 of 15 pages 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
• The National Cancer Institute (NCI) and other government agencies, like the Food and 
Drug Administration (FDA), which are involved in keeping research safe for people. 
• National Cancer Institute Institutional Review Board 
• Some of the specimens and/or data obtained may be sent to researchers outside of the 
National Cancer Institute to perform additional research studies designed to help us better 
understand lymphoma. 
• Biovest International, Inc. will have limited access to the clinical data and results in NIH’s 
possession and control as needed to support the registration of the Id-KLH Vaccine by the 
FDA in this disease. 
A description of this clinical trial will be available on http://www.Clinicaltrials.gov, as required 
by U.S. Law.  This Web site will not include information that can identify you.  At most the 
Web site will include a summary of the results.  You can search this Web site at any time. 
Certificate of Confidentiality 
To help us protect your privacy, we have obtained a Certificate of Confidentiality. The 
researchers can use this Certificate to legally refuse to disclose information that may identify you 
in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings, for 
example, if there is a court subpoena. The researchers will use the Certificate to resist any 
demands for information that would identify you, except as explained below. 
You should also know that there are several circumstances in which the Certificate does not 
provide coverage. These include when information:  
• will be used for auditing or program evaluation internally by the NIH; or  
• must be disclosed to meet the legal requirements of the federal Food and Drug 
Administration (FDA).  
• is necessary for your medical treatment and you have consented to this disclosure;  
• is for other research.  
In addition, identifiable, sensitive information protected by this Certificate cannot be admissible 
as evidence or used for any purpose in any action, suit, or proceeding without your consent. 
You should understand that a Certificate of Confidentiality does not prevent you or a member of 
your family from voluntarily releasing information about yourself or your involvement in this 
research. If an insurer, employer, or other person obtains your written consent to receive research 
information, then the researchers will not use the Certificate to withhold that information. 


MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate in A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
STUDY NUMBER: 00-C-0133 
CONTINUATION: page 13 of 15 pages 
 
PATIENT IDENTIFICATION 
CONTINUATION SHEET for either: 
NIH-2514-1 (07-09) 
NIH-2514-2 (10-84) 
P.A.:  09-25-0099 
File in Section 4:  Protocol Consent 
 
The Certificate of Confidentiality will not protect against the required reporting by hospital staff 
of information on suspected child abuse, reportable communicable diseases, and/or possible 
threat of harm to self or others. 
Conflict of Interest 
The National Institutes of Health (NIH) reviews NIH staff researchers at least yearly for conflicts 
of interest.  This process is detailed in a Protocol Review Guide.  You may ask your research 
team for a copy of the Protocol Review Guide or for more information.  Members of the research 
team who do not work for NIH are expected to follow these guidelines, but they do not need to 
report their personal finances to the NIH. 
Members of the research team working on this study may have up to $15,000 of stock in the 
companies that make products used in this study.  This is allowed under federal rules and is not a 
conflict of interest.  
Use of Specimens and Data for Future Research  
To advance science, it is helpful for researchers to share information they get from studying 
human samples.  They do this by putting it into one or more scientific databases, where it is 
stored along with information from other studies. A researcher who wants to study the 
information must apply to the database and be approved.  Researchers use specimens and data 
stored in scientific databases to advance science and learn about health and disease.   
We plan to keep some of your specimens and data that we collect, use them for future research 
and share them with other researchers. We will not contact you to ask about each of these future 
uses. These specimens and data will be stripped of identifiers such as name, address or account 
number, so that they may be used for future research on any topic and shared broadly for 
research purposes. Your specimens and data will be used for research purposes only and will not 
benefit you. It is also possible that the stored specimens and data may never be used.   
Results of research done on your specimens and data will not be available to you or your doctor.  
It might help people who have cancer and other diseases in the future.  If you do not want your 
stored specimens and data used for future research, please contact us in writing and let us know 
that you do not want us to use your specimens and data. Then any specimens that have not 
already been used or shared will be destroyed and your data will not be used for future research. 
However, it may not be possible to withdraw or delete materials or data once they have been 
shared with other researchers. 
 


MEDICAL RECORD 
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY 
• 
Adult Patient or 
• Parent, for Minor Patient 
 
STUDY NUMBER: 00-C-0133 
CONTINUATION: page 14 of 15 pages 
 
PATIENT IDENTIFICATION 
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH 
STUDY (Continuation Sheet) 
• 
Adult Patient or 
• Parent, for Minor Patient 
NIH-2514-1 (07-09) 
P.A.:  09-25-0099 
 
File in Section 4:  Protocol Consent 
 
 
OTHER PERTINENT INFORMATION 
1. 
Confidentiality.  When results of an NIH research study are reported in medical journals 
or at scientific meetings, the people who take part are not named and identified.  In most cases, 
the NIH will not release any information about your research involvement without your written 
permission.  However, if you sign a release of information form, for example, for an insurance 
company, the NIH will give the insurance company information from your medical record.  This 
information might affect (either favorably or unfavorably) the willingness of the insurance 
company to sell you insurance. 
The Federal Privacy Act protects the confidentiality of your NIH medical records.  However, you 
should know that the Act allows release of some information from your medical record without 
your permission, for example, if it is required by the Food and Drug Administration (FDA), 
members of Congress, law enforcement officials, or authorized hospital accreditation 
organizations. 
2. 
Policy Regarding Research-Related Injuries.  The Clinical Center will provide short-
term medical care for any injury resulting from your participation in research here.  In general, 
no long-term medical care or financial compensation for research-related injuries will be 
provided by the National Institutes of Health, the Clinical Center, or the Federal Government.  
However, you have the right to pursue legal remedy if you believe that your injury justifies such 
action. 
3. 
Payments.  The amount of payment to research volunteers is guided by the National 
Institutes of Health policies.  In general, patients are not paid for taking part in research studies at 
the National Institutes of Health.  Reimbursement of travel and subsistence will be offered 
consistent with NIH guidelines. 
4. 
Problems or Questions.  If you have any problems or questions about this study, or 
about your rights as a research participant, or about any research-related injury, contact the 
Principal Investigator, Christopher Melani, M.D., Building 10, Room 4N115, Telephone: 301-
814-7117. You may also call the Clinical Center Patient Representative at 301-496-2626. If you 
have any questions about the use of your specimens or data for future research studies, you may 
also contact the Office of the Clinical Director, Telephone:  240-760-6070. 
5. 
Consent Document.  Please keep a copy of this document in case you want to read it 
again. 


MEDICAL RECORD 
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH STUDY 
• 
Adult Patient or 
• Parent, for Minor Patient 
 
STUDY NUMBER: 00-C-0133 
CONTINUATION: page 15 of 15 pages 
 
PATIENT IDENTIFICATION 
CONSENT TO PARTICIPATE IN A CLINICAL RESEARCH 
STUDY (Continuation Sheet) 
• 
Adult Patient or 
• Parent, for Minor Patient 
NIH-2514-1 (07-09) 
P.A.:  09-25-0099 
 
File in Section 4:  Protocol Consent 
 
 
 
COMPLETE APPROPRIATE ITEM(S) BELOW: 
A. Adult Patient’s Consent 
B. Parent’s Permission for Minor Patient. 
I have read the explanation about this study 
and have been given the opportunity to discuss 
it and to ask questions.  I hereby consent to 
take part in this study. 
I have read the explanation about this study 
and have been given the opportunity to discuss 
it and to ask questions.  I hereby give 
permission for my child to take part in this 
study.   
(Attach NIH 2514-2, Minor’s Assent, if 
applicable.) 
 
  
  
 
 
 
Signature of Adult Patient/ 
Legal Representative 
Date 
Signature of Parent(s)/ Guardian Date 
 
 
Print Name 
 
 
Print Name 
C. Child’s Verbal Assent (If Applicable) 
The information in the above consent was described to my child and my child agrees to 
participate in the study. 
 
  
  
 
Signature of Parent(s)/Guardian 
Date 
Print Name 
THIS CONSENT DOCUMENT HAS BEEN APPROVED FOR USE  
FROM AUGUST 06, 2018 THROUGH AUGUST 05, 2019.  
 
 
 
 
 
 
 
 
Signature of Investigator 
Date 
Signature of Witness 
Date 
 
 
Print Name 
 
 
Print Name